Document ID: EPA-HQ-OAR-2003-0065-0533
Agency: epa
Document Type: Supporting & Related Material
Title: 
Posted Date: 2009-06-22T04:00Z

ABSTRACT

The developmental toxicity of gasoline with TBA (tert butyl alcohol)
vapor condensate (GTVC) was evaluated in 25 confirmed-mated female
Crl:CD®(SD)IGSBR rats/exposure group at target concentrations of 0,
2000, 10,000, and 20,000 mg/m3 in air.  The animals were exposed daily
for six hours from Gestation Day (GD) 5 through GD 20.  There was
evidence of maternal toxicity during the first half (GD 5-14) of the
exposure period as indicated by statistically significant decreases in
food consumption at the GD 5-8, GD 8-11, and GD 11-14 intervals for the
10,000 and 20,000 mg/m3 target concentration groups. The extent of these
early decreases in food consumption also produced statistically
significant decreases in food consumption for the GD 5-20 interval in
the 10,000 and 20,000 mg/m3 target concentration groups and for the GD
0-21 interval in the 20,000 mg/m3 target concentration group.  
Statistically significant dose-responsive decreases in body weight
change also were evident in the 10,000 mg/m3  and 20,000 mg/m3 target
concentration groups for the GD 5–8 interval and in the 20,000 mg/m3
target concentration group at the GD 8-11 interval.  Decreased body
weight changes also occurred for the GD 5-21 and GD 0-21 intervals and
the GD 0-21C interval when corrected for uterine weight in the 10,000
mg/m3 and 20,000 mg/m3 target concentration groups .  Reduced body
weight gain corresponded with statistically significant reduced body
weights at GDs 8, 11, 14, 17, 20, and 21 for the 20,000 mg/m3 target
concentration group.  However, the impact on late gestation body weight
by the statistically significantly reduced gravid uterus weight in
20,000 mg/m3 target concentration group is difficult to determine. 
There were no treatment-related statistically significant differences
for uterine implantation data.  There were statistically significant,
non-dose responsive decreases in the number of corpora lutea in the 2000
and 20,000 mg/m3 target concentration groups.  Since ovulation occurred
prior to exposure to the test substance, these decreases were not due to
the test substance.   There were also corresponding, non-dose responsive
reductions in implantations per litter; these differences were not
statistically significant when covaried by corpora lutea counts.  Fetal
body weight did not differ between groups when analyzed with litter size
as a covariate or with both litter size and fetal sex as covariates;
but, when mean corpora lutea count was an additional covariant along
with litter size and fetal sex, mean fetal body weight was statistically
reduced at 20,000 mg/m3.  Because of the complexity of this analysis and
the confounding of the CL count and because no other statistically
significant differences were noted in the fetal body weights with the
other statistical tests, it is not clear whether exposure to GTVC at
20,000 mg/m3 is directly linked with decreased fetal body weight. 
.There were no treatment-related statistically significant differences
for external and visceral observations.  There were statistically
significant increases in fetuses with skeletal variations and the
incidence of rudimentary lumbar ribs in the 20,000 mg/m3 target
concentration group.  The increase in fetuses with skeletal variations
was due to the incidence of rudimentary lumbar ribs.  As rudimentary
supernumerary ribs are often associated with maternal stress, this
increase may be  related to the reduced food consumption and reduced
body weight changes observed in the dams.  The No Adverse Effect Level
for this study was 2000 mg/m3 for maternal toxicity and 10,000 mg/m3 for
developmental toxicity (conservatively assuming that the minor
developmental effects are adverse).

i

	TABLE OF CONTENTS

   ABSTRACT		i

   TABLE OF CONTENTS		ii

   TITLE PAGE		vi

   APPROVAL SIGNATURES		vii

   PERSONNEL		viii

   QUALITY ASSURANCE STATEMENT 		ix

Section			Page

1.   SUMMARY		1-1

2.   INTRODUCTION		2-1

	STUDY INITIATION		2-1

	EXPERIMENTAL START DATE		2-1

	EXPERIMENTAL TERMINATION DATE		2-1

	INLIFE TEST PERIOD		2-1

	JUSTIFICATION FOR SELECTION OF TEST SYSTEM		2-1

	JUSTIFICATION OF DOSING ROUTE		2-2

	JUSTIFICATION OF DOSE SELECTION		2-2

	COMPLIANCE		2-2

3.   MATERIALS AND METHODS		3-1

	TEST SUBSTANCE		3-1

		Substance Identification		3-1

			Characterization of the Test Substance		3-1

			Analysis of Mixtures		3-2

			Sample Retention		3-2

			Carrier		3-2

		TEST SYSTEM		3-3

			Test Animal		3-3

			Animal Receipt Information		3-3

			Quarantine and Acclimation Period		3-3

			Number and Sex		3-3

			Age at Initiation of Gestation		3-3

			Weight at Initiation of Gestation		3-3

			Animal Identification		3-4

			Selection		3-4

			Feed		3-4

			Water		3-4

			Housing		3-5

			Environmental Conditions		3-5

ii

	TABLE OF CONTENTS (CONT’D)

		EXPERIMENTAL DESIGN		3-7

			Mating		3-7

			Experimental Groups		3-7

			Administration of Test Substance and Exposure Schedule		3-7

			The Chamber		3-7

			The Test Atmosphere		3-8

			Experimental Evaluation		3-8

			Euthanasia and Cesarean Section		3-8

			Examination of fetuses		3-9

			Tissue Preservation		3-9

			Records		3-9

			Statistical Analysis		3-9

4.   RESULTS and CONCLUSION/DISCUSSION		4-1

		CLINICAL INLIFE OBSERVATIONS AND SURVIVAL		4-1

		GESTATION BODY WEIGHT		4-1

		GESTATION FOOD CONSUMPTION		4-2

		GROSS POSTMORTEM OBSERVATIONS		4-2

		UTERINE IMPLANTATION DATA		4-3

		FETAL BODY WEIGHT		4-3

		FETAL OBSERVATIONS		4-4

			External Observations		4-4

			Visceral Observations		4-5

			Skeletal Observations		4-5

		EXPOSURE AND CHAMBER CONDITIONS		4-6

		DISCUSSION		4-8

		PROTOCOL EXCEPTIONS		4-10

5.   LIST OF ABBREVIATIONS		5-1

		STATISTICAL SYMBOLS AND ABBREVIATIONS		5-1

		UTERINE IMPLANTATION DATA ABBREVIATIONS		5-2

		FETAL EXTERNAL AND VISCERAL EXAMINATION

		ABBREVIATIONS		5-2

6.   REFERENCES		6-1

LIST OF TABLES

Table			Page

4-1.   Mean gestation body weight and mean gestation body weight
changeMean Implantation Sites and Corpora Lutea		4-13

4-2.   Mean gestation food consumptionMean Fetal Weight and the Least
Squares Mean Fetal Weight 

	 not Considering CL Count		4-24

4-3.   Mean Fetal Weight and the Least Squares Mean Fetal Weight 

	 Considering CL Count		4-4

4-4.   Percent Incidence of Total Skeletal Variations and Rudimentary
Lumbar Ribs		4-5

4-5.   Mean Exposure Concentrations (Analytical and Nominal)		4-6

4-6.   Summary of Chamber Uniformity		4-6

iii

	TABLE OF CONTENTS (CONT’D)

APPENDIX A

SURVIVAL BAR GRAPH		A-1

APPENDIX B

GESTATION OBSERVATIONS		B-1

APPENDIX C

GESTATION BODY WEIGHT		C-1

APPENDIX D

GESTATION FOOD CONSUMPTION		D-1

APPENDIX E

GROSS POSTMORTEM OBSERVATIONS		E-1

APPENDIX F

UTERINE IMPLANTATION DATA		F-1

APPENDIX G

FETAL BODY WEIGHT		G-1

APPENDIX H

FETAL OBSERVATIONS		H-1

APPENDIX I

INHALATION EXPOSURE DATA		I-1

APPENDIX J

ANALYTICAL CHEMISTRY REPORT		J-1

iv

	TABLE OF CONTENTS (CONT’D)

APPENDIX K

STATISTICIAN’S REPORT		K-1

APPENDIX L

HISTORICAL CONTROL DATA		L-1

APPENDIX M

FEED AND WATER ANALYSES		M-1

v



FINAL REPORT

STUDY NUMBER:  171834

Test Substance: Gasoline WITH TBA Vapor Condensate

(MRD-00-718)

Whole-Body Inhalation Developmental Toxicity Study in Rats

with Gasoline WITH TBA Vapor Condensate (MRD-00-718)

PERFORMED FOR:

AMERICAN PETROLEUM INSTITUTE

1220 L Street Northwest

Washington, D.C. 20005-4070

PERFORMED AT:

EXXONMOBIL BIOMEDICAL SCIENCES, INC.

Laboratory Operations, Mammalian Toxicology Laboratory

1545 Route 22 East, P.O. Box 971

Annandale, New Jersey 08801-0971

STUDY COMPLETION DATE:  TBD

vi

	APPROVAL SIGNATURES

										

D. J. Devlin, Ph.D.						Date	

Director, Toxicology and Environmental Sciences

I hereby accept responsibility for the validity of these data and
declare that to the best of my knowledge, the study contained herein was
performed under my supervision in compliance with the EPA, United States
Environmental Protection Agency, Good Laboratory Practices (GLP)
Standards for Inhalation Exposure Health Effects Testing, 40CFR, Part
79.60, 1994 with the following exceptions.

The storage of the sorbent tubes collected for the detailed capillary/GC
analysis was not documented.  The tubes were stored in the necropsy
freezer after sample collection until they were transferred to the
Analytical Chemistry Group for analysis.

Water and feed analyses were not performed in a GLP compliant
laboratory.  

These minor deviations from the EPA Good Laboratory Practice Standards
had no adverse effect on the integrity or results of the study.

										

G. W. Trimmer, B.A.						Date

Study Director

										

T.M. Gray, M.S., D.A.B.T.					Date

Sponsor

vii

	PERSONNEL

Study Director:						G. W. Trimmer, B.A.

	

Sponsor:							American Petroleum Institute

								1220 L Street Northwest

								Washington, D.C. 20005-4070

Sponsor Representative:					T. M. Gray, M.S., D.A.B.T.

Director, Laboratory Operations

(Study Initiation through October 31, 2004)			J. J. Freeman, Ph.D.,
D.A.B.T.

Laboratory Coordinator (effective November 1, 2004):	G. W. Trimmer, B.
A.

Toxicology and Animal Care Supervisor:			R. C. Forgash, B.S.

Compound Preparation Supervisor:				E. J. Febbo, M.S.

 

Analytical Chemistry Supervisor:				D. J. Letinski, M.S.

Quality Assurance/Archives Section Head

(Study Initiation through February 28, 2005)			W. J. Bover, Ph.D.

Quality Assurance/Archives Supervisor

(effective March 1, 2005):					R. Pristas, M.S.

Veterinarian:							R. L. Harris, D.V.M.

Reproductive Toxicology Consultant:				S. B. Harris, Ph.D.

Statistician:							M. J. Nicolich, Ph.D

Statistician Consultant:					G. Bukhbinder, Ph.D.

viii

DRAFT

												

QUALITY ASSURANCE STATEMENT  PRIVATE  

												

STUDY NUMBER:	171834

TEST SUBSTANCE:	MRD-00-718

STUDY SPONSOR:	American Petroleum Institute

												

Listed below are the inspections performed by the Quality Assurance Unit
of ExxonMobil Biomedical Sciences, Inc., the date(s) of inspection, and
the date(s) findings were reported to the Study Director and Management.

Study Phase 				Date(s) of		  Reported to	   	 Reported to

Inspected				Inspection		Study Director 	Management 

Protocol			05 Nov 01		05 Nov 01			06 Nov 01,

 										06,10 Sep 02

A.M. Viability Check 		10 Sep 02		10 Sep 02			13,16 Sep 02

													

Animal Transfer			17 Sep 02		17 Sep 02			17,19 Sep 02											01 Jul
01

Animal Health/Sanitation/		24 Sep 02		25 Sep 02			27 Sep 02,	

Chamber Cleaning											20 Oct 02

Sample Preparation/Sequence	27 Sep 02,		21 Nov 02			22 Nov 01,	

Setup (Analytical)		21 Nov 02								04 Dec 02

Processing Fetal Skeletons		14-16 Oct 02	16 Oct 02			01,08 Mar 07

First Review of Draft Report		04 Mar – 04 Apr 03	04 Apr 03			01,08 Mar
07

Second and Third Review		16,18,19 Jan 07	15 Feb 07			02,04 Apr 07

of Draft Report; First and 		12,13,15 Feb 07

Second Review of Appendix K;		 

Review Sponsor Comments

Fourth Review of Draft Report;	01 May 08		01 May 08			02 May 08	

Review Sponsor Comments 

Fifth Review of Draft Report	       17 Sep 08		      19 Sep 08		  
23-Sep-08

	 

The final report accurately reflects the methods, procedures and
observations documented in the raw data.

												

			Robert Pristas, M.S.				Date

			Quality Assurance Unit Coordinator

ix



SUMMARY

This study was conducted to evaluate the potential developmental
toxicity of the test substance, Gasoline with TBA Vapor Condensate
(GTVC).  GTVC was administered via whole-body inhalation exposure to
pregnant rats during the period of major organogenesis and fetal growth.
 GTVC was administered by whole-body inhalation exposure to 25
confirmed-mated Crl:CD®(SD)IGSBR female rats at target concentrations
of 0 (air control) 2000, 10,000, and 20,000 mg/m3 for six hours (plus
the theoretical equilibration time) daily from Gestation Day (GD) 5
through GD 20.  The Sponsor selected the exposure levels based upon
safety considerations and previously conducted mammalian toxicity
studies

Clinical observations were made daily during gestation.  Body weight and
food consumption measurements were made on GD 0, 5, 8, 11, 14, 17, 20,
and 21.  On GD 21 animals were sacrificed by CO2 asphyxiation followed
by exsanguination.  The reproductive organs and the abdominal and
thoracic cavities were examined grossly.  Uterine weights with ovaries
attached were recorded.  Uterine contents were examined, and the numbers
of live, dead and resorbed fetuses were recorded.  All fetuses were
weighed, sexed externally, and examined externally for gross
malformations.  Apparent non-gravid uteri were placed in 10% ammonium
sulfide solution for confirmation of non-pregnancy status.

The viscera of approximately one-half of the fetuses of each litter were
examined by fresh dissection.  After these fetuses were examined, they
were decapitated.  The heads were preserved in Bouin's solution for at
least two weeks, rinsed, and subsequently stored in 70% ethanol.  The
fetal heads were sectioned and examined with a dissecting microscope for
the presence of abnormalities.  The remaining fetuses judged to be alive
at the C-section were eviscerated, processed for skeletal staining,
stained for bone and cartilage, and examined for the presence of
skeletal malformations and variations.

There was evidence of maternal toxicity during the first half (GD 5-14)
of the exposure period as indicated by statistically significant
decreases in food consumption at the GD 5-8, GD 8-11, and GD 11-14
intervals for the 10,000 and 20,000 mg/m3 target concentration groups.
The extent of these early decreases in food consumption also produced
statistically significant decreases in food consumption for the GD 5-20
interval in the 10,000 and 20,000 mg/m3 target concentration groups and
for the GD 0-21 interval in the 20,000 mg/m3 target concentration
group.There was evidence of transient maternal toxicity during the first
half (GD 5-14) of the exposure period as indicated by statistically
significant decreases in food consumption at the GD 5-8, GD 8-11, and GD
11-14 intervals for the 10,000 and 20,000 mg/m3 targettarget
concentration groups.  The extent of these decreases also produced
statistically significant decreases in food consumption at the GD 5-20
interval for the 10,000 and 20,000 mg/m3 targettarget concentration
groups and at the GD 0-21 interval for the 20,000 mg/m3 targettarget
concentration group.

Statistically significant dose-responsive decreases in body weight
change also were evident in the 10,000 mg/m3  and 20,000 mg/m3 target
concentration groups for the GD 5–8 interval and in the 20,000 mg/m3
target concentration group at the GD 8-11 interval.  Decreased body
weight changes also occurred for the GD 5-21 and GD 0-21 intervals and
the GD 0-21C interval when corrected for uterine weight in the 10,000
mg/m3 and 20,000 mg/m3 target concentration groups .  Reduced body
weight gain corresponded with statistically significant reduced body
weights at GDs 8, 11, 14, 17, 20, and 21 for the 20,000 mg/m3 target
concentration group.  However, the impact on late gestation body weight
by the statistically significantly reduced gravid uterus weight in
20,000 mg/m3 target concentration group is difficult to determine.  

1-1

SUMMARY (CONT'D)

All dams survived to scheduled terminal sacrifice on GD 21.  At the GD
21 cesarean section two 2000 mg/m3 targettarget concentration animals,
two 10,000 mg/m3 targettarget concentration animals, and one 20,000
mg/m3 targettarget concentration animal were found to be not pregnant
(i.e. no evidence of implantation sites).

All animals were free of clinical or postmortem observations
attributable to treatment with GTVC. 

There were no treatment-related statistically significant differences
between the control and the GTVC treated groups for uterine implantation
data or for external observations, and visceral observations on either a
fetus or litter basis.  There were statistically significant, non-dose
responsive decreases in the number of corpora lutea in the 2000 and
20,000 mg/m3 target concentration groups.  Since ovulation occurred
prior to exposure to the test substance, these decreases were not due to
the test substance.   There were also corresponding, non-dose responsive
reductions in implantations per litter; these differences were not
statistically significant when covaried by corpora lutea counts.  

Fetal body weight did not differ between groups when analyzed with
litter size as a covariate or with both litter size and fetal sex as
covariates; but, when mean corpora lutea count was an additional
covariant along with litter size and fetal sex, mean fetal body weight
was statistically reduced at 20,000 mg/m3.  Because of the complexity of
this analysis and the confounding of the CL count and because no other
statistically significant differences were noted in the fetal body
weights with the other statistical tests, it is not clear whether
exposure to GTVC at 20,000 mg/m3 is directly linked with decreased fetal
body weight.  .

There were no treatment-related statistically significant differences
for external and visceral observations.  The only two fetal observations
that were considered related to treatment were statistically significant
increases in total fetuses with skeletal variations on a fetus basis and
statistically significant increases in rudimentary lumbar ribs on a
fetus basis in the 20,000 mg/m3 target concentration group.  As
rudimentary supernumerary ribs may be associated with maternal stress,
this increase may be related to the reductions in food consumption and
body weight changes observed in the dams.  However, the increased
incidence of these observations was not considered to be biologically
significant as the incidence was not statistically significantly
different on a litter basis (the basis unit of analysis).

In conclusion, administration of gasoline with TBA condensate to rats by
whole-body inhalation exposure during the period of organogenesis and
fetal growth produced transient signs of maternal toxicity during the
early period of dosing at the target concentrations of 10,000 and 20,000
mg/m3 as indicated by decreased food consumption, decreased body weight
change, and reduced body weight, and developmental effects at 20,000
mg/m3.  

Therefore, the No Observable Adverse Effect Level for maternal toxicity
was the target concentration of 2000 mg/m3 and the No Observable Adverse
Effect Level for developmental toxicity in this study was established at
the target concentration of 2010,000 mg/m3.

1-2



INTRODUCTION

This study was conducted to evaluate the developmental toxicity of
Gasoline with TBA Vapor Condensate (MRD-00-718) administered whole-body
inhalation exposure to pregnant rats during the period of major
organogenesis and fetal growth.

This study was conducted for the American Petroleum Institute, 1220 L
Street Northwest, Washington, D.C. 20005-4070 (subsequently referred to
as the Sponsor).

The study was conducted by ExxonMobil Biomedical Sciences, Inc. (EMBSI)
Laboratory Operations, Mammalian Toxicology Laboratory, 1545 Route 22
East, P.O. Box 971, Annandale, New Jersey 08801-0971.  The EMBSI
Mammalian Toxicology Laboratory is accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC
International).

STUDY INITIATION (PROTOCOL SIGNATURE DATE) 

August 23, 2002	

Experimental start date

August 31, 2002

Experimental termination date

November 22, 2002

Inlife Test Period

August 26, 2002 to September 27, 2002

Justification for Selection of Test System

The rat is one of the species required by the EPA for the developmental
toxicity testing requirement of Section 211b of the Clean Air Act (EPA,
1994).

2-1

INTRODUCTION (CONT'D)

Justification of Dosing Route

Exposure by inhalation is a likely route of human exposure.

Justification of Dose Selection

The target high dose of 20,000 mg/m3 was selected based on safety
concerns as one-half of the Lower Explosive Limit.  It was selected to
provide a margin of safety for the laboratory staff yet achieve a high
exposure concentration.  The low dose target (2000 mg/m3) was expected
to produce a No Observable Adverse Effect Level (NOAEL) based on the
results of previous subchronic and developmental studies conducted on
this material, related materials, or some combination thereof.  The mid
dose (10,000 mg/m3) was selected as the approximate mid point between
the low and high doses to produce a dose response relationship, if one
existed in this treatment range.The Sponsor selected the exposure levels
based upon safety considerations and previously conducted mammalian
toxicity studies.

Compliance 

This study was conducted to meet/exceed compliance with the following
standards and requirements:

EPA, United States Environmental Protection Agency, Good Laboratory
Practices (GLP) Standards for Inhalation Exposure Health Effects
Testing. 40 CFR, Part 79.60, 199479.60 CFR Vol. 59, No. 122, 27 June
1994.

EPA, United States Environmental Protection Agency, Vehicle Emissions
Inhalation Exposure Guideline. 40 CFR, Part 79.61, 199479.61.

Animal Welfare Act of 1966 (P.L. 89-544), as amended in 1970, 1976, and
1985.  Code of Federal Regulations, Title 9 [Animals and Animal
Products], Subchapter A - Animal Welfare Parts 1, 2, and 3.

This study was conducted in accord with the following guidelines and
standards:

EPA, United States Environmental Protection Agency, Health Effects Test
Guidelines OPPTS 870.3600 Inhalation Developmental Toxicity Study,
Public Draft, June 1996.

EPA, United States Environmental Protection Agency, Health Effects Test
Guidelines, OPPTS 870.3700, August 1998.

OECD, Organization for Economic Cooperation and Development, Guidelines
for the Testing Chemicals, Proposal for Updating Guideline 414, Jan
2001.

Guide for the Care and Use of Laboratory Animals, Institute of
Laboratory Animal Resources, Commission on Life Sciences, National
Research Council, National Academy Press, Washington, D.C., 1996.

2-2

MATERIALS AND METHODS

TEST SUBSTANCE 

Substance Identification

EMBSI Identification:  	MRD-00-718

Sponsor Identification:	Gasoline with TBA Vapor Condensate

Supplier:			Chevron Research and Technology Company

Lot #:				API 01-07

Description:			Colorless liquid

Storage Condition:		Ambient outdoor conditions under nitrogen

 

Date Received:		Container numbersa: 	Expiration Date:

March 18, 2002		1A (1 b), 2A (1 b), 3A (1 b),

				4A (1 b)			March 18, 2007

	

a - Numbers in () are the Supplier's tank identification numbers

b - Large cylinder number

Characterization of the Test Substance

The stability, identity, strength, purity, and composition or other
characteristics that appropriately identified the test substance was
performed by the testing laboratory (EMBSI).  Documentation is
maintained at ExxonMobil Biomedical Sciences, Inc., Annandale, New
Jersey.  Characterization will be reported as part of EMBSI Study
167490.  Additionally, Appendix J shows the stability of the test
substance over the course of the exposure interval.

The documentation of methods of synthesis, fabrication, and/or
derivation of the test fuel was the responsibility of the Sponsor.  This
was not completed when the study initiated, but is currently with the
Sponsor.

3-1

TEST SUBSTANCE   (CONT'D)

Analysis of Mixtures

Nominal Concentration.  A nominal exposure concentration was calculated
on a daily basis.  The net weight of test substance used was determined
and was divided by the total volume of air passing through the chamber
to give the nominal concentration.

Analytical Concentration.  The concentration of the test atmosphere in
each chamber and the chamber room was determined approximately hourly
during each exposure by on-line gas chromatography.  The chamber
concentrations were measured in the breathing zone of the rats.  A
backup analytical device (calibrated infrared vapor monitor) was also
available.  The hourly chromatographic analyses showed four of the major
components of the test atmosphere and was used to assess the stability
of the test substance over the duration of the study.

Additionally, a sorbent tube sample of the test atmosphere was collected
by drawing a known volume of the test atmosphere from each chamber
through a calibrated critical orifice once during each week of the
study.  These samples were stored in a freezer until after the end of
the exposure phase of the study and then transferred to the analytical
chemistry laboratory.  The samples were desorbed and analyzed by the
detailed capillary/GC method used for the initial characterization
analysis of the liquid test substance. This analysis was done to
determine component proportions of the test material atmosphere compared
to the liquid test material. 

Chamber Homogeneity.  Distribution samples were drawn from twelve
different points within the chamber at each exposure level during the
validation of the exposure system for this study.

Particle Size Analysis.  A particle size determination of the aerosol
portion of the test atmosphere was conducted at least once during the
chamber trials from the 20,000 mg/m3 target concentration.  The sample
was taken using a multistage cascade impactor.  Preweighed glass fiber
filters were used to collect aerosol on each stage, which are associated
with specific cutoff diameters for aerodynamic particle size in microns.
 Since minimal aerosol was present, no further calculations were
performed for the aerodynamic diameter, geometric standard deviation, or
the estimated percents of the aerosol less than or equal to 1, 10, and
15 microns in size.

Sample Retention 

No retention samples were taken due to the practical and safety
considerations of storing a mixed gas/liquid phase substance under
pressure.

Carrier 

Air

3-2

TEST SYSTEM 

Test Animal 

Species:		Rat 

Strain/stock:		Crl:CD®(SD)IGSBR

Supplier:		Charles River Laboratories, Inc.

			Raleigh, North Carolina

Animal Receipt Information (Females)

Receipt Date:				August 13, 2002

Shipping Reference Number:		70258477

Quarantine and Acclimation Period 

13 days; animals were checked for viability at least once daily. 

Number and Sex 

150 sexually mature virgin females

100 females were allocated to study groups after confirmation of mating;
the additional 50 females were ordered to assure there would be 100
mated females and to make the mating as efficient as possible without
exceeding the necropsy capacity of the laboratory.

50 sexually mature males (12 - 13 weeks old at the initiation of mating)
received for mating purposes from a different colony than the females to
assure they were not siblings.  The males were received on August 13,
2002.

Age at Initiation of Gestation (Designated GD 0)

Females:	Approximately 13 weeks 

Weight at Initiation of Gestation (Designated GD 0)

Females:	231 to 295 grams

3-3

TEST SYSTEM   (CONT'D)

Animal Identification

Individual ear tags and corresponding cage identification.   

Selection   

More animals than required for the conduct of the study were purchased
and acclimated.  Animals determined to be unsuitable for inclusion on
this study because of poor health, outlying body weights, or other
abnormalities were excluded from selection by the Study Director, and/or
technical staff.

  

Feed 

Certified Rodent Diet Meal 5002, ad libitum 

Manufacturer:		PMI Nutrition International, LLC (formerly PMI Feeds,
Inc.)

			Richmond, Indiana 

Analysis:		Performed by PMI Nutrition International, LLC.  Copies of the
feed analyses are maintained in the EMBSI Toxicology Laboratory.  The
feed analyses were not conducted by a GLP-compliant laboratory.

Contaminants:	There were no known contaminants in the feed believed to
have been present at levels that may have interfered with this study.  

The availability of feed was checked daily for all animals.  Animals
were without food while in the exposure chambers.

Water 

Automatic watering system, ad libitum

Supplier:		ExxonMobil Research and Engineering Clinton Facility
De-ionized Water System.

Analysis:		Periodic analysis is the responsibility of the testing
laboratory.  A copy of the results is maintained at the testing
laboratory.  The analysis was not performed in a GLP-compliant
laboratory.

Contaminants:	There were no known contaminants in the water believed to
have been present at levels that may have interfered with this study.  

The availability of water was checked daily for all animals.  Animals
were without water while in the exposure chambers.

3-4

TEST SYSTEM (CONT'D)

Housing 

Room Number:	PE103

Chamber rooms:	PE102, PE110

Housing:		Single housed during the study period, except during mating.

Caging:		Suspended stainless steel and wire mesh with absorbent paper
below cages. 

Environmental Conditions

Animal Room

Temperature:		67.1 to 73.7 degrees Fahrenheit  

Humidity:		34.7 to 66.7 percent relative humidity

Lighting:		Approximately 12 hours light (0600 to 1800 hours) and 12
hours dark (1800 to 0600 hours) by automatic timer.  

Temperature was monitored at least twice daily and humidity was
monitored at least once daily.  Additionally, a non-validated
computerized system monitored the temperature, humidity, and lighting
continuously for alarm purposes.

Chambers

Temperature:		66 to 78 degrees Fahrenheit (see Protocol Exceptions and
Appendix I) 

Humidity:		45 to 95 percent relative humidity (see Protocol Exceptions
and Appendix I)   

Temperature and humidity were monitored continuously and recorded
approximately every 30 minutes during the exposure.

Light Intensity

Animal Room Light Intensity:	7.31 to 11.8 foot-candles

Chamber Room Light Intensity:	31.2 to 43.7 foot-candles

Light intensity was measured three times during the study (the first day
of exposures, during the second week of exposures and the last day of
exposures) in both the animal room and the chamber room.  Light
intensity was measured in the animal room in a cage approximately three
feet above the floor level.  In the chamber room the light intensity was
measured three feet above floor level in the approximate center of each
generation room.

3-5

TEST SYSTEM (CONT'D)

Environmental Conditions (cont’d)

Chamber Noise Levels and Oxygen Levels

Noise Level:		70.8 to 82.9 db

Oxygen Level:	20.5 to 20.7%

The oxygen level and the noise level were measured in each exposure
chamber on the first day of exposures, during the second week of
exposures and on the last day of exposures.

3-6

EXPERIMENTAL DESIGN

Mating

On the initial scheduled mating day, females were placed in males' cages
in a 1:1 (male:female) ratio.  Males and females were paired based on
sequential Physical Identification Numbers.  A sufficient number of
animals were co-housed in an attempt to produce an acceptable number of
mated animals to accommodate lab scheduling.  Mating was confirmed on
the following morning by observation of a copulatory plug (vaginal). 
The day on which mating was confirmed was considered Day 0 of gestation
(GD 0).  After confirmation of mating, each mated female was returned to
its own cage.  New females then were placed in the males' cages until
the required number of mated females was obtained by continuous
cohabitation in consideration of lab scheduling.  Mated females
subsequently were assigned to dose groups by a computer generated body
weight sorting program (WEIGHT) using the GD 0 body weights to ensure
mean body weight was similar between all groups on GD 0.

Experimental Groups

Group

Number	Number of Females per Group	Target Dose

(mg/m3)

1. 	(Carrier Control)	25	 0

2. 	Low 	25	2000

3	. Intermediate 	25	10,000

4	. High	25	20,000

Administration of Test Substance and Exposure Schedule

The experimental and control animals were placed (whole body) into 1.0
M3inhalation chambers that were operated under dynamic conditions. The
exposure period was at least 6 hours per day. The test substance
atmosphere generation system was started after the last animal was
placed in the exposure chambers and the generation system was stopped
six hours later.  The animals remained in the chambers for at least an
additional 23 minutes (theoretical equilibration time) while the test
atmosphere cleared.  The animals were exposed from GD 5 through GD 20.

The Chamber

The chambers used for exposure are stainless steel and glass and have a
total volume of approximately 1.0 M3.  They operated at a flow rate
(approximately 12 air changes/hour) sufficient to ensure timely
equilibration.  The flow of air through each chamber was monitored
continuously using a calibrated flow measuring device and recorded
approximately every 30 minutes.  All chambers were maintained at a
slight negative pressure.  The pressure was monitored continuously and
recorded approximately every 30 minutes.

3-7

EXPERIMENTAL DESIGN   (CONT'D)

The Test Atmosphere

The control group was exposed to clean filtered air under conditions
identical to those used for groups exposed to the test substance.  The
test substance was administered fully vaporized in the breathing air of
the animals.  The test atmosphere composition and concentration remained
constant at each exposure level over the daily six-hour period. The
daily mean exposure concentrations were within + 10% of the target
exposure levels with the exceptions listed in the Protocol Exceptions
section. 

Experimental Evaluation

Animals were examined for viability at least twice daily during the
study.  Body weights were taken prior to selection, and on GD 0, 5, 8,
11, 14, 17, 20, and 21.  Food consumption was measured for mated females
on GD 5, 8, 11, 14, 17, 20, and 21.  A clinical examination was given to
each female prior to selection, and daily during gestation. 
Additionally, group observations of the animals for mortality and
obvious toxic signs while in the chambers were recorded at 15, 30, 45,
and 60 minutes after initiation of the exposure and then hourly during
each exposure.

Euthanasia and Cesarean Section

Euthanasia of the dams was by CO2 asphyxiation followed by
exsanguination.  A gross necropsy was performed on all confirmed-mated
females.

The fetuses were placed in a refrigerator to slow down and eventually
terminate vital signs after the external examination and weighing.  

Mated females were euthanized on GD 21.  Body weights were recorded on
the day of necropsy. Uterine weights with ovaries attached were recorded
at the time of necropsy.  Uterine contents were examined and the numbers
and locations of implantation sites, early and late resorptions, live
and dead (alive or dead in utero) fetuses were counted.  Corpora lutea
also were counted.  The uteri of all apparently non-pregnant females
were stained with 10% ammonium sulfide to confirm pregnancy status.

Evaluations of dams during cesarean section and subsequent fetal
evaluations were conducted without knowledge of treatment group in order
to minimize bias.

3-8

EXPERIMENTAL DESIGN   (CONT'D)

Examination of Fetuses

Each fetus was weighed and examined externally for gross malformations
and variations.  Fetal sex was determined by external examination and
confirmed internally only on those fetuses receiving visceral
examinations.

The viscera of approximately one-half of the fetuses of each litter were
examined by fresh dissection (Staples, 1974; Stuckhardt and Poppe,
1984).  After these fetuses were examined, they were decapitated.  The
heads were preserved in Bouin’s solution for at least two weeks, then
rinsed and subsequently stored in 70% ethanol.  Free-hand razor blade
sections of the Bouin’s-fixed fetal heads were examined for the
presence of abnormalities.  The remaining liver fetuses (alive in utero)
were eviscerated, processed by double staining with Alizarin red and
Alcian blue, and examined for the presence of bone and cartilage
malformations and ossification variations.

Fetal evaluations were conducted without knowledge of treatment group in
order to minimize bias.The Test Atmosphere

The control group was exposed to clean filtered air under conditions
identical to those used for groups exposed to the test substance.  The
test substance was administered fully vaporized in the breathing air of
the animals.  The test atmosphere composition and concentration remained
constant at each exposure level over the daily six-hour period. The
daily mean exposure concentrations were within + 10% of the target
exposure levels. 

Experimental Evaluation

Animals were examined for viability at least twice daily during the
study.  Body weights were taken prior to selection, and on GD 0, 5, 8,
11, 14, 17, 20, and 21.  Food consumption was measured for mated females
on GD 5, 8, 11, 14, 17, 20, and 21. A clinical examination was given to
each female prior to selection, and daily during gestation. 
Additionally, group observations of the animals for mortality and
obvious toxic signs while in the chambers were recorded at 15, 30, 45,
and 60 minutes after initiation of the exposure and then hourly during
each exposure.

Euthanasia and Cesarean Section

Euthanasia of the dams was by CO2 asphyxiation followed by
exsanguination.  A gross necropsy was performed on all confirmed-mated
females.

The fetuses were euthanized by hypothermia after the external
examination and weighing.  

Mated females were euthanized on GD 18.  Body weights were recorded on
the day of necropsy. Uterine weights with ovaries attached were recorded
at the time of necropsy.  Uterine contents were examined and the numbers
and locations of implantation sites, early and late resorptions, live
and dead (alive or dead in utero) fetuses were counted.  Corpora lutea
also were counted.  The uteri of all apparently non-pregnant females
were stained to confirm pregnancy status.

Evaluations of dams during cesarean section and subsequent fetal
evaluations were conducted without knowledge of treatment group in order
to minimize bias.

Examination of Fetuses

Each live fetus (alive in utero) was weighed and examined externally for
gross malformations.  Fetal sex was determined by external examination
and confirmed internally only on those fetuses receiving visceral
examinations.

EXPERIMENTAL DESIGN   (CONT'D)

Examination of Fetuses (cont'd)

Prior to visceral examinations any live fetuses were euthanized by a
subcutaneous injection with sodium pentobarbital.  The viscera of
approximately one-half of the live fetuses (alive in utero) of each
litter were examined by fresh dissection (Staples, 1974; Stuckhardt and
Poppe, 1984).  After these fetuses were examined, they were decapitated.
 The heads were preserved in Bouin's solution for at least two weeks,
then rinsed and subsequently stored in 70% ethanol.  Free-hand razor
blade sections of the Bouin's-fixed fetal heads were examined for the
presence of abnormalities.  The remaining live fetuses (alive in utero)
were eviscerated, processed by double staining with Alizarin red and
Alcian blue, and examined for the presence of bone and cartilage
malformations and ossification variations. 

Fetal evaluations were conducted without knowledge of treatment group in
order to minimize bias.

Tissue Preservation

Fetal heads were fixed in Bouin's solution and then preserved in
ethanol.  The fetal skeletons were preserved in glycerine with thymol
after they were processed and stained.

Records

A copy of the protocol, final report, raw data, computer generated
listings of raw data, supporting documentation, and tissue specimens
were maintained in the EMBSI Toxicology Laboratory Archives until they
were returned to the Sponsor’s archives.

Statistical Analysis 

Statistical evaluation of equality of means was done by an appropriate
one way analysis of variance and a test for ordered response in the dose
groups.  First, Bartlett's Test was performed to determine if the dose
groups had equal variance (Snedecor and Cochran, 1989).  If the
variances were equivalent, the hypothesis that there was no difference
in response between the groups was tested using a standard one-way
analysis of variance (Snedecor and Cochran, 1989).  If the variances
were equal, the testing was done using parametric methods, otherwise
nonparametric techniques were used.  

Continuous data was tested for statistical significance as follows: 
Where applicable, percentages were calculated and transformed by
Cochran's transformation, followed by the arc sine transformation
(Snedecor and Cochran, 1989).  The raw percentages and the transformed
percentages both were tested for statistical significance.  

3-9

EXPERIMENTAL DESIGN (CONT'D)

Statistical Analysis (Cont'd)

For the parametric procedures, a standard one way ANOVA using the F
distribution to assess significance was used (Snedecor and Cochran,
1989).  If significant differences among the means were indicated,
Dunnett's Test was used to determine which treatment groups differed
significantly from control (Dunnett, 1964).  In addition to the ANOVA, a
standard regression analysis for linear response in the dose groups was
performed.  The regression also tested for linear lack of fit in the
model.

For the nonparametric procedures, the test of equality of means was
performed using the Kruskal-Wallis Test (Hollander and Wolfe, 1973).  If
significant differences among the means were indicated, Dunn's Summed
Rank Test was used to determine which treatment groups differed
significantly from the control (Hollander and Wolfe, 1973).  In addition
to the Kruskal-Wallis Test, Jonckheere's Test for monotonic trend in the
dose response was performed.  

Bartlett's Test for equal variance was conducted at the 1% level of
significance.  All other tests were conducted at the 5% and 1% level of
significance.  However, the 5% level of significance was considered
statistically significant for these analyses.  The 1% level of
significance was reported as additional information.

The following data wasere not included in the statistical analyses:

Gestation body weight and body weight change data for females that were
not pregnant

Gestation food consumption for females that were not pregnant

Means and standard deviations were calculated for animal, exposure and
chamber environmental data.  The coefficient of variation also was
calculated when considered relevant for the exposure  data.

Fetal body weight was analyzed by a mixed model analysis of variance
that provided an accurate statistical model of the biology.  The
analysis used the litter as the basis for analysis and effectively used
the litter size as a covariate.  Two alternative models were used: one
model considered exposure group, litter size and fetal sex as
explanatory variables while the other model used these variables and
included the corpora lutea (CL) as an additional covariate.  The model
considered dose group, litter size, and fetal sex as explanatory
variables.  If the overall effect of dose, or the dose by sex effect,
was statistically significant the dose groups means were tested pairwise
vs. the control group using least squares means.  The least squares
means allowed comparisons that accounted for differences in litter size
and sex.  The mathematical model was based on a paper by Chen, et al
(1996).  The analysis was run using SAS with code suggested in Little,
et al (1997).  

3-10

EXPERIMENTAL DESIGN (CONT'D)

Statistical Analysis (Cont'd)

The number of implants per dam, the litter size per dam, and the dam
uterine weight were analyzed by a standard analysis of variance with CL
as a covariate.  When the overall effect of exposure, or the
interactions of exposure with CL, was statistically significant the
exposure groups’ means were tested pairwise vs. the control group
using least squares means (Snedecor and Cochran, 1989).

The analysis of anomalies (malformations or variations) was based on a
Generalized Estimating Equation (GEE) application of the linearized
model, Ryan (1992).  The model used the litter as the basis for analysis
and considered correlation among littermates by incorporating an
estimated constant correlation and the litter size as a covariate.  If
the overall effect of dose, or the dose by sex effect, was statistically
significant the dose groups were tested pairwise vs. the control group
using least squares means.  The least squares means allowed comparisons
that accounted for differences in litter size.  Three categories of
anomalies were tested, and within each category specific anomalies also
were tested.  In addition to the category specific anomalies a series of
combined analyses were performed within each category as applicable: 

Combined Malformations and Variations for All Fetuses

Combined Malformations and Variations for Alive Fetuses

Combined Malformations and Variations for Dead Fetuses 

Malformations for All Fetuses

Malformations for Alive Fetuses

Malformations for Dead Fetuses

Variations for All Fetuses

Variations for Alive Fetuses

	Variations for Dead Fetuses

	Combined – Delayed Ossification of the Sternabrae
(hypoplastic/unossified)

	Combined – Hypoplastic Vertebral Centra (bifid/dumbbell-shaped)

3-11



RESULTS AND CONCLUSIONS/DISCUSSION

CLINICAL INLIFE OBSERVATIONS AND SURVIVAL 

Survival Bar Graph:  Appendix A

Incidence of Gestation Observations:  Appendix B

Individual Gestation Observations:  Appendix B

All dams survived to scheduled terminal sacrifice on GD 21.  At the GD
21 cesarean section two 2000 mg/m3 target concentration animals, two
10,000 mg/m3 target concentration animals, and one 20,000 mg/m3 target
concentration animal were found to be not pregnant (i.e. no evidence of
implantation sites). 

There were no clinical signs indicative of maternal toxicity.  All dams
in all dose groups were free of observable abnormalities during the
entire gestation period. 

GESTATION BODY WEIGHT

Mean Gestation Body Weight and Body Weight Change:  Appendix C

Individual Gestation Body Weight and Body Weight Change:  Appendix C

Statistician’s Report:  Appendix K

Maternal toxicity was evident as statistically significant differences
in mean gestation body weight and mean gestation body weight change in
the 20,000 mg/m3 target concentration group and the mean gestation body
weight change in the 10,000 mg/m3 target concentration group. 
Statistically significant decreases in body weight change were evident
in the 10,000 mg/m3 and 20,000 mg/m3 target concentration groups for the
GD 5–8 interval and in the 20,000 mg/m3 target concentration group for
the GD 8-11 interval.  The extent of these decreases also produced
statistically significant decreased body weight change for the GD 5-21
and GD 0-21 intervals for the 10,000 and 20,000 mg/m3 target
concentration groups.  The reduced body weight gain also produced
statistically significant reduced body weights at GDs 8, 11, 14, 17, 20,
and 21 for the 20,000 mg/m3 target concentration group.  These changes
appear related to reduced food consumption during the same intervals. 
However, the effect on late gestation body weight by the statistically
significantly reduced gravid uterus weight in 20,000 mg/m3 target
concentration group is difficult to determine.  Additionally, linear
trends of decreasing mean body weight were detected in the treatment
groups for GD 8, GD 11, GD 14, GD 17, GD 20, and GD 21 as well as the GD
21 weights corrected for the uterine weights (GD 21C).  Linear trends or
ordered responses to dose of decreasing mean body weight change also
were detected in the treatment groups for the GD 5-8, GD8-11, GD 17-20,
GD 5-21, GD 0-21, and GD 0 -21C intervals.  Additional analyses were
conducted on the uterine weight data that included CL (corpora lutea)
count and a CL count by exposure interaction and indicated a
statistically significant decrease in the mean uterine weight in the
20,000 mg/m3 target exposure group when analyzed with a CL count by
exposure interaction.

4-1

 GESTATION FOOD CONSUMPTION

Mean Gestation Food Consumption:  Appendix D

Individual Gestation Food Consumption:  Appendix D

There was evidence of transient maternal toxicity during the first half
(GD 5-14) of the exposure period as indicated by statistically
significant decreases in food consumption at the GD 5-8, GD 8-11, and GD
11-14 intervals for the 10,000 and 20,000 mg/m3 target concentration
groups.  The extent of these decreases also produced statistically
significant decreases in food consumption at the GD 5-20 interval for
the 10,000 and 20,000 mg/m3 target concentration groups and at the GD
0-21 interval for the 20,000 mg/m3 target concentration group. 
Statistically significant decreases in food consumption were evident in
the 10,000 and 20,000 mg/m3 target groups for several intervals (see
Table 4-2 for affected intervals and values).  These decreases produced
the changes that were notedgenerally coincided with the  previously
noted decreases in body weight and body weight change.  Additionally,
linear trends or ordered responses to dose of decreasing mean food
consumption were detected in the treatment groups for the GD 5-8, GD
8-11, GD 11-14, GD 5-20, and GD 0-21 intervals.  There were no effects
on gestation food consumption for the 2000 mg/m3 target concentration
group.

GROSS POSTMORTEM OBSERVATIONS

Incidence of Gross Postmortem Observations:  Appendix E

Individual Gross Postmortem Observations:  Appendix E

The gross postmortem examination of the dams revealed a uterus that
exuded thin brown liquid for one 2000 mg/m3 target concentration dam and
dilated renal pelves and a calculus in the bladder for one 10,000 mg/m3
target concentration dam.  All other dams were free of grossly
observable abnormalities.

4-2

UTERINE IMPLANTATION DATA

Mean Uterine Implantation Data:  Appendix F

Individual Uterine Implantation Data:  Appendix F

Statistician’s Report:  Appendix K

The uterine implantation data revealed a statistically significant
decrease in the number of live male fetuses, implantation sites, and
corpora lutea in the 2000 mg/m3 target concentration group.  There also
was a statistically significant decrease in the number of corpora lutea
in the 20,000 mg/m3 group.  The values and level of statistical
significance are presented in Table 4-13. The mean number of corpora
lutea was one – two less per litter than observed in the control
group.  These decreases were not considered related to treatment as
ovulation,  and fertilization and implantation occuredoccurred prior to
exposure to the test substance.  The difference in mean number of
corpora lutea per litter alone is sufficient to explain the difference
in the mean number of implantations which occurred at the 2000 mg/m3
target concentration group.  and., tThere were no statistically
significant decreases in the number of live fetuses or increases in the
number of resorptions or dead fetuses.  Additionally, tThe statistical
analyses indicated an ordered response to dose in the treatment groups
for the number of implantation sites and the number of corpora lutea
(increasing trend for both).  

Table 4-1 - Mean Implantation Sites and Corpora Lutea

Target	Implantation sites	Corpora lutea

0 mg/m3	15.68	16.32

2000 mg/m3	13.30*	14.04*

10,000 mg/m3	14.61	14.91

20,000 mg/m3	14.71	15.13*

			* - p( 0.05

FETAL BODY WEIGHT

Mean Fetal Body Weight:  Appendix G

Individual Fetal Body Weight:  Appendix G

Mean Fetal Body Weight:  Appendix G

Individual Fetal Body Weight:  Appendix G

Statistician’s Report:  Appendix K

There were no statistically significant differences in mean fetal body
weight in either sex of any group when analyzed with litter size as a
covariate and without allowing for CL count interaction.  When the fetal
weight data wasere analyzed using an exposure by CL count interaction,
the mean fetal weights for the 20,000 mg/m3 target exposure group were
statistically significantly lower than the control group.  However,
because of the complexities of the analyses, it is not clear that the
difference is directly linked with exposure.  The mean fetal weights are
presented in Table 4-1 and Table 4-2.  Table 4-1 shows the mean fetal
weight analysis without CL count interaction..

4-3

FETAL BODY WEIGHT (CONT’D)

Table 4-2

Mean Fetal Weight, the Least Squares Mean Fetal Weight not Considering
CL Count

Exposure Group

(mg/m3)	n litters 	n fetuses	observed fetus mean (gm)	Least squares
fetus mean (gm)

0	25	385	5.29	5.32

2,000	23	302	5.33	5.29

10,000	23	327	5.29	5.29

20,000	24	345	5.13	 5.16

The bodyweight analysis that included CL count and a CL by exposure
interaction indicated a statistically significant difference in the mean
fetal litter weights among the exposure groups and an exposure by CL
count interaction (p<0.0025 and p<0.0005 respectively); the 20,000 mg/m3
exposure group was different from the 0 exposure group (p<0.02).  When
the model as fit without the exposure by CL count interaction there was
not a significant difference in fetal weights among the exposure groups
(p<0.14).  Table 4-2 shows the mean fetal weight and the least squares
mean fetal weight with CL count interaction.  

Table 4-3

Mean Fetal Weight, the Least Squares Mean Fetal Weight Considering CL
Count

Exposure Group

(mg/m3)	n litters 	n fetuses	n CL	observed fetus mean (gm)	Least squares
fetus mean (gm)

with CL*exposure	Least squares fetus mean (gm)

without CL*exposure

0	25	385	16.3	5.29	5.31	5.31

2,000	23	302	14.0	5.33	5.36	5.30

10,000	23	327	14.9	5.29	5.26 	5.29

20,000	24	345	15.1	5.13	 5.15 *	5.16

               * statistically significantly different from control,
p<0.02

FETAL OBSERVATIONS

Incidence of Fetal Observations:  Appendix H

Individual Fetal Observations:  Appendix H

Statistician’s Report:  Appendix K

There were no statistically significant differences between the control
and the treated groups for external and visceral variations and
malformations.  

External Observations

The external observations were limited to single or low incidences of
stunted fetuses, edema of the head, malrotated hindpaw and protruding
tongue.  Single incidences of adactyly, cleft palate, ectrodactyly,
hooked tail, microcephaly, and short tail were evident for Fetus 3 of
Dam IGL911.  

4-4

FETAL OBSERVATIONS (CONT'D)

Visceral Observations

Visceral observations were minimal and were limited to low incidences of
umbilical artery arises from left side of the bladder and single
incidences of malpositioned kidney and retinal fold.  

Skeletal Observations

There were two statistically significant differences between the control
and treated groups for the incidence of skeletal observations:  

A statistically significant increase in the incidence of rudimentary
lumbar ribs in the 20,000 mg/m3 target concentration group that produced
a statistically significant increase in total fetuses with skeletal
variations in the 20,000 mg/m3 target concentration group.  

The incidence of these findings and the historical control range for
this parameter are presented in Table 4-234.  The historical control
data shows that wWhile the incidence of total skeletal variations is
statistically significantly increased when compared to the concurrent
study control, it is only slightly greater than the upper end of the
historical control range.  However, the increase in rudimentary lumbar
ribs was not considered indicative of developmental toxicity due to the
absence of other conventional signs of embryo toxicity, i.e.
malformations, embryo lethality, or fetal weight reduction.  As
rudimentary supernumerary ribs are oftenmay be associated with maternal
stress, this increase is considered may be related to the reduced food
consumption and reduced body weight changes.  The biological and
developmental toxicological significance of the rudimentary
supernumerary ribs are discussed further in the Discussion.The increase
in total fetuses with skeletal variations in the 20,000 mg/m3 target
group was not considered biologically significant because the incidence
was not statistically significant on a litter basis (the basis unit of
analysis).

Table 4-244 - Percent Incidence of Total Skeletal Variations and
Rudimentary Lumbar Ribs*

Observation	Target   0 mg/m3	Target   2000 mg/m3	Target   10,000 mg/m3
Target   20,000 mg/m3

Fetuses with skeletal variations	12.4	13.6	9.1	22.4

Litters with skeletal variations	60	56.5	56.5	83.3

Historical control range of fetuses with skeletal variations 	5.1 - 21.6

Historical control range of litters with skeletal variations	28.0 - 76

Fetuses with rudimentary lumbar ribs 	8.3	7.1	4.8	17.1

Litters with rudimentary lumbar ribs	48.0	34.8	30.4	66.7

Historical control range – Fetuses with rudimentary lumbar ribs	1.7 -
9.7

Historical control range – Litters with rudimentary lumbar ribs 	12.5
- 40.0

* - (number of fetuses with observation/total number of fetuses
observed) x 100

4-5

FETAL OBSERVATIONS (CONT'D)

Skeletal Observations (cont'd)

The other skeletal findings included dumbbell shaped thoracic vertebral
anlage, and low incidences of unossified sternebrae, asymmetric
sternebrae, hypoplastic sternebrae, short last thoracic rib, bifid
thoracic vertebral centra, and malformed lumbar vertebral arch.  Single
incidences of bifid sternebrae, extra presacral vertebrae, malformed
sacral vertebral arch, multiple malformed skull bones, fused sternebrae,
multiple absent forepaw bones, multiple absent hindpaw bones, multiple
malformed ribs, multiple malformed vertebrae, and fused ribs also were
observed.

EXPOSURE DATA AND CHAMBER CONDITIONS

Summary of Exposure Data:  Appendix I

Analytical Chemistry Report:  Appendix J

	

The range of chamber concentrations for the exposure period as
represented by the daily mean analytical data and nominal data of each
day are listed in Table 4-5:

Table 4-5 - Mean Exposure Concentrations (Analytical and Nominal)

Target 	2000 mg/m3	10,000 mg/m3	20,000 mg/m3

	Analytical	Nominal	Analytical	Nominal	Analytical	Nominal

Mean	2020	1874	10395	9883	20777	18549

S.D.	105.6	118.6	228.5	233.5	394.0	454.3

Minimum	1717	1683	9985	8976	19881	17335

Maximum	2144	2094	10882	10169	21534	19475

	S.D. - Standard deviation

Satisfactory chamber uniformity was observed for the 12 points in the
chamber that were analyzed.  The range of  concentrations for each
chamber are listed in Table 4-6.

Table 4-6 - Summary of Chamber Uniformity

Target 	2000 mg/m3	10,000 mg/m3	20,000 mg/m3

Mean	1968	10362	20828

S.D.	47.3	370.4	433

CV (%)	2.4	3.6	2.1

Minimum	1910	9845	20415

Maximum	2038	10972	21990

	S.D. - Standard deviation

	CV - Coefficient of variation

The particle size determination for the control chamber and 20,000 mg/m3
target concentration chamber detected particles at a level of 0.5 mg/m3
for each chamber.  These particles were judged to be ambient background
particles (e.g. animal dander) and not from the generation of the test
substance.

4-6

EXPOSURE DATA AND CHAMBER CONDITIONS

The relative distribution of hydrocarbons and oxygenate measured on the
chamber characterization charcoal tubes that were collected each week of
the exposures was in good agreement with that measured in the
characterization of neat MRD-00-718 test substance. 

The oxygen levels in the chambers ranged from 20.5 to 20.7% at the
intervals when they were monitored.  The noise level in the chambers
ranged from 70.8 to 82.9 db.  The light intensity in the chamber room
ranged from 31.2 foot-candles to 43.7 foot candles.

4-7

DISCUSSION

There were slight signs of maternal toxicity that appeared to be
transient, based on the body weight change data and the food consumption
data.  The food consumption data indicated that maternal toxicity was
evidenta statistically significant decrease from GD 5 through GD 14 in
the 10,000 and 20,000 mg/m3 targettarget concentration groups.  The body
weight change data for these groups correlated well withreflected the
reduced food consumption data for the GD 5-8 interval with statistically
significant reductions.  However, the body weight change data only shows
a statistically significant decrease for the 20,000 mg/m3 targettarget
concentration group at the GD 8-11 interval and no statistical
significance in any group at the GD 11-14 interval.  After GD 14 the
food consumption and body weight change data were essentially the same
as the control values, thus indicating that the animals had adapted to
exposure to the test substance.  However, the mean body weights of the
10,000 and 20,000 mg/m3 targettarget concentration groups continued to
be depressed after GD 14 when compared to the control group due to the
toxicity during GD 5 - 14.

There also were decreases in body weight, body weight change, and food
consumption in the 2000 mg/m3 targettarget concentration group that were
not statistically significant.  The decreases in body weight, body
weight change, and food consumption were considered due to the reduced
number of fetuses in the 2000 mg/m3group.  The mean uterine weight, the
mean GD21 body weight corrected for the uterine weight, and the mean
fetal body weight of the 2000 mg/m3 targettarget concentration group
support this conclusion.  Additionally, the number of fetuses were not
reduced due to maternal or fetal toxicity, but rather due to the number
oocytes produced, fertilized, and implanted prior to exposure to the
test substance.  The implantation data for the 2000 mg/m3 targettarget
concentration group is are discussed later in this sectionbelow.

There were no treatment-related statistically significant differences
for uterine implantation data.  There was a statistically significant
decrease in the number of male fetuses in the 2000 mg/m3 target
concentration group.  However, this decrease was considered spurious as
decreases in male fetuses were not evident in the 10,000 and 20,000
mg/m3 target concentration groups and there was no increase in the
number of dead or resorbed fetuses in the 2000 mg/m3 target
concentration group that could account for this decrease.  There also
were decreases in the number of corpora lutea and implantation sites in
the 2000 mg/m3 target concentration group and corpora lutea in the
20,000 mg/m3 target concentration group.  However, these decreases were
not considered treatment related as the number of corpora lutea was set
at ovulation and the subsequent fertilization of the oocytes.  Both
ovulation and fertilization occurred prior to exposure of the animals to
the test substance.  The number of implantation sites is determined by
the number of corpora lutea minus any pre-implantation loss of
fertilized oocytes.  As the exposure to the test substance began after
implantation, the number of implantation sites would not be affected by
exposure to the test substance.  Additionally, the pre-implantation loss
for the 2000 mg/m3 target concentration group was not statistically
significantly different from the control group and was well within the
historical control range of the laboratory.  As the exposures to the
test substance began after the number of corporal lutea and implantation
sites were set, the decreases in these parameters were not related to
treatment.

4-8

DISCUSSION (CONT’D)

The fetal body weight data wasere subjected to three different
statistical analyses.  First the data were analyzed by a mixed model
analysis of variance that provides an accurate statistical model of the
biology.  The analysis used the litter as the basis for analysis and
effectively used the litter size as a covariate.  Two alternative models
were used: one model considered exposure group, litter size, and fetal
sex as explanatory variables while the other model used these variables
and included the corpora lutea (CL) as an additional covariate.  The
analyses with the CL by exposure interaction revealed that the fetal
body weights were statistically significantly different from the control
group in the 20,000 mg/m3 exposure group.  However, because of the
complexity of this analysis and the confounding of the CL count it is
not clear that exposure is directly linked with the decreased weights. 
No other statistically significant differences were noted in the fetal
body weights with this test or the other statistical tests.

There were two related fetal observations that appeared related to
treatmentwere statistically significantly different from the control.. 
The first observation was an increased incidence of total fetuses with
skeletal variations in the 20,000 mg/m3 targettarget concentration group
on a fetus basis.  The historical control data shows that wWhile the
incidence of total skeletal variations is statistically significantly
increased when compared to the concurrent study control, it is only
slightly greater than the upper end of the historical control range. 
The increase in total fetuses with skeletal variations in the 20,000
mg/m3 targettarget concentration group was not considered biologically
significant because the incidence was not statistically significant on a
litter basis (the basis unit of analysis).caused by the increased
incidence of rudimentary lumbar ribs which is discussed next.  

The second observation was an increased incidence of rudimentary lumbar
ribs in the 20,000 mg/m3 target concentration group.  These increased
incidences were not within the historical control range for this
laboratory.  Increases in skeletal variations such as rudimentary ribs
are common and often reversible, and it is not clear they represent an
adverse effect (Harris and DeSesso, 1994; Kimmel and Wilson, 1973;
Khera, 1981).  Furthermore, rudimentary ribs are frequently  considered
to be of low concern in the absence of other conventional signs of
embryo toxicity, i.e. malformations, embryo lethality, or fetal weight
reduction (Aliverti et al., 1979; Khera, 1981; Holson et al., 1976). 
Rudimentary ribs have been associated with maternal toxicity or stress
(Harris and DeSesso, 1994; Kimmel and Wilson, 1973).  Therefore, the
developmental significance of rudimentary ribs in the high dose fetuses
may relate to the maternal toxicity observed in the 20,000 mg/m3 target
concentration group during the early portion of the exposure phase of
this study.  

There were no treatment-related statistically significant differences
for external observations, and visceral observations in the fetuses on
either a fetus or litter basis. Additionally, there were no
statistically significant differences in the fetal body weights of
either sex.

In conclusion, administration of gasoline with TBA condensate to rats by
whole-body inhalation exposure during the period of organogenesis and
fetal growth at target concentrations of 10,000 and 20,000 mg/m3 caused
maternal toxicity as indicated by decreased food consumption, decreased
body weight, and decreased body weight change.

Therefore, the No Observable Adverse Effect Level for maternal toxicity
was 2000 mg/m3 target concentration and the No Observable Adverse Effect
Level for developmental toxicity in this study was established at the
target concentration of 2010,000 mg/m3 (conservatively assuming that the
minor developmental effects are adverse).

4-9

PROTOCOL EXCEPTIONS

MEAN CHAMBER CONCENTRATION:  The mean chamber concentration for the 2000
mg/m3 target treatment group chamber was 1717 mg/m3 on September 1,
2002.  The mean chamber concentration for the 2000 mg/m3 target
treatment group chamber was 1738 mg/m3 on September 17, 2002.  These
deviations were due to problems with the rotometer.  Additionally, on
September 16, 2002 the 3-hour concentration was 673 mg/m3.  However,
this low concentration did not reduce the mean chamber concentration
below the acceptable range.  This low concentration probably was due to
the same problem with the rotometer that occurred again on September 17,
2002. 

CHAMBER TEMPERATURE AND HUMIDITY:  Due to the method used to generate
the test substance atmospheres, the chamber-room air was kept as cool as
possible to keep the temperature in the 10,000 mg/m3 and the 20,000
mg/m3 target concentration chambers from exceeding the protocol-defined
range. The cooler room air resulted in numerous instances of the mean
temperature and humidity in the control chamber being outside the
protocol-defined range.  The decreased temperature also caused the
temperature and humidity in the chambers to be outside the
protocol-defined range on numerous occasions.    The individual
temperature and humidity deviations are noted in Appendix I as bold
italicized values.

VIABILITY CHECK:   One viability check was performed on September 2nd,
7th, and 8th 2002. The protocol requires that two viability checks be
performed. All animals that were exposed on those days were observed
after the exposure. The only animals that were not observed were those
not being exposed. 

These deviations had no adverse effect on the study results or
integrity.

No other circumstances occurred that would have affected the quality or
integrity of the data.

4-10

 

LIST OF ABBREVIATIONS

STATISTICAL SYMBOLS AND ABBREVIATIONS

No difference		p(0.05		p(0.01		Statistical Statement

(PARAMETRIC)

A-						No statistical difference among the means

			     A		     A+		Significant difference among the means

L-						No linear response to the dose levels

			      L		     L+		Response is linearly related to dose

			      Q		     Q+		Linear response shows lack of fit

			       *		      **		Mean significantly different from control

								mean

(NONPARAMETRIC)

		K-						No statistical difference among the means

				      K		      K+		Means differ significantly

		J-						No ordered response to the dose levels

				       J		       J+		An ordered response to the dose levels

			       *		      **		Mean significantly different from control

								mean

	NT						Data not tested

5-1



LIST OF ABBREVIATIONS

UTERINE IMPLANTATION DATA ABBREVIATIONS

ABBREVIATION	PARAMETER

Resorp			Resorptions (early and late)

Implants		Implantation sites

CL			Corpora Lutea

Preimplant	Pre implantation loss = (corpora lutea - implantation
sites)/corpora lutea x 100

Postimplant	Post implantation loss = (implantation sites - total
live)/implantation sites x 100

Mal			Fetuses with malformations

Var			Fetuses with variations

Affected		Resorptions + dead + malformations

F/I Tran		Fetuses/implantation sites transformed

R/I Tran		Resorptions/implantation sites transformed

D/I Tran		Dead/implantation sites transformed

FETAL EXTERNAL AND VISCERAL EXAMINATIONS

+ = No observable abnormalities

Stunted = Any fetus weighing less than 4.00 grams

Organs and tissues examined

External:  	General body size, contour, and integrity (e.g. head, spine,
abdomen); limbs; 

digits; pinnae; eye bulges; palate/lip; tongue; snout/jaw; anogenital
region; tail

Visceral:	Urogenital system; adrenals; stomach; spleen; pancreas;
thymus; large/small

			Intestines; liver; lungs; heart and associated major vessels;
thyroid; trachea;

			Esophagus; brain ventricles (single free-hand razor section)

Malformations are anomalies that will not allow the fetus to survive
beyond parturition.  Malformations are indicated by a capitalized
footnote (e.g. "A").  

Developmental variations are anomalies that will not affect the
postnatal survival of the fetus.  Developmental variations are indicated
by a lower case footnote (e.g. "a").  

Observations are anomalies that generally are non-specific anomalies
such as stunted, pale coloration or discoloration of tissues, etc.  They
are indicated by an asterisk (e.g. "*").

Clarification of location of supernumerary ribs (L1 vs T14)

Supernumerary ribs were classified as occurring at L1 if the number of
presacral vertebrae was 26.  If an extra presacral vertebra was present
and a supernumerary rib was present, the location was recorded as T14.  

5-2



REFERENCES

Aliverti, V., Bonanomi, L., Giavini, E., Leone, V.G., and Mariani, L.,
1979.  The Extent of Fetal Ossification as an Index of Delayed
Development in Teratogenic Studies in the Rat.  Teratology, 20: 
237-242.

Animal Welfare Act of 1966 (P.L. 89-544), as amended in 1970, 1976, and
1985.  Code of Federal Regulations, Title 9 [Animals and Animal
Products], Subchapter A -Animal Welfare Parts 1, 2, and 3.

Bradley, J.V., Distribution Free Statistical Tests.  Prentice Hall,
Englewood Cliffs, N.J., 1968, pp. 195-203.

Chen, J.J., Gaylor, J.B. and Laborde, D.W. “Dose-response modeling of
growth for developmental toxicity”, Environmetrics, vol 7, pg 135-144,
1996.  

Dunnett, C., New Tables for Multiple Comparisons with a Control,
Biometrics 20, 1964, pp. 482-491.

EPA, United States Environmental Protection Agency, Good Laboratory
Practices (GLP) Standards for Inhalation Exposure Health Effects
Testing. 40 CFR, Part 79.60, 1994.

EPA, United States Environmental Protection Agency, Vehicle Emissions
Inhalation Exposure Guideline. 40 CFR Part 79.61, 1994.

EPA, United States Environmental Protection Agency, Health Effects Test
Guidelines OPPTS 870.3600 Inhalation Developmental Toxicity Study,
Public Draft, June 1996.

EPA, United States Environmental Protection Agency, Health Effects Test
Guidelines, OPPTS 870.3700, August 1998.

Guide for the Care and Use of Laboratory Animals, Institute of
Laboratory Animal Resources, Commission on Life Sciences, National
Research Council, National Academy Press, Washington, D.C., 1996.

Harris, S.B. and DeSesso, J.M., 1994.  Practical Guidance for Evaluating
and Interpreting Developmental Toxicity Tests, Journal of Hazardous
Materials 39: 245-266.

Hollander, M. and Wolfe, D.A. Nonparametric Statistical Methods, John
Wiley and Sons, New York, 1973.

6-1

REFERENCES (CONT'D)

Holson, J.F., Jr., Gaylor, D.W., Schumacher, H.F., Collins, T.F.X.,
Ruggles, D.I., Keplinger, M.L., and Kennedy, G.L., Jr., 1976. 
Teratological Evaluation of FD&C Red No. 2 - A Collaborative
Government-Industry Study.  V. Combined Findings and Discussion.  J.
Toxicol. Environ. Hlth. 1: 875-885.

Khera, K.S., 1981.  Common Fetal Aberrations and Their Teratologic
Significance:  a Review.  Fundamen. Appl. Toxicol. 1: 13-18.

Kimmel, C.A. and Wilson, J.G., 1973.  Skeletal Deviations in Rats: 
Malformations or Variations?, Teratology, 8:  309-316.

Little, Milliken, Stroup, and Wolfinger, “SAS System for Mixed
Models“, SAS Institute, Cary, NC, 1997, section 5.6.2, pg 203.

OECD, Organization for Economic Cooperation and Development, Guidelines
for the Testing of Chemicals, Proposal for Updating Guideline 414,
January 2001.

Ryan, L., “The use of generalized estimating equations for risk
assessment in developmental toxicity”, Risk Analysis, 12(3), pg
439-447, 1992.

SAS/STAT, V8.02, copyright © 1999-2001, SAS Institute, Inc., Cary, NC.

Snedecor, G.W., and Cochran, W.G., Statistical Methods, 8th ed., Iowa
State University Press, Ames, Iowa, 1989.

Staples, R.E., Detection of Visceral Alterations in Mammalian Fetus,
Teratology, 9:A-37, 1974. 

Stuckhardt, J.L. and Poppe, S.M., Fresh Visceral Examination of Rat and
Rabbit Fetuses Used in Teratogenicity Testing, Terato. Carcino.
Mutagen., 4, 1984, pp. 181-188.

6-2

APPENDIX A - SURVIVAL BAR GRAPH

TARGET DOSE: 0 MG/M3

ANIMAL

GD:

	NUMBER

0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21

IGL897	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL899	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL874	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL857	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL865	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL876	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL880	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL894	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL902	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL891	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL901	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL904	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL910	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL933	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL956	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL920	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL931	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL953	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL869	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL921	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL928	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL952	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL957	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL988	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL969	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

A-1



APPENDIX A - SURVIVAL BAR GRAPH

TARGET DOSE:  2000 MG/M3

ANIMAL

GD:

	NUMBER

0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21

IGL889	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL893	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL885	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL890	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL863	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL878	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL882	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL911	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL868	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL912	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL913	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL925	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL944	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=N

IGL871	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL922	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL951	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL859	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL943	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL948	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL974	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL888	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL976	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL923	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL924	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL905	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=N

A-2



APPENDIX A - SURVIVAL BAR GRAPH

TARGET DOSE:  10,000 MG/M3

ANIMAL

GD:

	NUMBER

0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21

IGL870	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL875	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL862	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL858	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL883	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL896	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL906	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL861	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL903	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL914	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL918	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL907	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL909	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL946	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL954	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL955	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL934	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL973	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=N

IGL881	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL917	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL940	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL963	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL983	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=N

IGL972	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL895	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

A-3



APPENDIX A - SURVIVAL BAR GRAPH

TARGET DOSE: 20,000 MG/M3

ANIMAL

GD:

	NUMBER

0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21

IGL866	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL892	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL864	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL872	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL873	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL879	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL884	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL886	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL915	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=N

IGL867	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL898	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL929	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL877	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL937	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL950	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL958	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL945	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL967	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL959	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL962	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL949	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL916	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL938	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL961	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

IGL970	(21)	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=	=P

NOTE:  	GD  - GESTATION DAY	N    -  NOT PREGNANT	P  -  PREGNANT	=     - 
24 HOURS

	

A-4

APPENDIX B - GESTATION OBSERVATIONS

(INCIDENCE OF GESTATION OBSERVATIONS BY TARGET DOSE)

GESTATION

DAY	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21

SURVIVORS (A)

0 MG/M3	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25
25

2000 MG/M3	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23
23	23

10,000 MG/M3	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23
23	23

20,000 MG/M3	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24
24	24

NO OBSERVABLE ABNORMALITIES

	0 MG/M3	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25
25

2000 MG/M3	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23
23	23

10,000 MG/M3	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23
23	23

20,000 MG/M3	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24
24	24

NOTE:  (A) -  TOTALS DO NOT INCLUDE NON-PREGNANT ANIMALS

	

B-1



APPENDIX B - GESTATION OBSERVATIONS

(INDIVIDUAL GESTATION OBSERVATIONS BY TARGET DOSE)

DOSE: 0 MG/M3

ANIMAL

NUMBER	 OBSERVATION

DAY:	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21

IGL897

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL899

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL874

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL857

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL865

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL876

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL880

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL894

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL902

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL891

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL901

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL904

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL910

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

B-2



APPENDIX B - GESTATION OBSERVATIONS

(INDIVIDUAL GESTATION OBSERVATIONS BY TARGET DOSE)

DOSE: 0 MG/M3 (CONT'D)

ANIMAL

NUMBER	 OBSERVATION

DAY:	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21

IGL933

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL956

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL920

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL931

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL953

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL869

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL921

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL928

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL952

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL957

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL988

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL969

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

B-3



APPENDIX B - GESTATION OBSERVATIONS

(INDIVIDUAL GESTATION OBSERVATIONS BY TARGET DOSE)

DOSE: 2000 MG/M3

ANIMAL

NUMBER	 OBSERVATION

DAY:	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21

IGL889

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL893

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL885

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL890

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL863

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL878

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL882

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL911

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL868

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL912

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL913

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL925

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL944NP

NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

B-4



APPENDIX B - GESTATION OBSERVATIONS

(INDIVIDUAL GESTATION OBSERVATIONS BY TARGET DOSE)

DOSE: 2000 MG/M3 (CONT'D)

ANIMAL

NUMBER	 OBSERVATION

DAY:	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21

IGL871

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL922

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL951

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL859

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL943

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL948

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL974

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL888

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL976

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL923

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL924

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL905NP

NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

B-5



APPENDIX B - GESTATION OBSERVATIONS

(INDIVIDUAL GESTATION OBSERVATIONS BY TARGET DOSE)

DOSE: 10,000 MG/M3

ANIMAL

NUMBER	 OBSERVATION

DAY:	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21

IGL870

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL875

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL862

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL858

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL883

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL896

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL906

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL861

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL903

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL914

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL918

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL907

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL909

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

B-6



APPENDIX B - GESTATION OBSERVATIONS

(INDIVIDUAL GESTATION OBSERVATIONS BY TARGET DOSE)

DOSE: 10,000 MG/M3 (CONT'D)

ANIMAL

NUMBER	 OBSERVATION

DAY:	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21

IGL946

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL954

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL955

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL934

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL973NP

NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL881

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL917

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL940

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL963

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL983NP

NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL972

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL895

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

B-7



APPENDIX B - GESTATION OBSERVATIONS

(INDIVIDUAL GESTATION OBSERVATIONS BY TARGET DOSE)

DOSE: 20,000 MG/M3

ANIMAL

NUMBER	 OBSERVATION

DAY:	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21

IGL866

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL892

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL864

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL872

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL873

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL879

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL884

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL886

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL915NP

NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL867

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL898

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL929

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL877

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

B-8



APPENDIX B - GESTATION OBSERVATIONS

(INDIVIDUAL GESTATION OBSERVATIONS BY TARGET DOSE)

DOSE: 20,000 MG/M3 (CONT'D)

ANIMAL

NUMBER	 OBSERVATION

DAY:	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21

IGL937

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL950

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL958

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL945

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL967

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL959

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL962

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL949

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL916

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL938

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL961

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

IGL970

	NO OBSERVABLE ABNORMALITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

B-9

APPENDIX C - GESTATION BODY WEIGHT AND BODY WEIGHT CHANGE 

(MEAN GESTATION BODY WEIGHT AND BODY WEIGHT CHANGE BY TARGET DOSE)

(GRAMS)

	GD 0	GD 5	GD 8	GD 11	GD 14	GD 17	GD 20	GD 21	UTERUS	GD 21C

FEMALE	A-L-	A-L-	AL+	A+L+	A+L+	AL+	AL+	AL+	K+J+	AL+

0 MG/M3

MEAN	260.6	293.2	302.9	316.7	330.0	360.1	409.4	428.4	114.3	314.2

STD.DEV.	16.7	18.8	20.3	21.5	23.7	25.8	30.9	33.2	13.0	23.0

(N)	25	25	25	25	25	25	25	25	25	25

2000 MG/M3

	MEAN	261.0	291.3	299.5	311.3	324.1	351.7	394.6	413.5	100.6	312.9

STD.DEV.	14.0	16.7	16.6	19.9	20.6	21.8	29.3	31.5	25.1	17.7

(N)	23	23	23	23	23	23	23	23	23	23

10,000 MG/M3

	MEAN	260.3	290.4	294.5	305.6	316.9	346.0	390.9	410.4	105.5	304.9

STD.DEV.	15.8	14.3	15.5	16.6	18.6	19.3	23.0	24.8	10.7	17.8

(N)	23	23	23	23	23	23	23	23	23	23

20,000 MG/M3

    *	   **	   **	    *	    *	    *	   **

	MEAN	260.4	288.9	288.9	298.2	309.9	340.0	385.5	404.3	104.1	300.2

STD.DEV.	14.3	13.0	14.7	15.2	15.9	18.0	20.7	22.4	10.7	19.1

(N)	24	24	24	24	24	24	24	24	24	24

C-1



APPENDIX C - GESTATION BODY WEIGHT AND BODY WEIGHT CHANGE 

(MEAN GESTATION BODY WEIGHT AND BODY WEIGHT CHANGE BY TARGET DOSE)

(GRAMS)

	GD 0-5	GD 5-8	GD 8-11	GD 11-14	GD 14-17	GD 17-20	GD 20-21	GD 5-21	GD
0-21	GD 0-21C

FEMALE	A-L-	K+J+	A+L+	A-L-	A-L-	K-J	A-L-	A+L+	K+J+	A+L+

0 MG/M3

MEAN	32.5	9.8	13.8	13.2	30.2	49.3	19.0	135.3	167.8	53.5

STD.DEV.	8.5	6.1	4.4	4.1	5.3	6.9	4.4	20.3	23.2	15.6

(N)	25	25	25	25	25	25	25	25	25	25

2000 MG/M3

	MEAN	30.2	8.3	11.8	12.8	27.6	42.9	18.9	122.3	152.5	51.9

STD.DEV.	8.5	5.2	5.1	3.5	9.4	12.0	5.9	25.4	29.1	13.3

(N)	23	23	23	23	23	23	23	23	23	23

10,000 MG/M3	    *

  *	   *

	MEAN	30.0	4.1	11.1	11.3	29.1	45.0	19.5	120.0	150.0	44.6

STD.DEV.	6.1	3.0	3.1	5.0	5.8	6.3	5.8	13.0	14.8	12.2

(N)	23	23	23	23	23	23	23	23	23	23

20,000 MG/M3	  **	  **

	  **	  **	  **

MEAN	28.5	0	9.3	11.8	30.1	45.5	18.8	115.4	143.8	39.8

STD.DEV.	6.1	5.9	3.6	5.4	5.7	6.4	4.6	15.7	15.4	13.9

(N)	24	24	24	24	24	24	24	24	24	24

NOTE: 

GD  - GESTATION DAY

21C (DAY 21 CORRECTED) = DAY 21 BODY WEIGHT - UTERINE WEIGHT

	

C-2



APPENDIX C - GESTATION BODY WEIGHT AND BODY WEIGHT CHANGE 

(INDIVIDUAL GESTATION BODY WEIGHT BY TARGET DOSE)

(GRAMS)

DOSE:  0 MG/M3

ANIMAL	GD	GD	GD	GD	GD	GD	GD	GD	GD	UTERINE

NUMBER	0	5	8	11	14	17	20	21	21C	WEIGHT

IGL897	267	299	301	327	339	375	431	451	318	133

IGL899	237	279	283	292	303	324	370	386	286	100

IGL874	261	297	315	335	354	380	442	467	342	125

IGL857	250	284	288	298	313	344	398	419	298	121

IGL865	238	267	287	303	313	345	400	419	308	111

IGL876	247	274	278	294	308	336	378	394	296	98

IGL880	261	304	318	330	342	373	422	441	320	121

IGL894	249	278	287	303	318	353	410	435	318	117

IGL902	270	313	322	339	357	387	438	454	342	112

IGL891	275	320	326	335	346	381	432	450	330	120

IGL901	263	295	308	323	337	374	424	445	325	120

IGL904	295	346	359	377	400	435	500	522	376	146

IGL910	252	288	300	312	324	353	401	415	297	118

IGL933	250	281	294	302	308	341	383	405	313	92

IGL956	260	287	301	313	326	362	400	415	310	105

IGL920	238	282	293	312	325	347	394	413	300	113

IGL931	234	258	254	267	278	303	336	345	256	89

IGL953	293	317	323	336	349	378	429	457	323	134

IGL869	257	282	287	293	309	332	379	395	293	102

IGL921	269	299	303	312	325	352	395	414	303	111

IGL928	281	307	322	334	354	382	429	443	334	109

IGL952	267	302	313	326	332	357	405	423	316	107

IGL957	284	303	307	324	339	367	418	434	314	120

IGL988	252	284	301	314	320	349	400	420	302	118

IGL969	266	283	303	317	330	373	421	449	334	115

C-3



APPENDIX C - GESTATION BODY WEIGHT AND BODY WEIGHT CHANGE 

(INDIVIDUAL GESTATION BODY WEIGHT)

(GRAMS)

TARGET DOSE:  2000 MG/M3

ANIMAL	GD	GD	GD	GD	GD	GD	GD	GD	GD	UTERINE

NUMBER	0	5	8	11	14	17	20	21	21C	WEIGHT

IGL889	276	309	324	345	360	380	442	457	345	112

IGL893	281	323	327	347	356	385	443	457	328	129

IGL885	254	273	283	288	295	312	366	387	279	108

IGL890	275	307	313	321	339	370	415	439	326	113

IGL863	274	305	308	319	334	361	410	437	323	114

IGL878	269	313	313	334	349	385	431	456	338	118

IGL882	248	280	286	296	311	344	387	411	297	114

IGL911	235	282	284	295	311	352	392	406	292	114

IGL868	259	290	302	309	323	364	413	436	326	110

IGL912	246	274	285	297	310	340	390	403	295	108

IGL913	265	285	295	305	321	343	379	405	318	87

IGL925	244	278	285	297	309	339	380	403	308	95

IGL944 NP	241	269	271	272	271	284	292	293	NP	2

IGL871	237	265	266	267	279	324	361	384	295	89

IGL922	269	300	315	327	340	375	418	440	328	112

IGL951	264	288	298	306	320	352	397	411	299	112

IGL859	270	289	294	301	315	336	374	394	300	94

IGL943	250	265	287	306	319	350	403	422	320	102

IGL948	257	301	313	329	345	376	425	445	327	118

IGL974	273	296	307	317	324	328	333	337	320	17

IGL888	268	294	301	312	319	340	389	413	299	114

IGL976	261	288	291	307	312	328	349	359	317	42

IGL923	245	273	282	292	306	326	361	377	287	90

IGL924	284	321	330	343	357	379	418	432	330	102

IGL905 NP	286	304	309	306	299	310	312	310	NP	2

C-4



APPENDIX C - GESTATION BODY WEIGHT AND BODY WEIGHT CHANGE 

(INDIVIDUAL GESTATION BODY WEIGHT)

(GRAMS)

TARGET DOSE:  10,000 MG/M3

ANIMAL	GD	GD	GD	GD	GD	GD	GD	GD	GD	UTERINE

NUMBER	0	5	8	11	14	17	20	21	21C	WEIGHT

IGL870	256	288	295	304	315	330	376	402	312	90

IGL875	241	282	288	299	318	344	394	419	304	115

IGL862	237	272	276	283	292	319	366	374	286	88

IGL858	255	288	295	306	324	359	402	424	316	108

IGL883	259	293	296	312	322	353	394	421	312	109

IGL896	267	300	306	319	333	367	411	428	321	107

IGL906	244	277	276	283	286	323	360	385	278	107

IGL861	263	296	304	311	326	356	399	417	310	107

IGL903	269	296	301	311	325	357	412	426	311	115

IGL914	255	285	286	296	298	333	380	401	293	108

IGL918	254	282	281	285	296	328	366	387	286	101

IGL907	279	303	305	315	331	356	413	435	319	116

IGL909	284	311	313	323	334	370	419	437	322	115

IGL946	256	284	285	295	310	342	392	399	293	106

IGL954	286	307	314	324	342	368	418	444	329	115

IGL955	233	265	264	277	289	315	353	372	279	93

IGL934	251	272	276	287	299	331	374	382	276	106

IGL973 NP	263	301	309	316	298	302	299	301	NP	2

IGL881	267	294	300	316	322	359	408	426	316	110

IGL917	270	299	306	320	335	362	413	434	319	115

IGL940	239	263	269	283	284	303	335	351	274	77

IGL963	274	303	311	327	336	363	401	422	321	101

IGL983 NP	271	295	294	296	292	282	274	276	NP	2

IGL972	259	306	312	325	336	363	400	425	329	96

IGL895	290	313	315	328	335	356	405	428	307	121

C-5



APPENDIX C - GESTATION BODY WEIGHT AND BODY WEIGHT CHANGE 

(INDIVIDUAL GESTATION BODY WEIGHT)

(GRAMS)

TARGET DOSE:  20,000 MG/M3

ANIMAL	GD	GD	GD	GD	GD	GD	GD	GD	GD	UTERINE

NUMBER	0	5	8	11	14	17	20	21	21C	WEIGHT

IGL866	258	284	280	292	301	323	372	393	295	98

IGL892	254	292	290	307	318	344	393	409	298	111

IGL864	234	276	268	273	275	296	336	348	262	86

IGL872	231	265	261	267	285	315	359	373	265	108

IGL873	256	286	286	298	308	330	371	398	300	98

IGL879	269	302	291	301	315	350	393	399	267	132

IGL884	258	278	276	286	297	326	364	383	294	89

IGL886	272	302	302	313	333	359	396	416	318	98

IGL915 NP	266	303	303	305	288	291	294	294	NP	2

IGL867	262	295	293	298	311	351	406	431	306	125

IGL898	270	296	311	318	329	365	412	437	329	108

IGL929	265	289	297	298	312	340	386	403	296	107

IGL877	266	287	284	293	310	348	389	411	298	113

IGL937	238	265	261	269	283	316	369	385	281	104

IGL950	262	287	282	291	308	334	367	387	288	99

IGL958	272	288	294	302	312	346	394	416	311	105

IGL945	289	314	318	329	330	364	406	430	324	106

IGL967	266	300	303	317	332	370	426	446	332	114

IGL959	290	318	312	316	333	359	415	429	325	104

IGL962	252	284	283	291	300	321	370	388	292	96

IGL949	253	287	293	302	309	342	389	410	306	104

IGL916	246	273	275	290	303	338	376	396	309	87

IGL938	265	290	289	299	298	331	372	389	295	94

IGL961	263	295	296	308	326	351	405	423	316	107

IGL970	259	280	289	298	310	341	385	402	297	105

C-6



APPENDIX C - GESTATION BODY WEIGHT AND BODY WEIGHT CHANGE

(INDIVIDUAL GESTATION BODY WEIGHT CHANGE)

(GRAMS)

TARGET DOSE:  0 MG/M3

ANIMAL	GD	GD	GD	GD	GD	GD	GD	GD	GD	GD

NUMBER	0-5	5-8	8-11	11-14	14-17	17-20	20-21	5-21	0-21	0-21C

IGL897	32	2	26	12	36	56	20	152	184	51

IGL899	42	4	9	11	21	46	16	107	149	49

IGL874	36	18	20	19	26	62	25	170	206	81

IGL857	34	4	10	15	31	54	21	135	169	48

IGL865	29	20	16	10	32	55	19	152	181	70

IGL876	27	4	16	14	28	42	16	120	147	49

IGL880	43	14	12	12	31	49	19	137	180	59

IGL894	29	9	16	15	35	57	25	157	186	69

IGL902	43	9	17	18	30	51	16	141	184	72

IGL891	45	6	9	11	35	51	18	130	175	55

IGL901	32	13	15	14	37	50	21	150	182	62

IGL904	51	13	18	23	35	65	22	176	227	81

IGL910	36	12	12	12	29	48	14	127	163	45

IGL933	31	13	8	6	33	42	22	124	155	63

IGL956	27	14	12	13	36	38	15	128	155	50

IGL920	44	11	19	13	22	47	19	131	175	62

IGL931	24	-4	13	11	25	33	9	87	111	22

IGL953	24	6	13	13	29	51	28	140	164	30

IGL869	25	5	6	16	23	47	16	113	138	36

IGL921	30	4	9	13	27	43	19	115	145	34

IGL928	26	15	12	20	28	47	14	136	162	53

IGL952	35	11	13	6	25	48	18	121	156	49

IGL957	19	4	17	15	28	51	16	131	150	30

IGL988	32	17	13	6	29	51	20	136	168	50

IGL969	17	20	14	13	43	48	28	166	183	68

C-7



APPENDIX C - GESTATION BODY WEIGHT AND BODY WEIGHT CHANGE

(INDIVIDUAL GESTATION BODY WEIGHT CHANGE)

(GRAMS)

TARGET DOSE:  2000 MG/M3

ANIMAL	GD	GD	GD	GD	GD	GD	GD	GD	GD	GD

NUMBER	0-5	5-8	8-11	11-14	14-17	17-20	20-21	5-21	0-21	0-21C

IGL889	33	15	21	15	20	62	15	148	181	69

IGL893	42	4	20	9	29	58	14	134	176	47

IGL885	19	10	5	7	17	54	21	114	133	25

IGL890	32	6	8	18	31	45	24	132	164	51

IGL863	31	3	11	15	27	49	27	132	163	49

IGL878	44	0	21	15	36	46	25	143	187	69

IGL882	32	6	10	15	33	43	24	131	163	49

IGL911	47	2	11	16	41	40	14	124	171	57

IGL868	31	12	7	14	41	49	23	146	177	67

IGL912	28	11	12	13	30	50	13	129	157	49

IGL913	20	10	10	16	22	36	26	120	140	53

IGL925	34	7	12	12	30	41	23	125	159	64

IGL944 NP	28	2	1	-1	13	8	1	24	52	NP

IGL871	28	1	1	12	45	37	23	119	147	58

IGL922	31	15	12	13	35	43	22	140	171	59

IGL951	24	10	8	14	32	45	14	123	147	35

IGL859	19	5	7	14	21	38	20	105	124	30

IGL943	15	22	19	13	31	53	19	157	172	70

IGL948	44	12	16	16	31	49	20	144	188	70

IGL974	23	11	10	7	4	5	4	41	64	47

IGL888	26	7	11	7	21	49	24	119	145	31

IGL976	27	3	16	5	16	21	10	71	98	56

IGL923	28	9	10	14	20	35	16	104	132	42

IGL924	37	9	13	14	22	39	14	111	148	46

IGL905 NP	18	5	-3	-7	11	2	-2	6	24	NP

C-8



APPENDIX C - GESTATION BODY WEIGHT AND BODY WEIGHT CHANGE

(INDIVIDUAL GESTATION BODY WEIGHT CHANGE)

(GRAMS)

TARGET DOSE:  10,000 MG/M3

ANIMAL	GD	GD	GD	GD	GD	GD	GD	GD	GD	GD

NUMBER	0-5	5-8	8-11	11-14	14-17	17-20	20-21	5-21	0-21	0-21C

IGL870	32	7	9	11	15	46	26	114	146	56

IGL875	41	6	11	19	26	50	25	137	178	63

IGL862	35	4	7	9	27	47	8	102	137	49

IGL858	33	7	11	18	35	43	22	136	169	61

IGL883	34	3	16	10	31	41	27	128	162	53

IGL896	33	6	13	14	34	44	17	128	161	54

IGL906	33	-1	7	3	37	37	25	108	141	34

IGL861	33	8	7	15	30	43	18	121	154	47

IGL903	27	5	10	14	32	55	14	130	157	42

IGL914	30	1	10	2	35	47	21	116	146	38

IGL918	28	-1	4	11	32	38	21	105	133	32

IGL907	24	2	10	16	25	57	22	132	156	40

IGL909	27	2	10	11	36	49	18	126	153	38

IGL946	28	1	10	15	32	50	7	115	143	37

IGL954	21	7	10	18	26	50	26	137	158	43

IGL955	32	-1	13	12	26	38	19	107	139	46

IGL934	21	4	11	12	32	43	8	110	131	25

IGL973 NP	38	8	7	-18	4	-3	2	0	38	NP

IGL881	27	6	16	6	37	49	18	132	159	49

IGL917	29	7	14	15	27	51	21	135	164	49

IGL940	24	6	14	1	19	32	16	88	112	35

IGL963	29	8	16	9	27	38	21	119	148	47

IGL983 NP	24	-1	2	-4	-10	-8	2	-19	5	NP

IGL972	47	6	13	11	27	37	25	119	166	70

IGL895	23	2	13	7	21	49	23	115	138	17

C-9



APPENDIX C - GESTATION BODY WEIGHT AND BODY WEIGHT CHANGE

(INDIVIDUAL GESTATION BODY WEIGHT CHANGE)

(GRAMS)

TARGET DOSE:  20,000 MG/M3

ANIMAL	GD	GD	GD	GD	GD	GD	GD	GD	GD	GD

NUMBER	0-5	5-8	8-11	11-14	14-17	17-20	20-21	5-21	0-21	0-21C

IGL866	26	-4	12	9	22	49	21	109	135	37

IGL892	38	-2	17	11	26	49	16	117	155	44

IGL864	42	-8	5	2	21	40	12	72	114	28

IGL872	34	-4	6	18	30	44	14	108	142	34

IGL873	30	0	12	10	22	41	27	112	142	44

IGL879	33	-11	10	14	35	43	6	97	130	-2

IGL884	20	-2	10	11	29	38	19	105	125	36

IGL886	30	0	11	20	26	37	20	114	144	46

IGL915 NP	37	0	2	-17	3	3	0	-9	28	NP

IGL867	33	-2	5	13	40	55	25	136	169	44

IGL898	26	15	7	11	36	47	25	141	167	59

IGL929	24	8	1	14	28	46	17	114	138	31

IGL877	21	-3	9	17	38	41	22	124	145	32

IGL937	27	-4	8	14	33	53	16	120	147	43

IGL950	25	-5	9	17	26	33	20	100	125	26

IGL958	16	6	8	10	34	48	22	128	144	39

IGL945	25	4	11	1	34	42	24	116	141	35

IGL967	34	3	14	15	38	56	20	146	180	66

IGL959	28	-6	4	17	26	56	14	111	139	35

IGL962	32	-1	8	9	21	49	18	104	136	40

IGL949	34	6	9	7	33	47	21	123	157	53

IGL916	27	2	15	13	35	38	20	123	150	63

IGL938	25	-1	10	-1	33	41	17	99	124	30

IGL961	32	1	12	18	25	54	18	128	160	53

IGL970	21	9	9	12	31	44	17	122	143	38

NOTE: 	NP - ANIMAL NOT PREGNANT	GD  - GESTATION DAY

21C (DAY 21 CORRECTED) = DAY 21 BODY WEIGHT - UTERINE WEIGHT

C-10



APPENDIX D - GESTATION FOOD CONSUMPTION

(MEAN GESTATION FOOD CONSUMPTION BY TARGET DOSE)

(SEE LIST OF ABBREVIATIONS FOR STATISTICAL SYMBOLS)

(GRAMS)

GD 0-5	GD 5-8	GD 8-11	GD 11-14	GD 14-17	GD 17-20	GD 20-21	GD 5-20	GD
0-21

FEMALE	A-L-	A+L+	K+J+	A+L+	A-L-	A-L-	A-L-	A+L+	K+J+

0 MG/M3

	MEAN	117.3	71.6	71.3	71.1	72.9	77.8	23.9	364.8	505.9

STD.DEV.	13.0	8.2	9.3	8.5	7.8	7.5	3.3	37.7	50.5

(N)	25	25	25	25	25	25	25	25	25

	2000 MG/M3

MEAN	116.1	70.6	68.9	70.5	74.3	76.0	23.8	360.3	500.5

STD.DEV.	11.2	6.6	6.7	6.0	11.3	5.9	3.0	28.6	40.2

(N)	23	23	23	23	23	23	22	23	22

	10,000 MG/M3	   *	   *	   *

   *

	MEAN	116.0	65.6	64.1	65.1	68.8	73.7	23.6	337	476.5

STD.DEV.	10.6	6.1	5.8	6.4	6.2	6.4	3.0	28.3	39.6

(N)	23	23	22	22	23	23	23	22	22

	20,000 MG/M3	   **	   **	   **

   **	   **

MEAN	114.7	60.3	60.0	63.5	70.3	76.5	23.2	330.6	468.5

STD.DEV.	9.4	4.6	4.6	4.6	6.5	6.7	3.8	20.8	23.5

(N)	24	24	24	24	24	24	24	24	24

	NOTE:  GD - GESTATION DAY

D-1

APPENDIX D - GESTATION FOOD CONSUMPTION

(INDIVIDUAL GESTATION FOOD CONSUMPTION)

(GRAMS)

TARGET DOSE:  0 MG/M3

ANIMAL	GD	GD	GD	GD	GD	GD	GD

NUMBER	0-5	5-8	8-11	11-14	14-17	17-20	20-21

IGL897	115	66	72	67	76	84	26

IGL899	114	70	63	60	65	67	21

IGL874	116	78	77	75	75	81	27

IGL857	109	65	69	69	73	77	24

IGL865	101	71	80	66	70	75	23

IGL876	118	68	66	74	76	79	23

IGL880	130	87	87	80	81	83	25

IGL894	107	67	62	73	74	80	29

IGL902	133	83	85	81	78	80	26

IGL891	126	72	70	73	69	80	21

IGL901	111	69	69	69	72	84	23

IGL904	154	91	92	98	95	98	29

IGL910	122	75	65	72	68	73	19

IGL933	102	65	61	64	66	75	26

IGL956	114	67	69	72	74	76	23

IGL920	127	77	73	72	69	75	20

IGL931	93	52	52	52	56	56	16

IGL953	126	72	66	72	66	77	24

IGL869	111	62	61	61	62	70	22

IGL921	139	80	84	74	83	80	24

IGL928	112	69	72	76	76	76	22

IGL952	117	73	76	68	72	80	24

IGL957	115	65	67	69	71	76	22

IGL988	115	75	78	66	71	76	27

IGL969	105	71	67	75	84	88	31

D-2

APPENDIX D - GESTATION FOOD CONSUMPTION

(INDIVIDUAL GESTATION FOOD CONSUMPTION)

(GRAMS)

TARGET DOSE:  2000 MG/M3

ANIMAL	GD	GD	GD	GD	GD	GD	GD

NUMBER	0-5	5-8	8-11	11-14	14-17	17-20	20-21

IGL889	123	77	78	74	77	83	25

IGL893	133	79	79	74	79	77	24

IGL885	110	63	64	57	53	66	22

IGL890	130	73	70	75	77	79	27

IGL863	123	73	70	78	74	77	26

IGL878	134	73	74	76	83	82	26

IGL882	104	65	63	65	73	71	23

IGL911	127	74	76	75	89	86	25

IGL868	122	76	69	73	73	80	24

IGL912	107	69	66	70	68	78	21

IGL913	109	69	68	71	69	69	26

IGL925	112	69	67	71	75	76	25

IGL944 NP	100	61	61	58	62	62	22

IGL871	107	57	56	65	110	74	S

IGL922	127	78	76	77	79	79	27

IGL951	108	67	63	72	74	75	23

IGL859	105	66	58	65	64	73	21

IGL943	98	71	69	74	72	83	24

IGL948	125	79	75	72	86	85	26

IGL974	111	72	71	74	67	70	22

IGL888	111	64	64	62	64	71	23

IGL976	110	62	66	60	63	66	28

IGL923	101	64	62	64	63	69	14

IGL924	133	84	81	78	76	79	22

IGL905 NP	117	73	68	59	66	71	20

D-3

APPENDIX D - GESTATION FOOD CONSUMPTION

(INDIVIDUAL GESTATION FOOD CONSUMPTION)

(GRAMS)

TARGET DOSE:  10,000 MG/M3

ANIMAL	GD	GD	GD	GD	GD	GD	GD

NUMBER	0-5	5-8	8-11	11-14	14-17	17-20	20-21

IGL870	110	67	63	62	64	69	28

IGL875	111	71	67	68	71	71	22

IGL862	107	58	59	59	68	72	21

IGL858	116	68	N	N	72	76	24

IGL883	122	68	69	67	71	74	26

IGL896	124	77	76	81	84	85	27

IGL906	113	62	62	58	69	69	22

IGL861	113	63	60	70	68	73	24

IGL903	117	69	65	71	77	84	22

IGL914	113	59	57	58	63	67	22

IGL918	107	56	55	60	60	66	20

IGL907	119	71	69	68	71	76	26

IGL909	116	62	66	64	69	75	23

IGL946	105	60	56	60	66	71	19

IGL954	137	73	70	71	74	81	30

IGL955	91	56	57	56	58	60	21

IGL934	104	58	58	61	65	69	18

IGL973 NP	109	71	68	55	54	47	19

IGL881	128	66	68	66	74	79	24

IGL917	115	65	66	71	72	84	26

IGL940	110	64	61	56	62	66	21

IGL963	125	71	72	72	76	78	27

IGL983 NP	106	59	56	50	39	40	15

IGL972	135	75	71	69	60	76	26

IGL895	129	70	64	65	68	74	24

D-4

APPENDIX D - GESTATION FOOD CONSUMPTION

(INDIVIDUAL GESTATION FOOD CONSUMPTION)

(GRAMS)

TARGET DOSE:  20,000 MG/M3

ANIMAL	GD	GD	GD	GD	GD	GD	GD

NUMBER	0-5	5-8	8-11	11-14	14-17	17-20	20-21

IGL866	108	62	58	57	67	68	20

IGL892	124	64	66	63	71	72	19

IGL864	94	63	64	57	56	69	21

IGL872	139	50	53	58	66	71	18

IGL873	112	60	59	57	60	68	25

IGL879	130	62	61	65	74	67	11

IGL884	107	58	59	65	68	76	26

IGL886	120	68	64	67	72	75	25

IGL915 NP	127	66	62	48	53	51	19

IGL867	120	56	54	64	72	80	24

IGL898	119	65	63	66	75	85	25

IGL929	114	60	55	66	70	79	20

IGL877	106	54	61	66	78	77	24

IGL937	105	53	53	58	65	74	25

IGL950	115	53	51	62	69	69	20

IGL958	112	60	60	63	73	81	27

IGL945	124	64	59	62	62	70	24

IGL967	114	62	63	68	81	92	29

IGL959	117	59	58	61	65	81	23

IGL962	110	66	60	69	68	76	24

IGL949	112	66	62	62	69	79	25

IGL916	107	59	63	69	75	85	27

IGL938	117	58	58	57	69	73	23

IGL961	121	60	68	73	82	83	27

IGL970	105	65	68	69	81	86	24

			NOTE:  GD – GESTATION DAY     NP – NOT PREGNANT

			S – NOT MEASURED DUE TO EXCESS SPILLAGE    N – NOT MEASURED DUE
TO OVERSIGHT

D-5

APPENDIX E - GROSS POSTMORTEM OBSERVATIONS

(INCIDENCE OF GROSS POSTMORTEM OBSERVATIONS)

	FEMALES

TARGET 	0 MG/M3	2000MG/M3	10,000 MG/M3	20,000 MG/M3

TOTAL AT TERMINAL SACRIFICE (A)	25	25	25	25

NO OBSERVABLE ABNORMALITIES	25	24	24	25

UTERUS: Exuded thin brown liquid	0	1	0	0

KIDNEY: Dilated renal pelvis	0	0	1	0

URINARY BLADDER:  White, hard object	0	0	1	0

NO EVIDENCE OF UTERINE

IMPLANTATION SITES	0	2	2	1

E-1

APPENDIX E - GROSS POSTMORTEM OBSERVATIONS

(INDIVIDUAL GROSS POSTMORTEM OBSERVATIONS)

TARGET DOSE:  0 MG/M3

IGL897F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL899F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL874F  -  	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL857F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL865F   - 	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL876F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL880F  -  	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL894F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL902F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL891F -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL901F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL904F  - 	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL910F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL933F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL956F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL920F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL931F  -	ALL TISSUES AND ORGANS:  No observable abnormalities

E-2

APPENDIX E - GROSS POSTMORTEM OBSERVATIONS

(INDIVIDUAL GROSS POSTMORTEM OBSERVATIONS)

TARGET DOSE:  0 MG/M3  (CONT'D)

IGL953F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL869F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL921F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL928F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL952F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL957F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL988F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL969F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

E-3

APPENDIX E - GROSS POSTMORTEM OBSERVATIONS

(INDIVIDUAL GROSS POSTMORTEM OBSERVATIONS)

TARGET DOSE:  2000 MG/M3

IGL889F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

	

IGL893F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL885F  -  	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL890F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL863F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

	

IGL878F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL882F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL911F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL868F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL912F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL913F -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL925F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL944F  - 	ALL TISSUES AND ORGANS:  No observable abnormalities.

	NOTE:  No evidence of uterine implantation sites.

IGL871F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL922F  -	ALL TISSUES AND ORGANS:  No observable abnormalities

E-4

APPENDIX E - GROSS POSTMORTEM OBSERVATIONS

(INDIVIDUAL GROSS POSTMORTEM OBSERVATIONS)

TARGET DOSE:  2000 MG/M3  (CONT'D)

IGL951F  - 	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL859F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL943F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL948F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL974F  -	UTERUS: Exuded moderate amount of thin brown liquid.

IGL888F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL976F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL923F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL924F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL905F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

	NOTE:  No evidence of uterine implantation sites.

E-5

APPENDIX E - GROSS POSTMORTEM OBSERVATIONS

(INDIVIDUAL GROSS POSTMORTEM OBSERVATIONS)

TARGET DOSE:  10,000 MG/M3

IGL870F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL875F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL862F  -  	ALL TISSUES AND ORGANS:  No observable abnormalities.

	

IGL858F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL883F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

	

IGL896F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL906F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL861F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL903F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL914F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL918F -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL907F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL909F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL946F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL954F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL955F -	ALL TISSUES AND ORGANS:  No observable abnormalities.

E-6

APPENDIX E - GROSS POSTMORTEM OBSERVATIONS

(INDIVIDUAL GROSS POSTMORTEM OBSERVATIONS)

TARGET DOSE:  10000 MG/M3 (CONT'D)

IGL934F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL973F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

	NOTE:  No evidence of uterine implantation sites.

IGL881F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL917F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL940F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL963F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL983F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

	NOTE:  No evidence of uterine implantation sites.

IGL972F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL895F  -	KIDNEY: Dilated renal pelvis, Both.

	URINARY BLADDER: Object in bladder, 1.0 x 0.9 x 0.7 cm, white, hard. 

E-7

APPENDIX E - GROSS POSTMORTEM OBSERVATIONS

(INDIVIDUAL GROSS POSTMORTEM OBSERVATIONS)

TARGET DOSE:  20,000 MG/M3

IGL866F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL892F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL864F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL872F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL873F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL879F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL884F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL886F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL915F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

	NOTE:  No evidence of uterine implantation sites.

IGL867F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL898F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL929F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL877F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL937F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL950F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

E-8

APPENDIX E - GROSS POSTMORTEM OBSERVATIONS

(INDIVIDUAL GROSS POSTMORTEM OBSERVATIONS)

TARGET DOSE:  20,000 MG/M3 (CONT'D)

IGL958F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL945F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL967F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL959F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL962F  -	ALL TISSUES AND ORGANS:  No observable abnormalities

IGL949F  - 	ALL TISSUES AND ORGANS:  No observable abnormalities

IGL916F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL938F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL961F  -	ALL TISSUES AND ORGANS:  No observable abnormalities.

IGL970F  -	ALL TISSUES AND ORGANS:  No observable abnormalities. 

E-9



APPENDIX F - UTERINE IMPLANTATION DATA

(MEAN UTERINE IMPLANTATION DATA BY TARGET DOSE)

(SEE LIST OF ABBREVIATIONS FOR STATISTICAL SYMBOLS AND ABBREVIATIONS)

Total	Male	Female

Implantation	Corpora	Total	Fetuses/	Resorptions/

	Live	Fetuses	Fetuses	Resorptions	Sites	Lutea	Dead	Implantation
Implantation

FEMALE	K-J-	A+L-Q+	A-L-	A-L-	KJ	KJ+	K-J-	A-L-	A-L-

0 MG/M3

	MEAN	15.36	7.84	7.52	0.28	15.68	16.32	0.04	0.98	0.02

STD.DEV.	1.78	2.1	2.18	0.61	1.82	1.99	0.2	0.04	0.04

(N)	25	25	25	25	25	25	25	25	25

	2000 MG/M3	   **

	      *	        *

	MEAN	13.13	5.91	7.22	0.17	13.30	14.04	0	0.99	0.01

STD.DEV.	3.62	2.37	2.68	0.49	3.66	3.54	0	0.03	0.03

(N)	23	23	23	23	23	23	23	23	23

	10,000 MG/M3

MEAN	14.22	7.13	7.09	0.39	14.61	14.91	0	0.97	0.03

STD.DEV.	1.98	2.14	2.27	0.58	1.8	1.78	0	0.05	0.05

(N)	23	23	23	23	23	23	23	23	23

	20,000 MG/M3

	        *

	MEAN	14.38	6.42	7.96	0.29	14.71	15.13	0	0.98	0.02

STD.DEV.	2.12	1.53	2.07	0.55	2.07	2.66	0	0.04	0.04

(N)	24	24	24	24	24	24	24	24	24

	F-1



APPENDIX F - UTERINE IMPLANTATION DATA

(MEAN UTERINE IMPLANTATION DATA BY TARGET DOSE)

(SEE LIST OF ABBREVIATIONS FOR STATISTICAL SYMBOLS AND ABBREVIATIONS)

Dead/	F/I	R/I 	D/I	% Preimplant	% Postimplant	Total	Total	Total 

	Implantation	Tran	Tran	Tran	Loss	Loss	Malformations	Variations	Affected

FEMALE	K-J-	A-L-	A-L-	K-J-	K-J-	A-L-	K-J-	AL-	A-L-

0 MG/M3

	MEAN	0	80.49092	9.2078	7.594	3.7	1.9	0.12	1.0	0.4

STD.DEV.	0	4.194734	4.05511	1.6	5.3	3.8	0.44	1.2	0.7

(N)	25	25	25	25	25	25	25	25	25

	2000 MG/M3

MEAN	0	79.880609	10.119957	8.843	5.4	1.2	0.17	1.0	0.3

STD.DEV.	0	5.653898	5.653812	4.763	11.2	3.4	0.83	1.0	1.1

(N)	23	23	23	23	23	23	23	23	23

	10,000 MG/M3

MEAN	0	79.428044	10.572435	7.562	2.0	2.8	0.13	0.7	0.5

STD.DEV.	0	4.716547	4.716461	0.501	3.2	4.6	0.46	0.7	0.8

(N)	23	23	23	23	23	23	23	23	23

	20,000 MG/M3

MEAN	0	79.9575	9.704375	7.542	2.3	2.3	0.08	1.6	0.4

STD.DEV.	0	4.151503	3.962848	0.503	4.1	3.8	0.28	1.2	0.6

(N)	24	24	24	24	24	24	24	24	24

F-2



APPENDIX F  - UTERINE IMPLANTATION DATA 

(INDIVIDUAL UTERINE IMPLANTATION DATA)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE:  0 MG/M3

ANIMAL 

	NUMBER	Live	Male	Female	Resorp	Implants	CL	Dead	Mal	Var

IGL897	18	11	7	0	18	18	0	0	2

IGL899	14	7	7	1	15	16	0	0	0

IGL874	17	11	6	0	17	17	0	0	1

IGL857	16	6	10	0	16	16	0	0	0

IGL865	15	4	11	0	15	15	0	1	2

IGL876	14	9	5	0	15	15	1	0	0

IGL880	15	9	6	0	15	16	0	0	1

IGL894	15	7	8	0	15	17	0	0	1

IGL902	15	7	8	2	17	17	0	0	1

IGL891	17	10	7	1	18	18	0	0	2

IGL901	17	5	12	1	18	22	0	0	0

IGL904	19	12	7	0	19	19	0	0	0

IGL910	15	8	7	0	15	16	0	0	1

IGL933	11	6	5	0	11	12	0	0	1

IGL956	14	9	5	0	14	14	0	0	1

IGL920	16	6	10	0	16	18	0	0	0

IGL931	13	9	4	0	13	14	0	0	2

IGL953	18	10	8	0	18	18	0	0	5

IGL869	14	8	6	0	14	16	0	0	0

IGL921	15	6	9	0	15	15	0	0	0

IGL928	14	8	6	0	14	14	0	0	2

IGL952	14	8	6	2	16	17	0	0	0

IGL957	16	4	12	0	16	16	0	0	1

IGL988	15	8	7	0	15	15	0	2	2

IGL969	17	8	9	0	17	17	0	0	0

F-3



APPENDIX F  - UTERINE IMPLANTATION DATA 

(INDIVIDUAL UTERINE IMPLANTATION DATA)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE:  0 MG/M3

ANIMAL 	F/I	R/I	D/I

NUMBER	Tran	Tran	Tran

IGL897	83.232	6.768	6.7681

IGL899	75.037	14.963	7.4176

IGL874	83.035	6.965	6.9653

IGL857	82.82	7.181	7.1808

IGL865	82.583	7.418	7.4176

IGL876	75.037	7.418	14.9633

IGL880	82.583	7.418	7.4176

IGL894	82.583	7.418	7.4176

IGL902	69.941	20.06	6.9653

IGL891	76.367	13.633	6.7681

IGL901	76.367	13.633	6.7681

IGL904	83.414	6.587	6.5868

IGL910	82.583	7.418	7.4176

IGL933	81.33	8.671	8.6708

IGL956	82.321	7.679	7.6795

IGL920	82.82	7.181	7.1808

IGL931	82.029	7.971	7.9712

IGL953	83.232	6.768	6.7681

IGL869	82.321	7.679	7.6795

IGL921	82.583	7.418	7.4176

IGL928	82.321	7.679	7.6795

IGL952	69.296	20.705	7.1808

IGL957	82.82	7.181	7.1808

IGL988	82.583	7.418	7.4176

IGL969	83.035	6.965	6.9653

F-4



APPENDIX F  - UTERINE IMPLANTATION DATA 

(INDIVIDUAL UTERINE IMPLANTATION DATA)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE:  2000 MG/M3

ANIMAL 

	NUMBER	Live	Male	Female	Resorp	Implants	CL	Dead	Mal	Var

IGL889	14	8	6	0	14	14	0	0	1

IGL893	17	9	8	0	17	17	0	0	2

IGL885	14	6	8	0	14	14	0	0	0

IGL890	15	8	7	0	15	16	0	0	0

IGL863	16	3	13	0	16	16	0	0	3

IGL878	16	11	5	0	16	18	0	0	3

IGL882	16	6	10	0	16	16	0	0	0

IGL911	14	5	9	1	15	15	0	4	3

IGL868	14	6	8	0	14	14	0	0	0

IGL912	15	8	7	0	15	15	0	0	1

IGL913	11	5	6	0	11	11	0	0	0

IGL925	13	6	7	0	13	13	0	0	0

IGL944 NP

	IGL871	11	8	3	0	11	12	0	0	1

IGL922	15	7	8	0	15	18	0	0	0

IGL951	15	7	8	0	15	16	0	0	0

IGL859	12	6	6	2	14	14	0	0	1

IGL943	13	5	8	0	13	13	0	0	1

IGL948	15	7	8	1	16	16	0	0	2

IGL974	1	0	1	0	1	1	0	0	1

IGL888	15	5	10	0	15	16	0	0	0

IGL976	5	3	2	0	5	10	0	0	1

IGL923	12	4	8	0	12	12	0	0	1

IGL924	13	3	10	0	13	16	0	0	1

IGL905 NP

	

F-5



APPENDIX F  - UTERINE IMPLANTATION DATA 

(INDIVIDUAL UTERINE IMPLANTATION DATA)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE:  2000 MG/M3

ANIMAL 	F/I	R/I	D/I

NUMBER	Tran	Tran	Tran

IGL889	82.321	7.679	7.6795

IGL893	83.035	6.965	6.9653

IGL885	82.321	7.679	7.6795

IGL890	82.583	7.418	7.4176

IGL863	82.820	7.181	7.1808

IGL878	82.820	7.181	7.1808

IGL882	82.820	7.181	7.1808

IGL911	75.037	14.963	7.4176

IGL868	82.321	7.679	7.6795

IGL912	82.583	7.418	7.4176

IGL913	81.330	8.671	8.6708

IGL925	82.029	7.971	7.9712

IGL944 NP

	IGL871	81.330	8.671	8.6708

IGL922	82.583	7.418	7.4176

IGL951	82.583	7.418	7.4176

IGL859	67.793	22.208	7.6795

IGL943	82.029	7.971	7.9712

IGL948	75.523	14.478	7.1808

IGL974	60.000	30.000	30.0002

IGL888	82.583	7.418	7.4176

IGL976	77.079	12.921	12.921

IGL923	81.702	8.299	8.299

IGL924	82.029	7.971	7.9712

IGL905 NP

	

F-6



APPENDIX F  - UTERINE IMPLANTATION DATA 

(INDIVIDUAL UTERINE IMPLANTATION DATA)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE:  10,000 MG/M3

ANIMAL 

	NUMBER	Live	Male	Female	Resorp	Implants	CL	Dead	Mal	Var

IGL870	12	6	6	1	13	13	0	0	0

IGL875	16	11	5	0	16	16	0	0	0

IGL862	11	4	7	0	11	12	0	0	0

IGL858	15	6	9	1	16	16	0	0	0

IGL883	16	5	11	1	17	17	0	2	1

IGL896	14	10	4	1	15	15	0	1	2

IGL906	14	7	7	1	15	16	0	0	1

IGL861	14	5	9	0	14	15	0	0	1

IGL903	16	7	9	0	16	16	0	0	2

IGL914	14	8	6	1	15	16	0	0	1

IGL918	14	9	5	0	14	14	0	0	1

IGL907	16	6	10	0	16	17	0	0	1

IGL909	16	6	10	0	16	16	0	0	0

IGL946	15	10	5	0	15	15	0	0	0

IGL954	15	6	9	0	15	16	0	0	2

IGL955	13	5	8	0	13	14	0	0	1

IGL934	14	10	4	0	14	14	0	0	0

IGL973 NP

	IGL881	14	4	10	1	15	15	0	0	1

IGL917	16	8	8	0	16	16	0	0	0

IGL940	9	6	3	2	11	11	0	0	1

IGL963	13	7	6	0	13	13	0	0	1

IGL983 NP

	IGL972	12	7	5	0	12	12	0	0	0

IGL895	18	11	7	0	18	18	0	0	0

F-7



APPENDIX F  - UTERINE IMPLANTATION DATA 

(INDIVIDUAL UTERINE IMPLANTATION DATA)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE:  10,000 MG/M3

ANIMAL 	F/I	R/I	D/I

NUMBER	Tran	Tran	Tran

IGL870	73.898	16.102	7.9712

IGL875	82.820	7.181	7.1808

IGL862	81.330	8.671	8.6708

IGL858	75.523	14.478	7.1808

IGL883	75.964	14.036	6.9653

IGL896	75.037	14.963	7.4176

IGL906	75.037	14.963	7.4176

IGL861	82.321	7.679	7.6795

IGL903	82.820	7.181	7.1808

IGL914	75.037	14.963	7.4176

IGL918	82.321	7.679	7.6795

IGL907	82.820	7.181	7.1808

IGL909	82.820	7.181	7.1808

IGL946	82.583	7.418	7.4176

IGL954	82.583	7.418	7.4176

IGL955	82.029	7.971	7.9712

IGL934	82.321	7.679	7.6795

IGL973 NP

	IGL881	75.037	14.963	7.4176

IGL917	82.820	7.181	7.1808

IGL940	64.761	25.240	8.6708

IGL963	82.029	7.971	7.9712

IGL983 NP

	IGL972	81.702	8.299	8.299

IGL895	83.232	6.768	6.7681

F-8



APPENDIX F  - UTERINE IMPLANTATION DATA 

(INDIVIDUAL UTERINE IMPLANTATION DATA)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE:  20,000 MG/M3

ANIMAL 

	NUMBER	Live	Male	Female	Resorp	Implants	CL	Dead	Mal	Var

IGL866	12	5	7	0	12	12	0	1	1

IGL892	15	9	6	0	15	15	0	0	1

IGL864	12	8	4	0	12	12	0	0	1

IGL872	16	5	11	0	16	16	0	0	2

IGL873	13	4	9	0	13	14	0	0	1

IGL879	21	9	12	0	21	25	0	0	2

IGL884	12	7	5	0	12	13	0	0	2

IGL886	13	8	5	1	14	15	0	0	3

IGL915 NP

	IGL867	17	7	10	1	18	19	0	0	1

IGL898	16	7	9	0	16	16	0	0	0

IGL929	15	8	7	0	15	15	0	0	1

IGL877	16	8	8	0	16	16	0	0	1

IGL937	15	7	8	0	15	15	0	0	1

IGL950	14	6	8	0	14	14	0	0	3

IGL958	15	5	10	0	15	16	0	0	0

IGL945	15	4	11	0	15	15	0	0	1

IGL967	15	7	8	2	17	17	0	0	0

IGL959	13	6	7	1	14	14	0	0	3

IGL962	13	7	6	1	14	15	0	0	4

IGL949	14	4	10	0	14	14	0	0	4

IGL916	11	5	6	1	12	12	0	0	1

IGL938	12	5	7	0	13	13	0	1	3

IGL961	15	7	8	0	15	15	0	0	0

IGL970	15	6	9	0	15	15	0	0	2

F-9



APPENDIX F  - UTERINE IMPLANTATION DATA 

(INDIVIDUAL UTERINE IMPLANTATION DATA)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE:  20,000 MG/M3

ANIMAL 	F/I	R/I	D/I

NUMBER	Tran	Tran	Tran

IGL866	81.702	8.299	8.299

IGL892	82.583	7.418	7.4176

IGL864	81.702	8.299	8.299

IGL872	82.820	7.181	7.1808

IGL873	82.029	7.971	7.9712

IGL879	83.737	6.264	6.264

IGL884	81.702	8.299	8.299

IGL886	74.499	15.501	7.6795

IGL915 NP

	IGL867	76.367	13.633	6.7681

IGL898	82.820	7.181	7.1808

IGL929	82.583	7.418	7.4176

IGL877	82.820	7.181	7.1808

IGL937	82.583	7.418	7.4176

IGL950	82.321	7.679	7.6795

IGL958	82.583	7.418	7.4176

IGL945	82.583	7.418	7.4176

IGL967	69.941	20.06	6.9653

IGL959	74.499	15.501	7.6795

IGL962	74.499	15.501	7.6795

IGL949	82.321	7.679	7.6795

IGL916	73.222	16.779	8.299

IGL938	73.898	7.971	7.9712

IGL961	82.583	7.418	7.4176

IGL970	82.583	7.418	7.4176

NOTE:	NP - ANIMAL NOT PREGNANT

F-10

APPENDIX G - FETAL BODY WEIGHTS

MEAN FETAL WEIGHT AND LEAST SQUARES MEAN FETAL WEIGHT

Exposure Group

(mg/m3)	n litters 	n fetuses	observed fetus mean (gm)	Least squares
fetus mean (gm)

0	25	385	5.29	5.32

2,000	23	302	5.33	5.29

10,000	23	327	5.29	5.29

20,000	24	345	5.13	 5.16

MEAN FETAL BODY WEIGHTS BY SEX

MALES

FEMALES

	0 MG/M3

	MEAN

5.40

5.17

	STD. DEV.

0.43

0.42

	(N)

25

25

2000 MG/M3

MEAN

5.50

5.19

	STD. DEV.

0.35

0.38

	(N)

22

23

10,000 MG/M3

MEAN

5.41

5.17

	STD. DEV.

0.44

0.33

	(N)

23

23

20,000 MG/M3

	    

	MEAN

5.29

5.01

	STD. DEV.

0.46

0.37

	(N)

24

24

	

G-1



APPENDIX G - INDIVIDUAL AND MEAN FETAL BODY WEIGHT AND LITTER WEIGHTS

(GRAMS)

TARGET DOSE: 0 MG/M3

ANIMAL

	Litter Weights	Fetus Weight

	NUMBER 	SEX

Litter

	Males	Females

	IGL897	M	5.21	5.11	5.33	5.36	5.42	6.31	5.29	5.22	5.34	5.38	5.33

	95.02

Mean	5.39	5.10

	IGL897	F	4.94	4.94	5.20	5.43	4.91	5.20	5.10

	S.D.	0.32	0.19

	IGL899	M	5.11	5.73	5.61	4.77	5.29	5.05	5.11

	70.89

Mean	5.24	4.89

	IGL899	F	5.08	4.59	4.85	4.99	4.82	4.88	5.01

	S.D.	0.33	0.16

	IGL874	M	5.35	5.84	5.46	5.64	5.34	5.69	5.96	5.59	5.22	5.72	5.04

	91.92

Mean	5.53	5.18

	IGL874	F	5.24	5.47	5.24	5.05	4.88	5.19

S.D.	0.28	0.20

	IGL857	M	5.70	5.41	5.94	5.49	5.54	5.93

88.57

Mean	5.67	5.46

	IGL857	F	5.24	5.32	5.21	5.30	5.32	5.38	5.80	5.70	5.81	5.48

S.D.	0.23	0.23

	IGL865	M	5.31	5.61	5.41	4.90

76.16

Mean	5.31	4.99

	IGL865	F	4.84	4.74	4.98	5.16	4.84	5.39	4.98	5.07	4.72	5.22	4.99

	S.D.	0.30	0.21

	IGL876	M	3.77	3.99	4.97	4.91	5.08	5.12	5.33	4.61	5.18

	69.38

Mean	4.77	4.40

	IGL876	F	4.76	1.96	4.72	4.69	5.08	5.21

S.D.	0.55	1.22

	IGL880	M	5.80	6.03	6.08	5.48	5.57	5.64	6.11	5.99	6.11

	87.14

Mean	5.87	5.72

	IGL880	F	5.49	5.49	5.52	5.83	6.12	5.88

S.D.	0.25	0.26

	IGL894	M	5.79	5.90	6.04	5.81	6.02	5.99	5.86

	84.81

Mean	5.92	5.43

	IGL894	F	5.51	5.66	5.47	5.17	5.48	5.62	5.11	5.38

S.D.	0.10	0.20

	IGL902	M	5.41	5.66	5.80	5.51	5.44	5.21	4.73

	79.53

Mean	5.39	5.22

	IGL902	F	5.01	5.30	5.41	5.07	5.24	5.11	5.27	5.36

S.D.	0.35	0.14

	IGL891	M	5.26	5.15	5.07	5.02	4.87	5.01	5.00	4.87	5.22	5.38

85.76

Mean	5.09	4.99

	IGL891	F	4.80	5.08	5.26	5.20	4.73	4.96	4.88

	S.D.	0.17	0.20

	IGL901	M	5.38	5.12	5.01	5.41	5.38

	87.14

Mean	5.26	5.07

	IGL901	F	5.11	4.90	4.99	5.09	5.16	5.03	5.14	5.13	5.34	5.03	4.99	4.93

S.D.	0.18	0.12

	IGL904	M	5.75	5.63	5.43	5.82	5.64	5.20	5.43	4.70	5.57	5.23	5.33	5.29

102.59

Mean	5.42	5.37

	IGL904	F	5.00	5.48	5.69	5.44	5.42	5.43	5.11

	S.D.	0.30	0.23

	IGL910	M	4.94	5.65	5.43	5.45	5.82	5.58	5.86	5.99

81.94

Mean	5.59	5.32

	IGL910	F	4.98	5.30	5.78	5.18	5.55	5.20	5.23

	S.D.	0.33	0.27

	IGL933	M	5.59	5.84	6.22	5.82	6.42	6.01

64.28

Mean	5.98	5.68

	IGL933	F	5.49	5.67	5.55	5.93	5.74

	S.D.	0.30	0.17

	IGL956	M	5.68	5.46	5.70	5.76	4.05	5.88	5.57	5.33	5.38

	75.84

Mean	5.42	5.41

	IGL956	F	5.75	5.28	5.57	5.52	4.91

	S.D.	0.55	0.32

	

G-2



APPENDIX G - INDIVIDUAL AND MEAN FETAL BODY WEIGHT AND LITTER WEIGHTS

(GRAMS)

TARGET DOSE: 0 MG/M3

ANIMAL

	Litter Weights	Fetus Weight

	NUMBER 	SEX

Litter

	Males	Females

	IGL920	M	5.70	5.44	4.97	5.60	5.73	5.23

82.39

Mean	5.45	4.97

	IGL920	F	4.59	5.18	4.85	5.12	4.90	5.13	5.30	4.44	5.29	4.92

S.D.	0.30	0.29

	IGL931	M	4.88	5.16	5.16	5.47	4.97	4.77	5.11	4.91	4.80

	64.44

Mean	5.03	4.80

	IGL931	F	4.29	4.78	5.33	4.81

S.D.	0.22	0.42

	IGL953	M	5.30	5.50	5.59	5.49	5.92	5.75	5.25	5.39	5.31	5.19

94.66

Mean	5.47	5.00

	IGL953	F	4.75	4.78	4.89	5.00	5.15	5.28	5.42	4.70

S.D.	0.23	0.26

	IGL869	M	5.32	5.17	5.18	5.25	5.15	5.73	5.72	5.70

72.70

Mean	5.40	4.91

	IGL869	F	4.99	5.09	4.99	4.60	4.77	5.04

S.D.	0.27	0.19

	IGL921	M	5.31	5.33	5.47	5.33	5.46	5.27

77.92

Mean	5.36	5.08

	IGL921	F	5.48	5.22	4.98	4.79	4.91	5.12	4.90	4.91	5.44

	S.D.	0.08	0.25

	IGL928	M	5.15	4.40	5.00	5.35	5.29	5.53	5.84	5.38

73.50

Mean	5.24	5.26

	IGL928	F	5.11	5.09	5.61	5.22	5.15	5.38

S.D.	0.42	0.20

	IGL952	M	5.31	5.80	5.58	5.16	5.44	5.50	5.31	5.46

75.03

Mean	5.45	5.25

	IGL952	F	4.84	5.45	5.12	5.20	5.41	5.45

S.D.	0.19	0.24

	IGL957	M	5.54	5.87	5.82	5.60

86.24

Mean	5.71	5.28

	IGL957	F	5.04	5.22	5.27	5.19	5.15	5.13	5.85	5.97	5.29	5.19	5.17	4.94

S.D.	0.16	0.31

	IGL988	M	5.76	5.63	5.94	3.76	5.73	5.99	6.46	5.74

85.34

Mean	5.63	5.76

	IGL988	F	5.35	5.77	5.84	5.50	6.39	5.76	5.72

	S.D.	0.80	0.33

	IGL969	M	4.78	4.91	4.92	4.98	4.99	4.84	4.92	5.05

82.50

Mean	4.92	4.79

	IGL969	F	4.39	4.59	5.17	4.48	5.20	4.62	4.94	4.87	4.85

	S.D.	0.09	0.29

	NOTE: NP- NOT PREGNANT

G-3



APPENDIX G - INDIVIDUAL AND MEAN FETAL BODY WEIGHT AND LITTER WEIGHTS

(GRAMS)

TARGET DOSE: 2000 MG/M3

ANIMAL

	Litter Weights	Fetus Weight

	NUMBER 	SEX

Litter

	Males	Females

	IGL889	M	5.89	5.99	5.76	6.14	5.70	5.93	5.48	5.84

78.76

Mean	5.84	5.34

	IGL889	F	4.86	5.53	5.74	5.83	4.86	5.21

S.D.	0.20	0.43

	IGL893	M	6.08	5.89	4.56	5.76	6.07	5.45	5.36	5.72	5.46

	93.84

Mean	5.59	5.44

	IGL893	F	5.64	5.47	4.96	5.34	5.38	5.57	5.67	5.46

S.D.	0.47	0.23

	IGL885	M	5.81	5.60	5.92	5.59	4.59	5.41

76.56

Mean	5.49	5.46

	IGL885	F	5.78	5.59	5.05	5.36	5.72	5.67	5.05	5.42

S.D.	0.47	0.29

	IGL890	M	5.47	5.39	5.63	5.73	5.68	5.97	5.55	5.56

81.50

Mean	5.62	5.22

	IGL890	F	5.54	5.35	5.55	5.04	5.02	4.70	5.32

	S.D.	0.18	0.31

	IGL863	M	5.30	5.73	5.48

	81.63

Mean	5.50	5.01

	IGL863	F	5.00	5.34	5.08	4.77	5.33	4.86	5.19	5.04	5.02	4.91	4.92	4.84
4.82

	S.D.	0.22	0.19

	IGL878	M	5.34	5.74	5.39	5.77	5.17	5.42	5.13	5.58	5.29	5.60	5.97

	85.51

Mean	5.49	5.02

	IGL878	F	4.84	5.46	5.07	5.02	4.72

	S.D.	0.26	0.28

	IGL882	M	5.38	5.59	5.03	5.18	5.52	5.28

80.82

Mean	5.33	4.88

	IGL882	F	5.05	5.11	4.80	5.06	4.72	4.91	4.57	4.61	5.14	4.87

S.D.	0.21	0.21

	IGL911	M	5.07	5.45	5.47	5.63	5.50

	71.88

Mean	5.42	4.97

	IGL911	F	5.21	5.51	2.65	5.39	5.39	5.27	5.12	4.91	5.31

	S.D.	0.21	0.89

	IGL868	M	5.18	5.37	5.58	5.77	5.12	5.46

71.66

Mean	5.41	4.90

	IGL868	F	5.45	5.15	5.16	5.22	4.40	4.82	4.32	4.66

S.D.	0.24	0.41

	IGL912	M	5.25	5.18	5.58	5.43	5.11	5.18	5.28	5.22

76.83

Mean	5.28	4.94

	IGL912	F	4.53	5.28	4.85	5.01	4.95	5.13	4.85

	S.D.	0.15	0.24

	IGL913	M	5.72	5.72	5.99	5.27	5.62

	60.64

Mean	5.66	5.39

	IGL913	F	5.09	5.65	5.57	5.12	5.16	5.73

S.D.	0.26	0.29

	IGL925	M	5.50	5.39	5.52	5.52	5.57	5.00

68.75

Mean	5.42	5.18

	IGL925	F	5.13	5.37	5.06	5.20	5.49	5.06	4.94

	S.D.	0.21	0.19

	   IGL944 NP

	   IGL944NP

	IGL871	M	5.44	5.22	5.07	6.02	5.45	5.74	5.60	5.25

59.16

Mean	5.47	5.12

	IGL871	F	5.05	5.30	5.02

	S.D.	0.31	0.15

	IGL922	M	5.51	5.50	5.79	5.56	5.76	5.50	5.78

	81.86

Mean	5.63	5.31

	IGL922	F	5.11	5.32	5.18	5.08	5.45	5.36	5.31	5.65

S.D.	0.14	0.19

	

G-4



APPENDIX G - INDIVIDUAL AND MEAN FETAL BODY WEIGHT AND LITTER WEIGHTS 

(GRAMS)

TARGET DOSE: 2000 MG/M3

ANIMAL

	Litter Weights	Fetus Weight

	NUMBER 	SEX

Litter

	Males	Females

	IGL951	M	5.49	5.19	5.49	5.66	5.33	5.35	5.56

	80.74

Mean	5.44	5.33

	IGL951	F	5.30	5.51	5.30	5.59	5.34	5.31	5.28	5.04

S.D.	0.16	0.16

	IGL859	M	5.64	5.75	5.66	6.06	5.58	5.38

66.02

Mean	5.68	5.33

	IGL859	F	5.51	5.46	5.24	5.57	5.27	4.90

S.D.	0.22	0.25

	IGL943	M	5.52	5.64	4.67	5.39	5.20

	68.12

Mean	5.28	5.21

	IGL943	F	5.31	5.27	5.38	5.34	5.02	5.14	5.05	5.19

S.D.	0.38	0.13

	IGL948	M	5.79	5.83	6.39	5.61	5.85	6.08	5.36

	86.40

Mean	5.84	5.69

	IGL948	F	5.26	5.61	5.85	5.52	5.95	5.84	5.87	5.59

S.D.	0.33	0.23

	IGL974	M

4.66

Mean

4.66

	IGL974	F	4.66

	S.D.

	IGL888	M	5.00	5.76	5.38	5.22	6.02

	80.85

Mean	5.48	5.35

	IGL888	F	5.41	5.32	5.85	5.44	5.29	4.86	5.13	5.31	5.43	5.43

S.D.	0.41	0.25

	IGL976	M	5.32	5.15	4.79

	25.45

Mean	5.09	5.10

	IGL976	F	5.09	5.10

S.D.	0.27	0.01

	IGL923	M	5.72	5.32	3.81	5.63

60.72

Mean	5.12	5.03

	IGL923	F	4.94	5.39	5.02	5.19	5.05	5.34	5.46	3.85

S.D.	0.89	0.51

	IGL924	M	5.59	5.42	4.78

	67.67

Mean	5.26	5.19

	IGL924	F	5.40	5.32	5.40	5.21	5.16	4.47	5.00	5.33	5.44	5.15

S.D.	0.43	0.29

	   IGL905 NP

	   IGL905 NP

	NOTE: NP- NOT PREGNANT

G-5



APPENDIX G - INDIVIDUAL AND MEAN FETAL BODY WEIGHT AND LITTER WEIGHTS 

(GRAMS)

TARGET DOSE: 10,000 MG/M3

ANIMAL

	Litter Weights	Fetus Weight

	NUMBER 	SEX

Litter

	Males	Females

	IGL870	M	5.64	5.42	5.57	5.38	5.15	5.55

63.34

Mean	5.45	5.11

	IGL870	F	5.03	4.90	5.24	5.17	5.07	5.22

S.D.	0.18	0.13

	IGL875	M	5.08	5.23	5.64	5.39	5.00	5.23	5.72	5.38	5.42	5.39	4.84

	83.52

Mean	5.30	5.04

	IGL875	F	5.04	5.18	4.94	4.88	5.16

	S.D.	0.26	0.13

	IGL862	M	5.30	6.05	5.86	6.06

61.86

Mean	5.82	5.51

	IGL862	F	5.66	5.42	5.66	5.71	5.30	5.42	5.42

	S.D.	0.36	0.16

	IGL858	M	4.97	4.65	5.10	5.03	5.40	5.03

74.46

Mean	5.03	4.92

	IGL858	F	5.00	4.77	4.79	4.78	4.77	4.96	5.24	4.90	5.07

	S.D.	0.24	0.16

	IGL883	M	4.88	4.99	5.21	4.76	5.02

	78.10

Mean	4.97	4.84

	IGL883	F	4.49	4.79	4.81	4.73	4.85	4.73	5.17	5.11	4.97	4.59	5.00

	S.D.	0.17	0.21

	IGL896	M	5.41	5.32	5.26	5.54	5.72	5.51	5.27	5.48	5.91	5.65

75.99

Mean	5.51	5.23

	IGL896	F	5.16	5.29	5.11	5.36

S.D.	0.21	0.12

	IGL906	M	5.56	5.60	5.98	5.44	5.43	5.67	5.88

	77.22

Mean	5.65	5.38

	IGL906	F	5.49	5.26	5.66	5.12	5.57	5.47	5.09

	S.D.	0.21	0.22

	IGL861	M	5.72	5.08	5.33	5.37	2.55

	73.26

Mean	4.81	5.47

	IGL861	F	5.04	5.38	5.80	5.75	5.09	5.42	5.64	5.39	5.70

	S.D.	1.28	0.28

	IGL903	M	5.52	5.52	5.38	5.57	5.32	5.19	5.39

	83.52

Mean	5.41	5.07

	IGL903	F	5.07	5.12	5.01	5.27	5.10	4.94	5.00	4.87	5.25

	S.D.	0.13	0.13

	IGL914	M	5.18	5.44	5.82	5.71	5.80	5.53	5.79	5.46

76.84

Mean	5.59	5.35

	IGL914	F	5.22	5.26	5.50	5.30	5.39	5.44

S.D.	0.23	0.11

	IGL918	M	5.63	5.79	5.44	5.18	5.65	5.39	5.12	5.10	5.55

	74.17

Mean	5.43	5.06

	IGL918	F	4.52	5.38	5.29	4.97	5.16

	S.D.	0.25	0.34

	IGL907	M	6.18	5.36	5.77	5.24	5.58	5.72

85.71

Mean	5.64	5.19

	IGL907	F	5.04	5.60	5.09	5.19	5.37	5.03	4.98	4.99	5.14	5.43

S.D.	0.33	0.21

	IGL909	M	4.36	5.06	5.17	5.66	5.58	4.94

81.48

Mean	5.13	5.07

	IGL909	F	4.59	5.12	5.22	4.99	5.24	5.19	5.50	4.72	5.04	5.10

S.D.	0.47	0.26

	IGL946	M	5.35	5.09	5.38	5.04	5.63	5.43	5.49	5.24	4.90	5.36

77.80

Mean	5.29	4.98

	IGL946	F	5.22	5.08	4.82	4.61	5.16

	S.D.	0.22	0.26

	IGL954	M	6.11	5.58	5.83	6.07	5.83	5.27

82.44

Mean	5.78	5.31

	IGL954	F	5.44	5.50	5.51	5.38	3.45	5.55	5.80	5.49	5.63

	S.D.	0.32	0.71

	

G-6



APPENDIX G - INDIVIDUAL AND MEAN FETAL BODY WEIGHT AND LITTER WEIGHTS 

(GRAMS)

TARGET DOSE: 10,000 MG/M3

ANIMAL

	Litter Weights	Fetus Weight

	NUMBER 	SEX

Litter

	Males	Females

	IGL955	M	5.43	4.81	5.40	5.44	5.67

	67.58

Mean	5.35	5.10

	IGL955	F	5.02	5.28	4.82	5.12	4.72	4.89	5.33	5.65

S.D.	0.32	0.31

	IGL934	M	5.33	5.81	5.76	5.45	5.77	5.20	4.98	5.41	5.49	5.79

75.30

Mean	5.50	5.08

	IGL934	F	4.90	5.16	5.42	4.83

S.D.	0.28	0.27

	   IGL973 NP

	   IGL973 NP

	IGL881	M	5.53	5.73	5.19	5.29

75.29

Mean	5.44	5.36

	IGL881	F	4.89	5.05	5.70	5.84	5.29	5.52	5.46	5.26	5.29	5.25

S.D.	0.24	0.28

	IGL917	M	4.94	4.93	4.60	4.81	5.08	5.03	5.37	4.95

77.94

Mean	4.96	4.78

	IGL917	F	4.48	4.95	4.96	4.98	4.77	5.02	4.49	4.58

S.D.	0.22	0.23

	IGL940	M	5.78	5.92	5.83	6.18	5.95	6.17

53.40

Mean	5.97	5.86

	IGL940	F	5.75	5.89	5.93

	S.D.	0.17	0.09

	IGL963	M	5.83	5.82	5.64	5.43	5.57	5.52	5.92

	72.02

Mean	5.68	5.38

	IGL963	F	5.45	5.46	5.20	5.46	5.39	5.33

S.D.	0.18	0.10

	   IGL983 NP

	   IGL983 NP

	IGL972	M	5.43	5.78	5.93	5.49	5.69	5.37	5.80

	66.02

Mean	5.64	5.31

	IGL972	F	5.31	5.49	5.19	5.24	5.30

	S.D.	0.21	0.11

	IGL895	M	4.94	5.02	5.14	5.20	5.85	5.53	5.69	5.54	5.64	4.88	3.42

	92.67

Mean	5.17	5.12

	IGL895	F	5.15	4.92	5.22	4.90	5.34	5.21	5.08

	S.D.	0.67	0.16

	NOTE: NP- NOT PREGNANT

G-7



APPENDIX G - INDIVIDUAL AND MEAN FETAL BODY WEIGHT AND LITTER WEIGHTS 

(GRAMS)

TARGET DOSE: 20,000 MG/M3

ANIMAL

	Litter Weights	Fetus Weight

	NUMBER 	SEX

Litter

	Males	Females

	IGL866	M	6.04	6.29	6.19	6.06	5.80

	69.71

Mean	6.08	5.62

	IGL866	F	5.58	6.00	5.61	5.88	4.79	5.89	5.58

	S.D.	0.18	0.40

	IGL892	M	5.56	5.37	5.46	5.29	5.64	5.29	5.25	5.30	5.42

	78.99

Mean	5.40	5.07

	IGL892	F	4.55	5.73	5.06	5.03	5.06	4.98

S.D.	0.13	0.38

	IGL864	M	5.00	5.24	4.98	5.38	5.46	5.17	5.35	5.58

62.27

Mean	5.27	5.03

	IGL864	F	5.17	5.05	5.10	4.79

S.D.	0.21	0.17

	IGL872	M	4.86	4.84	4.99	4.67	3.53

	74.02

Mean	4.58	4.65

	IGL872	F	4.32	4.72	4.73	4.66	4.73	4.30	4.70	4.39	5.08	4.88	4.62

	S.D.	0.60	0.24

	IGL873	M	5.55	5.77	5.45	5.86

70.15

Mean	5.66	5.28

	IGL873	F	5.27	5.21	5.16	5.36	5.37	5.70	5.16	5.28	5.01

	S.D.	0.19	0.19

	IGL879	M	4.68	4.87	4.91	5.09	5.10	5.02	4.73	4.58	4.66

	96.13

Mean	4.85	4.37

	IGL879	F	4.18	4.20	4.70	4.31	4.61	4.35	4.08	4.35	4.53	4.44	4.32	4.42

S.D.	0.20	0.18

	IGL884	M	5.38	5.57	5.32	5.86	5.87	5.56	5.63

	65.27

Mean	5.60	5.22

	IGL884	F	5.24	5.44	4.87	5.48	5.05

	S.D.	0.21	0.26

	IGL886	M	5.37	5.12	5.44	5.47	5.23	6.00	5.78	5.26

69.68

Mean	5.46	5.20

	IGL886	F	5.24	5.07	5.41	5.03	5.26

	S.D.	0.30	0.15

	   IGL915 NP

	   IGL915 NP

	IGL867	M	5.52	5.49	5.30	5.41	5.37	5.61	5.25

	87.97

Mean	5.42	5.00

	IGL867	F	4.03	5.33	5.23	5.32	4.82	4.95	5.24	4.98	4.96	5.16

S.D.	0.13	0.38

	IGL898	M	3.86	4.95	5.35	5.38	5.06	5.30	4.99

	77.98

Mean	4.98	4.79

	IGL898	F	4.78	4.43	4.76	4.77	4.74	4.59	4.91	5.00	5.11

	S.D.	0.53	0.20

	IGL929	M	5.15	4.94	4.93	5.31	5.29	3.98	5.77	5.19

74.25

Mean	5.07	4.81

	IGL929	F	5.00	4.96	4.88	4.52	4.97	4.66	4.70

	S.D.	0.51	0.19

	IGL877	M	5.14	4.99	5.19	5.00	4.98	5.07	5.13	5.09

79.87

Mean	5.07	4.91

	IGL877	F	5.18	4.74	5.17	4.73	5.15	4.62	4.99	4.70

S.D.	0.08	0.24

	IGL937	M	5.58	4.74	5.06	4.34	5.21	4.89	4.83

	74.00

Mean	4.95	4.92

	IGL937	F	4.85	4.74	4.90	4.69	5.33	5.10	5.03	4.71

S.D.	0.39	0.22

	IGL950	M	5.32	5.52	5.91	5.41	5.58	5.53

73.98

Mean	5.55	5.09

	IGL950	F	5.00	5.39	4.97	5.18	5.09	5.06	5.17	4.85

S.D.	0.20	0.16

	

G-8



APPENDIX G - INDIVIDUAL AND MEAN FETAL BODY WEIGHT AND LITTER WEIGHTS 

(GRAMS)

TARGET DOSE: 20,000 MG/M3

ANIMAL

	Litter Weights	Fetus Weight

	NUMBER 	SEX

Litter

	Males	Females

	IGL958	M	4.78	5.64	4.99	4.95	5.19

	74.73

Mean	5.11	4.92

	IGL958	F	4.42	4.97	4.88	4.82	4.89	5.25	5.12	5.35	4.82	4.66

S.D.	0.33	0.27

	IGL945	M	4.98	5.45	5.46	5.52

77.07

Mean	5.35	5.06

	IGL945	F	5.28	5.30	4.89	5.31	5.19	5.19	4.88	4.93	4.72	5.19	4.78

	S.D.	0.25	0.22

	IGL967	M	5.50	6.08	5.96	5.18	5.62	5.55	5.47

	81.81

Mean	5.62	5.31

	IGL967	F	5.13	5.36	5.30	5.37	5.13	5.37	5.25	5.54

S.D.	0.31	0.14

	IGL959	M	5.55	6.09	6.09	5.54	5.82	5.30

72.74

Mean	5.73	5.48

	IGL959	F	5.28	5.76	5.72	5.53	5.58	5.16	5.32

	S.D.	0.32	0.23

	IGL962	M	4.45	3.14	5.20	4.82	5.19	5.49	5.06

	62.04

Mean	4.76	4.78

	IGL962	F	4.61	4.54	5.06	4.97	4.45	5.06

S.D.	0.79	0.28

	IGL949	M	5.47	5.39	5.76	5.15

71.89

Mean	5.44	5.01

	IGL949	F	5.08	4.87	5.21	5.16	4.49	4.82	5.08	5.11	5.16	5.14

S.D.	0.25	0.22

	IGL916	M	5.58	5.95	6.25	5.87	5.33

	60.32

Mean	5.80	5.22

	IGL916	F	5.06	5.46	5.15	4.46	5.46	5.75

S.D.	0.35	0.45

	IGL938	M	5.82	5.61	5.57	5.63	5.74

	66.70

Mean	5.67	5.48

	IGL938	F	5.69	5.28	5.43	5.40	5.77	5.62	5.14

	S.D.	0.10	0.23

	IGL961	M	5.43	4.93	5.52	5.22	5.11	4.87	5.06

	75.29

Mean	5.16	4.89

	IGL961	F	4.62	4.80	4.59	5.09	4.79	5.09	4.98	5.19

S.D.	0.24	0.23

	IGL970	M	4.95	5.04	5.34	5.05	5.20	4.94

74.00

Mean	5.09	4.83

	IGL970	F	4.88	4.90	4.83	4.79	4.84	4.77	4.98	4.88	4.61

	S.D.	0.16	0.10

	NOTE: NP- NOT PREGNANT

G-9

APPENDIX H  -  FETAL OBSERVATIONS

(INCIDENCE OF FETAL OBSERVATIONS)

	TARGET DOSE:	0 MG/M3

2000 MG/M3

10,000 MG/M3

20,000 MG/M3

TOTAL FETUSES WITH EXTERNAL VARIATIONS	0/385

2/302

0/327

0/345

TOTAL LITTERS WITH EXTERNAL VARIATIONS	[0/25]

[2/23]

[0/23]

[0/24]

	TOTAL FETUSES WITH EXTERNAL MALFORMATIONS	1/385

2/302

2/327

0/345

TOTAL LITTERS WITH EXTERNAL MALFORMATIONS	[1/25]

[1/23]

[1/23]

[0/24]

	TOTAL FETUSES WITH VISCERAL VARIATIONS	1/192

0/151

1/162

0/175

TOTAL LITTERS WITH VISCERAL VARIATIONS	[1/25]

[0/23]

[1/23]

[0/24]

	TOTAL FETUSES WITH VISCERAL MALFORMATIONS	0/192

1/151

0/162

1/175

TOTAL LITTERS WITH VISCERAL MALFORMATIONS	[0/25]

[1/23]

[0/23]

[1/24]

	TOTAL FETUSES WITH SKELETAL VARIATIONS	24/193

21/153

15/165

  38/170

TOTAL LITTERS WITH SKELETAL VARIATIONS	[15/25]

[13/23]

[13/23]

[20/24]

	TOTAL FETUSES WITH SKELETAL MALFORMATIONS	2/193

1/153

1/165

1/170

TOTAL LITTERS WITH SKELETAL MALFORMATIONS	[2/25]

[1/23]

[1/23]

[1/24]

	EXTERNAL EXAMINATIONS

	               - TOTAL FETUSES EXAMINED:	385

302

327

345

               - TOTAL LITTERS EXAMINED:	[25]

[23]

[23]

[24]

	INDIVIDUAL EXTERNAL OBSERVATIONS

	               STUNTED  (<4.0 grams)	4

3

3

4

	[2]

[2]

[3]

[4]

	               EDEMA HEAD	0

1

0

0

	[0]

[1]

[0]

[0]

	

H-1



APPENDIX H  -  FETAL OBSERVATIONS 

(INCIDENCE OF FETAL OBSERVATIONS)

	TARGET DOSE:	0 MG/M3

2000 MG/M3

10,000 MG/M3

20,000 MG/M3

INDIVIDUAL EXTERNAL VARIATIONS

	               PROTRUDING TONGUE	0

2

0

0

	[0]

[2]

[0]

[0]

INDIVIDUAL EXTERNAL MALFORMATIONS 

	             MALROTATED HINDPAW	1

2

2

0

	[1]

[1]

[1]

[0]

	             ADACTYLY	0

1

0

0

	[0]

[1]

[0]

[0]

	             CLEFT PALATE	0

1

0

0

	[0]

[1]

[0]

[0]

	             ECTRODACTYLY	0

1

0

0

	[0]

[1]

[0]

[0]

	             HOOKED TAIL	0

1

0

0

	[0]

[1]

[0]

[0]

	             MICROCEPHALY	0

1

0

0

	[0]

[1]

[0]

[0]

	             SHORT TAIL	0

1

0

0

	[0]

[1]

[0]

[0]

	

H-2



APPENDIX H  -  FETAL OBSERVATIONS 

(INCIDENCE OF FETAL OBSERVATIONS)

	TARGET DOSE:	0 MG/M3

2000 MG/M3

10,000 MG/M3

20,000 MG/M3

VISCERAL EXAMINATIONS

	             - TOTAL FETUSES EXAMINED:	192

151

162

175

             - TOTAL LITTERS EXAMINED:	[25]

[23]

[23]

[24]

	INDIVIDUAL VISCERAL VARIATIONS

	             UMBILICAL ARTERY ARISES FROM LEFT SIDE OF 	1

0

1

0

             URINARY BLADDER	[1]

[0]

[1]

[0]

	INDIVIDUAL VISCERAL MALFORMATIONS

	             MALPOSITIONED KIDNEY	0

1

0

0

	[0]

[1]

[0]

[0]

	             RETINA FOLD	0

0

0

1

	[0]

[0]

[0]

[1]

SKELETAL EXAMINATIONS

	               - TOTAL FETUSES EXAMINED:	193

153

165

170

               - TOTAL LITTERS EXAMINED:	[25]

[23]

[23]

[24]

	INDIVIDUAL OSSIFICATION VARIATIONS

	               STERNEBRAE

	                         ASYMMETRIC	0

2

1

1

	[0]

[2]

[1]

[1]

	                         BIFID	0

1

0

0

	[0]

[1]

[0]

[0]

	                         HYPOPLASTIC	1

1

0

2

	[1]

[1]

[0]

[1]

H-3



APPENDIX H  -  FETAL OBSERVATIONS 

(INCIDENCE OF FETAL OBSERVATIONS)

	TARGET DOSE:	0 MG/M3

2000 MG/M3

10,000 MG/M3

20,000 MG/M3

INDIVIDUAL OSSIFICATION VARIATIONS (CONT'D)

	                STERNEBRAE (CONT'D)

	                          UNOSSIFIED	1

6

4

1

	[1]

[4]

[4]

[1]

	                RIBS

	                         RUDIMENTARY LUMBAR	16

11

8

29

	[12]

[8]

[7]

[16]

	                         SHORT LAST THORACIC	3

1

1

0

	[3]

[1]

[1]

[0]

                 VERTEBRAE

	                         THORACIC CENTRA BIFID	4

0

0

3

	[3]

[0]

[0]

[3]

	                         THORACIC CENTRA DUMBBELL SHAPED	1

0

0

2

	[1]

[0]

[0]

[2]

	                         EXTRA PRESACRAL	0

0

0

1

	[0]

[0]

[0]

[1]

	

H-4



APPENDIX H  -  FETAL OBSERVATIONS 

(INCIDENCE OF FETAL OBSERVATIONS)

	TARGET DOSE:	0 MG/M3

2000 MG/M3

10,000 MG/M3

20,000 MG/M3

INDIVIDUAL CARTILAGINOUS STRUCTURAL VARIATIONS

	               VERTEBRAE ANLAGE

	                         THORACIC CENTRA DUMBBELL SHAPED	2

1

1

4

	[1]

[1]

[1]

[3]

INDIVIDUAL OSSIFICATION MALFORMATIONS

	               SKULL

	                        MULTIPLE BONES MALFORMED	0

1

0

0

	[0]

[1]

[0]

[0]

              STERNEBRAE

	                        FUSED	1

0

0

0

	[1]

[0]

[0]

[0]

              FOREPAW

	                        MULTIPLE BONES ABSENT	0

1

0

0

	[0]

[1]

[0]

[0]

              RIBS

	                        MULTIPLE BONES MALFORMED	0

1

0

0

	[0]

[1]

[0]

[0]

              VERTEBRAE

	                        LUMBAR ARCH MALFORMED	1

0

0

1

	[1]

[0]

[0]

[1]

	                        SACRAL ARCH MALFORMED	0

0

1

0

	[0]

[0]

[1]

[0]

	                        MULTIPLE VERTEBRAE MALFORMED	0

1

0

0

	[0]

[1]

[0]

[0]

	

H-5



APPENDIX H  -  FETAL OBSERVATIONS 

(INCIDENCE OF FETAL OBSERVATIONS)

	TARGET DOSE:	0 MG/M3

2000 MG/M3

10,000 MG/M3

20,000 MG/M3

INDIVIDUAL OSSIFICATION MALFORMATIONS (CONT'D)

              HINDPAW

	                        MULTIPLE BONES ABSENT	0

1

0

0

	[0]

[1]

[0]

[0]

INDIVIDUAL CARTILAGINOUS MALFORMATIONS

	               RIBS ANLAGE

	                         FUSED	1

0

0

0

	[1]

[0]

[0]

[0]

	

H-6

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL897

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	2          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+	+	+

	2	A	F	+

	+

3	A	F	+	+	+

	4	A	M	+

	+

5	A	M	+	+	+

	6	A	M	+

	+

7	A	M	+	+	+

	8	A	F	+

	+

  9C	A	F	+	+	+

	10	A	M	+

	+

11	A	F	+	+	+

	12	A	M	+

	+

13	A	F	+	+	+

	14	A	M	+

	+

15	A	M	+	+	+

	16	A	F	+

	(b)

17	A	M	+	+	+

	18	A	M	+

	(a)

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Left

(b) - SKELETAL/VERTEBRAE (T11): Bifid centra

H-7

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL899

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+	+	+

	2	A	F	+

	+

3	A	M	+	+	+

	4	A	F	+

	+

5	A	F	+	+	+

	6	A	F	+

	+

E

7	A	F	+	+	+

	  8C	A	F	+

	+

9	A	M	+	+	+

	10	A	M	+

	+

11	A	M	+	+	+

	12	A	M	+

	+

13	A	M	+	+	+

	14	A	F	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-8

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL874

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	F	+	+	+

	3	A	M	+

	+

4	A	M	+	+	+

	5	A	M	+

	+

6	A	F	+	+	+

	7	A	M	+

	+

8	A	M	+	+	+

	  9C	A	M	+

	+

10	A	M	+	+	+

	11	A	F	+

	+

12	A	F	+	+	+

	13	A	F	+

	+

14	A	M	+	+	+

	15	A	M	+

	+

16	A	M	+	+	+

	17	A	F	+

	(a)

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

- SKELETAL/RIBS (L1): Rudimentary; Bilateral

H-9

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL857

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+	+	+

	2	A	M	+

	+

3	A	F	+	+	+

	4	A	F	+

	+

5	A	F	+	+	+

	6	A	F	+

	+

7	A	F	+	+	+

	8	A	F	+

	+

  9C	A	M	+	+	+

	10	A	F	+

	+

11	A	M	+	+	+

	12	A	M	+

	+

13	A	F	+	+	+

	14	A	F	+

	+

15	A	F	+	+	+

	16	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-10

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL865

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	2          
MALFORMATIONS:   	1

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	+

3	A	M	+	+	+

	4	A	F	+

	(a)

5	A	F	+	+	+

	6	A	F	+

	+

  7C	A	M	+	+	+

	8	A	F	+

	+

9	A	F	+	+	+

	10	A	F	+

	+

11	A	M	+	+	+

	12	A	M	+

	(b,C)

13	A	F	+	+	+

	14	A	F	+

	+

15	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Left

(b) - SKELETAL/RIBS (T13): Short last rib; Right

(C) - SKELETAL/VERTEBRAE (L6): Malformed arch; Left

H-11

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL876

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	  1*	A	M	+

	+

  2*	A	M	+	+	+

	3	A	F	+

	+

  4*	D	F	+	+	+

	5	A	M	+

	+

6	A	F	+	+	+

	7	A	F	+

	+

8	A	M	+	+	+

	9	A	M	+

	+

  10C	A	M	+	+	+

	11	A	F	+

	+

12	A	F	+	+	+

	13	A	M	+

	+

14	A	M	+	+	+

	15	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

* - Stunted

H-12

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL880

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	(a)

2	A	F	+	+	+

	3	A	M	+

	+

4	A	M	+	+	+

	5	A	F	+

	+

6	A	M	+	+	+

	7	A	M	+

	+

8	A	M	+	+	+

	9	A	F	+

	+

10	A	M	+	+	+

	  11C	A	F	+

	+

12	A	M	+	+	+

	13	A	M	+

	+

14	A	F	+	+	+

	15	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

- SKELETAL/RIBS (L1): Rudimentary; Bilateral

H-13

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL894

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	+

2	A	F	+	+	+

	3	A	M	+

	+

4	A	M	+	+	+

	5	A	M	+

	+

6	A	M	+	+	+

	7	A	M	+

	+

8	A	F	+	+	+

	  9C	A	F	+

	(a)

10	A	M	+	+	+

	11	A	M	+

	+

12	A	F	+	+	+

	13	A	F	+

	+

14	A	F	+	+	+

	15	A	F	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

- SKELETAL/RIBS (T13): Short last rib; Right

H-14

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL902

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	(a)

2	A	M	+	+	+

	3	A	M	+

	+

4	A	F	+	+	+

	E

  EC

5	A	F	+

	+

6	A	F	+	+	+

	7	A	F	+

	+

8	A	M	+	+	+

	9	A	M	+

	+

10	A	M	+	+	+

	11	A	F	+

	+

12	A	F	+	+	+

	13	A	M	+

	+

14	A	F	+	+	+

	15	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Left

H-15

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL891

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	2          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	M	+

	+

3	A	F	+	+	+

	E

4	A	F	+

	+

  5C	A	M	+	+	+

	6	A	F	+

	+

7	A	M	+	+	+

	8	A	M	+

	(b)

9	A	M	+	+	+

	10	A	F	+

	(a)

11	A	M	+	+	+

	12	A	M	+

	+

13	A	M	+	+	+

	14	A	F	+

	+

15	A	F	+	+	+

	16	A	M	+

	+

17	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/STERNEBRAE (II): Hypoplastic

(b) - SKELETAL/RIBS (L1): Rudimentary; Left

H-16

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL901

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+	+	+

	2	A	F	+

	+

3	A	F	+	+	+

	4	A	M	+

	+

5	A	M	+	+	+

	6	A	F	+

	+

7	A	M	+	+	+

	  8C	A	F	+

	+

9	A	F	+	+	+

	10	A	F	+

	+

E

11	A	F	+	+	+

	12	A	F	+

	+

13	A	M	+	+	+

	14	A	F	+

	+

15	A	F	+	+	+

	16	A	F	+

	+

17	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-17

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL904

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	M	+	+	+

	3	A	M	+

	+

4	A	M	+	+	+

	5	A	M	+

	+

6	A	F	+	+	+

	7	A	M	+

	+

8	A	M	+	+	+

	  9C	A	F	+

	+

10	A	F	+	+	+

	11	A	F	+

	+

12	A	F	+	+	+

	13	A	F	+

	+

14	A	M	+	+	+

	15	A	M	+

	+

16	A	M	+	+	+

	17	A	F	+

	+

18	A	M	+	+	+

	19	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-18

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL910

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	M	+	+	+

	3	A	F	+

	+

4	A	M	+	+	+

	5	A	M	+

	+

6	A	M	+	+	+

	7	A	F	+

	+

8	A	M	+	+	+

	  9C	A	M	+

	+

10	A	M	+	+	+

	11	A	F	+

	+

12	A	F	+	+	+

	13	A	F	+

	+

14	A	F	+	+	+

	15	A	F	+

	(a)

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:  Fetus numbers 7, 9, 11, and 13 found with identification tags
detached, numbers arbitrarily assigned for skeletal exams.

(a) - SKELETAL/RIBS (L1): Rudimentary; Left

H-19

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL933

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	(a)

3	A	M	+	+	+

	4	A	F	+

	+

5	A	M	+	+	+

	6	A	M	+

	+

7	A	F	+	+	+

	8	A	M	+

	+

  9C	A	M	+	+	+

	10	A	M	+

	+

11	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/STERNEBRAE (V): Unossified

H-20

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL956

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	F	+	+	+

	3	A	M	+

	(a)

4	A	F	+	+	+

	5	A	M	+

	+

  6C	A	M	+	+	+

	7	A	M	+

	+

8	A	F	+	+	+

	9	A	M	+

	+

10	A	M	+	+	+

	11	A	F	+

	+

12	A	M	+	+	+

	13	A	F	+

	+

14	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Left

H-21

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL920

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	+

2	A	F	+	+	+

	3	A	F	+

	+

4	A	F	+	+	+

	5	A	F	+

	+

6	A	M	+	+	+

	7	A	F	+

	+

8	A	M	+	+	+

	9	A	M	+

	+

10	A	F	+	+	+

	  11C	A	F	+

	+

12	A	F	+	+	+

	13	A	M	+

	+

14	A	F	+	+	+

	15	A	M	+

	+

16	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-22

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL931

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	2          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	M	+

	(a,c)

3	A	M	+	+	+

	4	A	F	+

	+

5	A	M	+	+	+

	  6C	A	F	+

	+

7	A	M	+	+	+

	8	A	M	+

	+

9	A	M	+	+	+

	10	A	M	+

	(b,d)

11	A	F	+	+	+

	12	A	M	+

	+

13	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/VERTEBRAE (T11): Bifid centra

(b) - SKELETAL/VERTEBRAE (T12): Bifid centra

(c) - SKELETAL/VERTEBRAE (T11 anlage): Dumbbell shaped centra

(d) - SKELETAL/VERTEBRAE (T12 anlage): Dumbbell shaped centra

H-23

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL953

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	5          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	(a)

3	A	M	+	+	+

	4	A	F	+

	+

5	A	M	+	+	+

	6	A	F	+

	+

7	A	F	+	+	+

	8	A	M	+

	(b)

9	A	M	+	+	+

	10	A	F	+

	(a)

  11C	A	F	+	+	+

	12	A	M	+

	+

13	A	M	+	+	+

	14	A	M	+

	+

15	A	M	+	+	+

	16	A	M	+

	(a)

17	A	F	+	+	+

	18	A	M	+

	(a)

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Bilateral

(b) - SKELETAL/RIBS (L1): Rudimentary; Left

H-24

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL869

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	+

3	A	M	+	+	+

	4	A	M	+

	+

5	A	M	+	+	+

	6	A	F	+

	+

7	A	M	+	+	+

	8	A	M	+

	+

  9C	A	F	+	+	+

	10	A	M	+

	+

11	A	F	+	+	+

	12	A	M	+

	+

13	A	M	+	+	+

	14	A	F	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-25

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL921

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+	+	+

	2	A	M	+

	+

3	A	F	+	+	+

	4	A	F	+

	+

5	A	F	+	+	+

	6	A	F	+

	+

  7C	A	M	+	+	+

	8	A	F	+

	+

9	A	M	+	+	+

	10	A	M	+

	+

11	A	M	+	+	+

	12	A	F	+

	+

13	A	F	+	+	+

	14	A	F	+

	+

15	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-26

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL928

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	1          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	F	+	+	+

	3	A	M	+

	+

4	A	M	+	+	(a)

	5	A	F	+

	+

6	A	M	+	+	+

	7	A	F	+

	+

8	A	M	+	+	+

	9	A	F	+

	+

10	A	M	+	+	+

	  11C	A	M	+

	+

12	A	M	+	+	+

	13	A	F	+

	(b)

14	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - ABDOMEN/THORAX:  Umbilical artery arises from left side of urinary
bladder

(b) - SKELETAL/RIBS (L1): Rudimentary; Right

H-27

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL952

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	M	+	+	+

	E

3	A	F	+

	+

4	A	M	+	+	+

	5	A	F	+

	+

6	A	F	+	+	+

	E

7	A	F	+

	+

  8C	A	M	+	+	+

	9	A	M	+

	+

10	A	M	+	+	+

	11	A	F	+

	+

12	A	F	+	+	+

	13	A	M	+

	+

14	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-28

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL957

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	M	+

	+

3	A	F	+	+	+

	4	A	F	+

	+

5	A	F	+	+	+

	6	A	F	+

	+

  7C	A	F	+	+	+

	8	A	F	+

	+

9	A	F	+	+	+

	10	A	M	+

	+

11	A	M	+	+	+

	12	A	F	+

	+

13	A	F	+	+	+

	14	A	F	+

	(a)

15	A	M	+	+	+

	16	A	F	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Right

H-29

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL988

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	1

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	2          
MALFORMATIONS:   	1

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	+

2	A	M	+	+	+

	3	A	M	+

	+

4	A	M	+	+	+

	  5*	A	M	+

	(B,C,d,f,g,h)

6	A	F	+	+	+

	7	A	F	+

	(e)

8	A	F	+	+	+

	9C	A	M	+

	+

10	A	F	(A)	+	+

	11	A	M	+

	+

12	A	F	+	+	+

	13	A	M	+

	+

14	A	M	+	+	+

	15	A	F	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

 *   	- Stunted

(A) - EXTERNAL: Malrotated hindpaw; Right

(B) - SKELETAL/STERNEBRAE (IV-VI): Fused

(C) - SKELETAL/RIBS (T1-2 anlage): Fused; Right

(d) - SKELETAL/RIBS (L1): Rudimentary; Bilateral

(e) - SKELETAL/RIBS (T13): Short last rib; Right

(f) - SKELETAL/VERTEBRAE (T1): Bifid centra

(g) - SKELETAL/VERTEBRAE (T2): Dumbbell shaped centra

(h) - SKELETAL/VERTEBRAE (T9): Dumbbell shaped centra

H-30

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 0 MG/M3

ANIMAL NUMBER:  IGL969

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	+

3	A	F	+	+	+

	4	A	M	+

	+

5	A	M	+	+	+

	  6C	A	F	+

	+

7	A	F	+	+	+

	8	A	M	+

	+

9	A	M	+	+	+

	10	A	F	+

	+

11	A	M	+	+	+

	12	A	F	+

	+

13	A	M	+	+	+

	14	A	M	+

	+

15	A	F	+	+	+

	16	A	F	+

	+

17	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-31

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL889

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	+

3	A	M	+	+	+

	4	A	M	+

	+

5	A	F	+	+	+

	6	A	F	+

	+

7	A	F	+	+	+

	  8C	A	M	+

	(a)

9	A	F	+	+	+

	10	A	M	+

	+

11	A	M	+	+	+

	12	A	M	+

	+

13	A	M	+	+	+

	14	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/VERTEBRAE (T11 anlage): Dumbbell shaped centra

H-32

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL893

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	2          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+	+	+

	2	A	M	+

	+

3	A	F	+	+	+

	4	A	F	+

	+

  5C	A	F	+	+	+

	6	A	M	+

	(a)

7	A	F	+	+	+

	8	A	M	+

	+

9	A	F	+	+	+

	10	A	M	+

	+

11	A	M	+	+	+

	12	A	F	+

	+

13	A	M	+	+	+

	14	A	M	+

	+

15	A	F	+	+	+

	16	A	F	+

	(b)

17	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/STERNEBRAE (II-IV): Asymmetric

(b) - SKELETAL/RIBS (L1): Rudimentary; Right

H-33

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL885

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+	+	+

	2	A	M	+

	+

3	A	F	+	+	+

	4	A	M	+

	+

5	A	F	+	+	+

	  6C	A	F	+

	+

7	A	F	+	+	+

	8	A	F	+

	+

9	A	F	+	+	+

	10	A	M	+

	+

11	A	F	+	+	+

	12	A	F	+

	+

13	A	M	+	+	+

	14	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-34

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL890

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	F	+	+	+

	3	A	M	+

	+

4	A	F	+	+	+

	5	A	M	+

	+

6	A	M	+	+	+

	7	A	F	+

	+

  8C	A	M	+	+	+

	9	A	M	+

	+

10	A	F	+	+	+

	11	A	F	+

	+

12	A	M	+	+	+

	13	A	F	+

	+

14	A	F	+	+	+

	15	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-35

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL863

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	3          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	+

3	A	F	+	+	+

	4	A	F	+

	+

5	A	M	+	+	+

	6	A	M	+

	(a)

7	A	F	+	+	+

	8	A	F	+

	+

  9C	A	F	+	+	+

	10	A	F	+

	(a)

11	A	M	+	+	+

	12	A	F	+

	(a)

13	A	F	+	+	+

	14	A	F	+

	+

15	A	F	+	+	+

	16	A	F	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/STERNEBRAE (V) - Unossified

H-36

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL878

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	3          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	+

2	A	F	+	+	+

	3	A	M	+

	(c)

4	A	M	+	+	+

	5	A	M	+

	+

6	A	F	+	+	+

	7	A	M	+

	(c)

8	A	F	+	+	+

	9	A	M	+

	+

10	A	M	+	+	+

	11	A	M	+

	(a,b)

  12C	A	F	+	+	+

	13	A	M	+

	+

14	A	M	+	+	+

	15	A	M	+

	+

16	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/STERNEBRAE (I, II): Bifid

(b) - SKELETAL/STERNEBRAE (III, IV): Asymmetric

(c) - SKELETAL/RIBS (L1): Rudimentary; Bilateral

H-37

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL882

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	+

2	A	F	+	+	+

	3	A	F	+

	+

4	A	F	+	+	+

	5	A	M	+

	+

6	A	F	+	+	+

	7	A	M	+

	+

8	A	M	+	+	+

	  9C	A	M	+

	+

10	A	F	+	+	+

	11	A	M	+

	+

12	A	F	+	+	+

	13	A	F	+

	+

14	A	F	+	+	+

	15	A	F	+

	+

16	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-38

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL911

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	1          
MALFORMATIONS:  	2

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	1

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	3          
MALFORMATIONS:   	1

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	+

  3*	A	F	(A,B,c,D,E,F,H,I)

(J)	(K,L,m,n,O,Q,R)

4	A	M	(G)

	+

5	A	F	+	+	+

	6	A	F	+

	+

7	A	M	+	+	+

	  8C	A	M	+

	(p)

9	A	M	+	+	+

	10	A	F	+

	+

E

11	A	M	+	+	+

	12	A	F	+

	+

13	A	F	+	+	+

	14	A	F	+

	(p)

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

  *	- Stunted					      (n) - SKELETAL/STERNEBRAE (IV,V):Unossified	

(A)	- EXTERNAL: Cleft palate			      (O) - SKELETAL/RIBS: Multiple bones
malformed	

(B)	- EXTERNAL: Microcephaly	(p) - SKELETAL/RIBS (L1): Rudimentary; Left

(c)	- EXTERNAL: Protruding tongue		      (Q) - SKELETAL/VERTEBRAE:
Multiple bones 

(D)	- EXTERNAL: Adactyly forepaw; Bilateral		  malformed

(E)	- EXTERNAL: Ectrodactyly hindpaw; Bilateral  (R) - SKELETAL/HINDPAW:
Multiple bones absent

	(2 digits on each paw)

(F)	- EXTERNAL: Malrotated hindpaw; Left

(G) - EXTERNAL: Malrotated hindpaw; Right

(H)	- EXTERNAL: Short tail		

(I)	- EXTERNAL: Hooked tail 			

(J)	- ABDOMEN/THORAX:  Malpositioned kidney; Bilateral

(K) - SKELETAL/SKULL: Multiple bones malformed

(L) - SKELETAL/FOREPAW: Multiple bones absent

(m) - SKELETAL/STERNEBRAE (III): Hypoplastic

H-39

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL868

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	F	+	+	+

	3	A	F	+

	+

4	A	M	+	+	+

	5	A	F	+

	+

6	A	F	+	+	+

	7	A	F	+

	+

  8C	A	M	+	+	+

	9	A	F	+

	+

10	A	M	+	+	+

	11	A	F	+

	+

12	A	F	+	+	+

	13	A	M	+

	+

14	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-40

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL912

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	(a)

2	A	M	+	+	+

	3	A	M	+

	+

4	A	F	+	+	+

	5	A	F	+

	+

  6C	A	F	+	+	+

	7	A	M	+

	+

8	A	M	+	+	+

	9	A	M	+

	+

10	A	M	+	+	+

	11	A	F	+

	+

12	A	F	+	+	+

	13	A	M	+

	+

14	A	F	+	+	+

	15	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Left

H-41

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL913

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	+

3	A	F	+	+	+

	4	A	M	+

	+

5	A	F	+	+	+

	6	A	F	+

	+

  7C	A	M	+	+	+

	8	A	M	+

	+

9	A	F	+	+	+

	10	A	M	+

	+

11	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-42

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL925

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	+

3	A	M	+	+	+

	4	A	M	+

	+

  5C	A	M	+	+	+

	6	A	M	+

	+

7	A	F	+	+	+

	8	A	F	+

	+

9	A	F	+	+	+

	10	A	M	+

	+

11	A	M	+	+	+

	12	A	F	+

	+

13	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-43

 APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL871

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+	+	+

	2	A	M	+

	+

3	A	F	+	+	+

	4	A	M	+

	(a)

5	A	M	+	+	+

	  6C	A	M	+

	+

7	A	F	+	+	+

	8	A	M	+

	+

9	A	M	+	+	+

	10	A	M	+

	+

11	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/STERNEBRAE (V): Unossified

H-44

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL922

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	M	+	+	+

	3	A	F	+

	+

4	A	F	+	+	+

	5	A	F	+

	+

6	A	F	+	+	+

	7	A	F	+

	+

8	A	M	+	+	+

	  9C	A	M	+

	+

10	A	M	+	+	+

	11	A	M	+

	+

12	A	M	+	+	+

	13	A	F	+

	+

14	A	F	+	+	+

	15	A	F	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-45

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL951

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+	+	+

	2	A	F	+

	+

3	A	F	+	+	+

	4	A	F	+

	+

5	A	M	+	+	+

	6	A	M	+

	+

7	A	M	+	+	+

	  8C	A	F	+

	+

9	A	M	+	+	+

	10	A	M	+

	+

11	A	M	+	+	+

	12	A	F	+

	+

13	A	F	+	+	+

	14	A	F	+

	+

15	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-46

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL859

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+	+	+

	2	A	F	+

	+

3	A	M	+	+	+

	E

4	A	F	+

	+

5	A	M	+	+	+

	  6C	A	F	+

	+

7	A	M	+	+	+

	8	A	M	+

	+

9	A	F	+	+	+

	10	A	M	+

	+

11	A	F	+	+	+

	E

12	A	F	+

	(a)

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE: Fetus numbers 8, 10 and 12 found with identification tags
incorrectly numbered, numbers arbitrarily assigned for skeletal exams.

(a) - SKELETAL/RIBS (L1): Rudimentary; Right

H-48

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL943

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	+

3	A	F	+	+	+

	4	A	F	+

	+

5	A	M	+	+	+

	6	A	F	+

	+

  7C	A	F	+	+	+

	8	A	M	+

	+

9	A	F	+	+	+

	10	A	M	+

	+

11	A	M	+	+	+

	12	A	M	+

	(a)

13	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Left

H-48

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL948

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	2          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	+

2	A	F	+	+	+

	3	A	F	+

	+

4	A	M	+	+	+

	5	A	F	+

	+

6	A	F	+	+	+

	7	A	M	+

	+

  8C	A	M	+	+	+

	E

9	A	F	+

	(a)

10	A	M	+	+	+

	11	A	M	+

	(a)

12	A	F	+	+	+

	13	A	M	+

	+

14	A	M	+	+	+

	15	A	F	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Right

H-49

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL974

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	1          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1C	A	F	(*,a)

+	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

  *  - Edema head

(a)	- EXTERNAL:  Protruding tongue

H-50

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL888

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	F	+	+	+

	3	A	M	+

	+

4	A	F	+	+	+

	5	A	M	+

	+

6	A	F	+	+	+

	7	A	F	+

	+

8	A	F	+	+	+

	9	A	F	+

	+

10	A	M	+	+	+

	11	A	F	+

	+

  12C	A	F	+	+	+

	13	A	F	+

	+

14	A	M	+	+	+

	15	A	F	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-51

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL976

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	F	+	+	+

	  3C	A	M	+

	(a)

4	A	M	+	+	+

	5	A	F	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (T13): Short last rib; Left

H-52

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL923

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	M	+

	+

3	A	M	+	+	+

	4	A	F	+

	+

  5C	A	F	+	+	+

	6	A	F	+

	+

7	A	F	+	+	+

	8	A	F	+

	+

9	A	F	+	+	+

	  10*	A	M	+

	(a)

  11*	A	F	+	+	+

	12	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

  *	- Stunted

(a) -  SKELETAL/STERNEBRAE (V): Unossified

H-53

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 2000 MG/M3

ANIMAL NUMBER:  IGL924

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SFX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	+

2	A	F	+	+	+

	  3C	A	M	+

	+

4	A	F	+	+	+

	5	A	F	+

	+

6	A	F	+	+	+

	7	A	M	+

	+

8	A	F	+	+	+

	9	A	F	+

	+

10	A	F	+	+	+

	11	A	F	+

	+

12	A	M	+	+	+

	13	A	F	+

	(a)

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Bilateral

H-54

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL870

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	+

2	A	M	+	+	+

	3	A	F	+

	+

4	A	F	+	+	+

	5	A	M	+

	+

6	A	M	+	+	+

	  7C	A	F	+

	+

8	A	M	+	+	+

	9	A	F	+

	+

10	A	M	+	+	+

	11	A	M	+

	+

E

12	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-55

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL875

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	M	+

	+

3	A	M	+	+	+

	4	A	M	+

	+

5	A	M	+	+	+

	6	A	M	+

	+

  7C	A	M	+	+	+

	8	A	M	+

	+

9	A	F	+	+	+

	10	A	F	+

	+

11	A	F	+	+	+

	12	A	M	+

	+

13	A	M	+	+	+

	14	A	M	+

	+

15	A	F	+	+	+

	16	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:  Fetus numbers 10 and 14 found with identification tags detached,
numbers arbitrarily assigned for skeletal exams.

H-56

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL862

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	F	+	+	+

	3	A	F	+

	+

4	A	M	+	+	+

	5	A	F	+

	+

6	A	M	+	+	+

	  7C	A	M	+

	+

8	A	F	+	+	+

	9	A	F	+

	+

10	A	F	+	+	+

	11	A	F	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-57

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL858

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	F	+	+	+

	3	A	M	+

	+

4	A	F	+	+	+

	5	A	F	+

	+

6	A	M	+	+	+

	7	A	F	+

	+

8	A	M	+	+	+

	9	A	F	+

	+

  10C	A	F	+	+	+

	E

11	A	M	+

	+

12	A	F	+	+	+

	13	A	M	+

	+

14	A	F	+	+	+

	15	A	F	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-58

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL883

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	2

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	M	+

	+

3	A	F	+	+	+

	4	A	F	(A)

	+

5	A	F	+	+	+

	6	A	F	+

	+

7	A	M	(A)	+	+

	8	A	M	+

	+

9	A	F	+	+	+

	  10C	A	M	+

	+

11	A	F	+	+	+

	12	A	F	+

	+

13	A	F	+	+	+

	E

14	A	F	+

	+

15	A	M	+	+	+

	16	A	F	+

	(b)

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(A) - EXTERNAL:  Malrotated hindpaw; Left

(b)  - SKELETAL/STERNEBRAE (V): Unossified

H-59

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL896

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	2          
MALFORMATIONS:   	1

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	(a)

2	A	M	+	+	+

	E

3	A	M	+

	+

4	A	F	+	+	+

	5	A	F	+

	+

6	A	M	+	+	+

	7	A	M	+

	+

8	A	M	+	+	+

	  9C	A	M	+

	(a, B)

10	A	M	+	+	+

	11	A	M	+

	+

12	A	M	+	+	+

	13	A	F	+

	+

14	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Left

(B) - SKELETAL/VERTEBRAE (S1): Malformed arch; Left

H-60

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL906

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	M	+	+	+

	3	A	M	+

	+

4	A	F	+	+	+

	5	A	F	+

	+

   6C	A	F	+	+	+

	7	A	M	+

	(a)

8	A	F	+	+	+

	E

9	A	M	+

	+

10	A	F	+	+	+

	11	A	M	+

	+

12	A	F	+	+	+

	13	A	M	+

	+

14	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Left

H-61

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL861

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	M	+

	+

3	A	F	+	+	+

	4	A	M	+

	+

5	A	F	+	+	+

	6	A	F	+

	+

7	A	F	+	+	+

	8	A	M	+

	+

   9C	A	F	+	+	+

	10	A	F	+

	+

11	A	F	+	+	+

	12	A	F	+

	+

13	A	M	+	+	+

	  14*	A	M	+

	(a)

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

  * - Stunted

(a) - SKELETAL/STERNEBRAE (VI) – Unossified

H-62

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL903

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	1          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	+

3	A	M	+	+	+

	4	A	M	+

	+

5	A	M	+	+	+

	6	A	M	+

	+

7	A	F	+	+	+

	8	A	F	+

	+

   9C	A	F	+	+	(a)

	10	A	F	+

	(b)

11	A	M	+	+	+

	12	A	M	+

	+

13	A	F	+	+	+

	14	A	F	+

	+

15	A	F	+	+	+

	16	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a)	- ABDOMEN/THORAX:  Umbilical artery arises from left side of urinary
bladder

(b) - SKELETAL/STERNEBRAE (V) – Unossified

H-63

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL914

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	F	+	+	+

	3	A	M	+

	+

4	A	F	+	+	+

	5	A	F	+

	+

6	A	M	+	+	+

	7	A	M	+

	+

8	A	F	+	+	+

	9	A	M	+

	(a)

   EC

10	A	M	+	+	+

	11	A	F	+

	+

12	A	F	+	+	+

	13	A	M	+

	+

14	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/STERNEBRAE (II,IV) - Asymmetric

H-64

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL918

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	+

2	A	M	+	+	+

	3	A	M	+

	+

4	A	F	+	+	+

	   5C	A	M	+

	+

6	A	M	+	+	+

	7	A	M	+

	(a)

8	A	M	+	+	+

	9	A	M	+

	+

10	A	F	+	+	+

	11	A	F	+

	+

12	A	M	+	+	+

	13	A	F	+

	+

14	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Bilateral

H-65

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL907

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+	+	+

	2	A	F	+

	+

3	A	F	+	+	+

	4	A	F	+

	(a)

5	A	M	+	+	+

	6	A	F	+

	+

7	A	F	+	+	+

	8	A	M	+

	+

   9C	A	F	+	+	+

	10	A	F	+

	+

11	A	F	+	+	+

	12	A	F	+

	+

13	A	M	+	+	+

	14	A	M	+

	+

15	A	F	+	+	+

	16	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Left

H-66

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL909

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	+

3	A	F	+	+	+

	4	A	F	+

	+

5	A	F	+	+	+

	6	A	F	+

	+

7	A	M	+	+	+

	8	A	M	+

	+

   9C	A	M	+	+	+

	10	A	M	+

	+

11	A	F	+	+	+

	12	A	M	+

	+

13	A	F	+	+	+

	14	A	F	+

	+

15	A	M	+	+	+

	16	A	F	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-67

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL946

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	M	+	+	+

	3	A	F	+

	+

  4C	A	M	+	+	+

	5	A	M	+

	+

6	A	F	+	+	+

	7	A	F	+

	+

8	A	M	+	+	+

	9	A	M	+

	+

10	A	M	+	+	+

	11	A	M	+

	+

12	A	F	+	+	+

	13	A	M	+

	+

14	A	F	+	+	+

	15	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-68

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL954

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	2          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	+

2	A	M	+	+	+

	3	A	F	+

	(b)

4	A	F	+	+	+

	5	A	F	+

	(a)

  6*	A	F	+	+	+

	  7C	A	F	+

	+

8	A	F	+	+	+

	9	A	M	+

	+

10	A	F	+	+	+

	11	A	M	+

	+

12	A	F	+	+	+

	13	A	M	+

	+

14	A	M	+	+	+

	15	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

 *  - Stunted

(a) - SKELETAL/STERNEBRAE (V): Unossified

(b) - SKELETAL/RIBS (L1): Rudimentary; Left

H-69

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL955

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	+

3	A	M	+	+	+

	4	A	F	+

	+

5	A	M	+	+	+

	   6C	A	M	+

	+

7	A	F	+	+	+

	8	A	M	+

	+

9	A	F	+	+	+

	10	A	F	+

	+

11	A	F	+	+	+

	12	A	M	+

	(a)

13	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/VERTEBRAE (T11 anlage): Dumbbell shaped centra

H-70

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL934

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	M	+	+	+

	3	A	M	+

	+

4	A	M	+	+	+

	5	A	M	+

	+

6	A	F	+	+	+

	7	A	M	+

	+

8	A	M	+	+	+

	   9C	A	F	+

	+

10	A	M	+	+	+

	11	A	M	+

	+

12	A	M	+	+	+

	13	A	F	+

	+

14	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-71

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL881

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	+

3	A	M	+	+	+

	4	A	M	+

	+

5	A	F	+	+	+

	   6C	A	M	+

	+

7	A	F	+	+	+

	8	A	F	+

	+

9	A	F	+	+	+

	E

10	A	F	+

	+

11	A	F	+	+	+

	12	A	F	+

	+

13	A	F	+	+	+

	14	A	M	+

	(a)

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (T13): Short last rib; Right

H-72

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL917

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+	+	+

	2	A	M	+

	+

3	A	M	+	+	+

	4	A	F	+

	+

5	A	M	+	+	+

	6	A	F	+

	+

7	A	M	+	+	+

	   8C	A	F	+

	+

9	A	M	+	+	+

	10	A	F	+

	+

11	A	M	+	+	+

	12	A	F	+

	+

13	A	F	+	+	+

	14	A	F	+

	+

15	A	F	+	+	+

	16	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-73

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL940

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	(a)

2	A	M	+	+	+

	E

3	A	M	+

	+

  4C	A	F	+	+	+

	5	A	F	+

	+

6	A	M	+	+	+

	7	A	M	+

	+

E

8	A	M	+	+	+

	9	A	F	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Right

H-74

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL963

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	M	+

	+

3	A	F	+	+	+

	  4C	A	M	+

	+

5	A	M	+	+	+

	6	A	M	+

	+

7	A	M	+	+	+

	8	A	F	+

	+

9	A	M	+	+	+

	10	A	F	+

	+

11	A	M	+	+	+

	12	A	F	+

	(a)

13	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Right

H-75

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL972

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	F	+	+	+

	3	A	M	+

	+

4	A	M	+	+	+

	  5C	A	F	+

	+

6	A	M	+	+	+

	7	A	F	+

	+

8	A	F	+	+	+

	9	A	M	+

	+

10	A	F	+	+	+

	11	A	M	+

	+

12	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-76

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 10,000 MG/M3

ANIMAL NUMBER:  IGL895

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+	+	+

	2	A	M	+

	+

3	A	F	+	+	+

	4	A	F	+

	+

5	A	F	+	+	+

	6	A	M	+

	+

7	A	M	+	+	+

	8	A	M	+

	+

   9C	A	M	+	+	+

	10	A	F	+

	+

11	A	M	+	+	+

	12	A	M	+

	+

13	A	F	+	+	+

	14	A	M	+

	+

15	A	F	+	+	+

	16	A	M	+

	+

  17*	A	M	+	+	+

	18	A	F	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

*	-  Stunted

H-77

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL866

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	1

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	+

2	A	M	+	+	+

	3	A	F	+

	+

4	A	F	+	+	+

	   5C	A	M	+

	+

6	A	M	+	(A)	+

	7	A	F	+

	(b)

8	A	F	+	+	+

	9	A	M	+

	+

10	A	F	+	+	+

	11	A	M	+

	+

12	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(A) - VISCERAL/HEAD:  Retinal fold; Left

(b)  - SKELETAL/RIBS (L1): Rudimentary; Bilateral

H-78

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL892

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	+

2	A	M	+	+	+

	3	A	M	+

	+

4	A	M	+	+	+

	   5C	A	F	+

	+

6	A	F	+	+	+

	7	A	F	+

	(a)

8	A	F	+	+	+

	9	A	M	+

	+

10	A	M	+	+	+

	11	A	M	+

	+

12	A	F	+	+	+

	13	A	M	+

	+

14	A	M	+	+	+

	15	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Right

H-79

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL864

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	M	+	+	+

	3	A	M	+

	+

4	A	M	+	+	+

	5	A	F	+

	+

6	A	M	+	+	+

	7	A	M	+

	+

   8C	A	F	+	+	+

	9	A	M	+

	+

10	A	M	+	+	+

	11	A	F	+

	(a)

12	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Bilateral

H-80

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL872

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	2          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	+

2	A	M	+	+	+

	3	A	F	+

	+

4	A	F	+	+	+

	5	A	F	+

	+

6	A	F	+	+	+

	7	A	F	+

	+

8	A	F	+	+	+

	   9C	A	F	+

	(a)

10	A	F	+	+	+

	11	A	F	+

	+

12	A	M	+	+	+

	13	A	M	+

	+

14	A	M	+	+	+

	  15*	A	M	+

	(a)

16	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

 *  - Stunted

(a) - SKELETAL/STERNEBRAE (VI): Hypoplastic

H-81

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL873

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	M	+

	+

3	A	F	+	+	+

	4	A	M	+

	+

5	A	F	+	+	+

	6	A	F	+

	+

7	A	M	+	+	+

	   8C	A	M	+

	+

9	A	F	+	+	+

	10	A	F	+

	+

11	A	F	+	+	+

	12	A	F	+

	(a,b)

13	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/VERTEBRAE (T12): Bifid centra

(b) - SKELETAL/VERTEBRAE (T12 anlage): Dumbbell shaped centra

H-82

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL879

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	2          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	+

3	A	M	+	+	+

	4	A	M	+

	(a)

5	A	F	+	+	+

	6	A	F	+

	+

7	A	F	+	+	+

	8	A	F	+

	+

9	A	F	+	+	+

	   10C	A	M	+

	(b,c)

11	A	M	+	+	+

	12	A	F	+

	+

13	A	M	+	+	+

	14	A	F	+

	+

15	A	M	+	+	+

	16	A	M	+

	+

17	A	F	+	+	+

	18	A	F	+

	+

19	A	F	+	+	+

	20	A	M	+

	+

21	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/VERTEBRAE (T9): Dumbbell shaped centra

(b) - SKELETAL/VERTEBRAE (T12): Bifid centra

(c) - SKELETAL/VERTEBRAE (T12 anlage): Dumbbell shaped centra

H-83

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL884

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	2          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	(a)

2	A	F	+	+	+

	3	A	F	+

	+

4	A	M	+	+	+

	5	A	M	+

	+

6	A	M	+	+	+

	7	A	F	+

	+

   8C	A	M	+	+	+

	9	A	M	+

	(b)

10	A	M	+	+	+

	11	A	F	+

	+

12	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Bilateral

(b) - SKELETAL/RIBS (L1): Rudimentary; Left

H-84

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL886

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	3          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	(a)

2	A	M	+	+	+

	3	A	M	+

	+

4	A	M	+	+	+

	5	A	F	+

	+

6	A	F	+	+	+

	7	A	M	+

	+

   8C	A	M	+	+	+

	9	A	M	+

	+

10	A	F	+	+	+

	11	A	F	+

	(b)

E

12	A	M	+	+	+

	13	A	F	+

	(a)

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Bilateral

(b) - SKELETAL/RIBS (L1): Rudimentary; Left

H-85

 APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL867

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	+

3	A	M	+	+	+

	4	A	F	+

	+

5	A	M	+	+	+

	E

   6C	A	M	+

	+

7	A	F	+	+	+

	8	A	F	+

	+

9	A	F	+	+	+

	10	A	M	+

	+

11	A	M	+	+	+

	12	A	F	+

	(a)

13	A	M	+	+	+

	14	A	F	+

	+

15	A	F	+	+	+

	16	A	F	+

	+

17	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Left

H-86

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL898

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	  1*	A	M	+

	+

2	A	F	+	+	+

	3	A	F	+

	+

4	A	M	+	+	+

	5	A	F	+

	+

6	A	M	+	+	+

	7	A	M	+

	+

8	A	M	+	+	+

	9	A	F	+

	+

10	A	F	+	+	+

	11	A	F	+

	+

  12C	A	F	+	+	+

	13	A	F	+

	+

14	A	F	+	+	+

	15	A	M	+

	+

16	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

*	- Stunted

H-87

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL929

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+	+	+

	2	A	M	+

	+

3	A	M	+	+	+

	4	A	F	+

	+

5	A	F	+	+	+

	6	A	M	+

	+

7	A	F	+	+	+

	8	A	M	+

	+

  9*	A	M	+	+	+

	   10C	A	M	+

	(a)

11	A	F	+	+	+

	12	A	F	+

	+

13	A	M	+	+	+

	14	A	F	+

	+

15	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

 *  - Stunted

(a) - SKELETAL/RIBS (L1): Rudimentary; Bilateral

H-88

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL877

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+	+	+

	2	A	F	+

	+

3	A	F	+	+	+

	4	A	M	+

	+

5	A	M	+	+	+

	   6C	A	F	+

	+

7	A	M	+	+	+

	8	A	F	+

	+

9	A	M	+	+	+

	10	A	M	+

	+

11	A	F	+	+	+

	12	A	M	+

	(a)

13	A	F	+	+	+

	14	A	M	+

	+

15	A	F	+	+	+

	16	A	F	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Left

H-89

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL937

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	+

3	A	M	+	+	+

	4	A	F	+

	(a)

5	A	M	+	+	+

	6	A	M	+

	+

  7C	A	F	+	+	+

	8	A	F	+

	+

9	A	M	+	+	+

	10	A	M	+

	+

11	A	M	+	+	+

	12	A	F	+

	+

13	A	M	+	+	+

	14	A	F	+

	+

15	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Left

H-90

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL950

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	3          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	+

2	A	M	+	+	+

	3	A	F	+

	+

4	A	F	+	+	+

	   5C	A	M	+

	+

6	A	F	+	+	+

	7	A	F	+

	+

8	A	F	+	+	+

	9	A	M	+

	(a)

10	A	M	+	+	+

	11	A	F	+

	(a)

12	A	F	+	+	+

	13	A	M	+

	(b)

14	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Left

(b) - SKELETAL/RIBS (L1): Rudimentary; Bilateral

H-91

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL958

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

2	A	F	+	+	+

	3	A	F	+

	+

4	A	F	+	+	+

	5	A	F	+

	+

6	A	F	+	+	+

	7	A	M	+

	+

8	A	M	+	+	+

	   9C	A	F	+

	+

10	A	F	+	+	+

	11	A	F	+

	+

12	A	F	+	+	+

	13	A	M	+

	+

14	A	F	+	+	+

	15	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-92

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL945

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+	+	+

	2	A	F	+

	(a)

3	A	F	+	+	+

	4	A	M	+

	+

5	A	F	+	+	+

	   6C	A	F	+

	+

7	A	M	+	+	+

	8	A	F	+

	+

9	A	F	+	+	+

	10	A	M	+

	+

11	A	F	+	+	+

	12	A	F	+

	+

13	A	F	+	+	+

	14	A	F	+

	+

15	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/VERTEBRAE (T11): Bifid centra

H-93

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL967

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+	+	+

	2	A	F	+

	+

3	A	M	+	+	+

	4	A	F	+

	+

5	A	F	+	+	+

	6	A	F	+

	+

   7C	A	M	+	+	+

	8	A	M	+

	+

9	A	M	+	+	+

	10	A	F	+

	+

11	A	F	+	+	+

	12	A	M	+

	+

13	A	F	+	+	+

	     E

14	A	M	+

	+

15	A	F	+	+	+

	     E

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-94

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL959

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	3          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	M	+

	(a)

3	A	F	+	+	+

	4	A	F	+

	+

5	A	M	+	+	+

	   6C	A	M	+

	+

7	A	F	+	+	+

	8	A	F	+

	+

E

9	A	F	+	+	+

	10	A	M	+

	(b)

11	A	M	+	+	+

	12	A	M	+

	(c)

13	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Left

(b) - SKELETAL/RIBS (L1): Rudimentary; Right

(c) - SKELETAL/RIBS (L1): Rudimentary; Bilateral

H-95

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL962

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	4          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	M	+

	+

  2*	A	M	+	+	+

	3	A	M	+

	(a,b,d)

4	A	M	+	+	+

	5	A	F	+

	(e)

6	A	F	+	+	+

	7	A	F	+

	(f)

8	A	F	+	+	+

	E

9	A	M	+

	+

  10C	A	F	+	+	+

	11	A	M	+

	(c)

12	A	F	+	+	+

	13	A	M	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

*	- Stunted

(a) - SKELETAL/STERNEBRAE (II-IV): Asymmetric

(b) - SKELETAL/STERNEBRAE (VI): Unossified

(c) - SKELETAL/RIBS (L1): Rudimentary; Left

(d) - SKELETAL/VERTEBRAE (T11-13 anlage): Dumbbell shaped centra

(e) - SKELETAL/VERTEBRAE (T9): Dumbbell shaped centra

(f) - SKELETAL/VERTEBRAE (T10 anlage): Dumbbell shaped centra

H-96

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL949

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	4          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	(a)

3	A	M	+	+	+

	4	A	F	+

	(b)

5	A	F	+	+	+

	6	A	F	+

	(a)

7	A	F	+	+	+

	   8C	A	M	+

	+

9	A	M	+	+	+

	10	A	M	+

	(b)

11	A	F	+	+	+

	12	A	F	+

	+

13	A	F	+	+	+

	14	A	F	+

	+

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Right

(b) - SKELETAL/RIBS (L1): Rudimentary; Left

H-97

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL916

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	1          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	M	+

	+

3	A	F	+	+	+

	4	A	F	+

	+

5	A	M	+	+	+

	   EC

6	A	M	+

	(a)

7	A	M	+	+	+

	8	A	F	+

	+

9	A	F	+	+	+

	10	A	F	+

	+

11	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Right  

H-98

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL938

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	3          
MALFORMATIONS:   	1

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	+

2	A	F	+	+	+

	3	A	F	+

	(a,b,C)

E

  4C	A	M	+	+	+

	5	A	F	+

	(a)

6	A	M	+	+	+

	7	A	M	+

	+

8	A	F	+	+	+

	9	A	M	+

	(a)

10	A	F	+	+	+

	11	A	M	+

	+

12	A	F	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Bilateral

(b) - SKELETAL/VERTEBRAE (L): Presacral vertebrae

(C) - SKELETAL/VERTEBRAE (L7): Malformed arch; Left

H-99

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL961

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	0          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+	+	+

	2	A	F	+

	+

3	A	M	+	+	+

	4	A	F	+

	+

  5C	A	F	+	+	+

	6	A	M	+

	+

7	A	F	+	+	+

	8	A	M	+

	+

9	A	M	+	+	+

	10	A	F	+

	+

11	A	F	+	+	+

	12	A	M	+

	+

13	A	M	+	+	+

	14	A	F	+

	+

15	A	M	+	+	+

	

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

H-100

APPENDIX H - FETAL OBSERVATIONS

(INDIVIDUAL FETAL OBSERVATIONS)

(SEE LIST OF ABBREVIATIONS FOR ABBREVIATIONS)

TARGET DOSE: 20,000 MG/M3

ANIMAL NUMBER:  IGL970

NUMBER OF FETUSES WITH EXTERNAL VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH VISCERAL  VARIATIONS:   	0          
MALFORMATIONS:  	0

NUMBER OF FETUSES WITH SKELETAL VARIATIONS:   	2          
MALFORMATIONS:   	0

FETUS

NO.	

STATUS	

SEX	

EXTERNAL	VISCERAL	

SKELETAL

HEAD	ABDOMEN/THORAX

	1	A	F	+

	+

2	A	F	+	+	+

	3	A	M	+

	+

4	A	M	+	+	+

	5	A	F	+

	+

6	A	F	+	+	+

	   7C	A	F	+

	+

8	A	F	+	+	+

	9	A	F	+

	+

10	A	F	+	+	+

	11	A	M	+

	+

12	A	M	+	+	+

	13	A	F	+

	(a)

14	A	M	+	+	+

	15	A	M	+

	(b)

A = ALIVE	M = MALE	E = EARLY RESORPTION	C = CERVIX

D = DEAD	F = FEMALE	L = LATE RESORPTION		+ = NO OBSERVABLE ABNORMALITIES

NOTE:

(a) - SKELETAL/RIBS (L1): Rudimentary; Bilateral

(b) - SKELETAL/RIBS (L1): Rudimentary; Left

H-101

APPENDIX I  -  INHALATION EXPOSURE DATA

TABLE OF CONTENTS

EXPOSURE CHAMBERS 		I-2

TEST ATMOSPHERE GENERATION		I-2

CHAMBER ENVIRONMENTAL CONDITIONS		I-2

ANALYTICAL PROCEDURES 		I-3

CHAMBER HOMOGENEITY 		I-4

LIGHTING, NOISE, AND OXYGEN LEVELS		I-4

PARTICLE SIZE ANALYSIS		I-4

TABLES

TABLE I-1 -  MEAN EXPOSURE DATA		I-7

TABLE  I-2 - GAS CHROMATOGRAPH OPERATING CONDITIONS		I-8

TABLE  I-3 - SUMMARY OF EXPOSURE DATA		I-10

TABLE  I-4 - SUMMARY OF CHAMBER DISTRIBUTION SAMPLES		I-19

TABLE  I-5 - LIGHTING, NOISE, AND OXYGEN LEVELS		I-20

TABLE  I-6 - PARTICLE SIZE DATA		I-21

TABLE  I-7 – CHAMBER TEMPERATURES AND HUMIDITIES		I-23

FIGURES

FIGURE  I-1 - SCHEMATIC OF GENERATION AND EXPOSURE SYSTEM		I-5

FIGURE  I-2 - SCHEMATIC OF ANALYTICAL CALIBRATION SYSTEM		I-6

FIGURE  I-3 - ANALYTICAL CALIBRATION RESPONSE CURVES		I-9

I-1

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

Exposure Chambers

   

	The chambers used in this study were constructed of stainless steel and
glass and had a total volume of approximately 1.0 m3.  They were
operated at an airflow rate of 200 liters per minute ensuring 12 air
changes per hour and a theoretical equilibration time (T99) of 23
minutes.  The chamber volume and airflow were considered adequate to
ensure an oxygen level greater than 19% and an animal loading below 5%. 
The chamber airflow rate was monitored continuously with a calibrated
flow-limiting orifice and differential pressure gauge and recorded
approximately every 30 minutes.  All of the chambers were maintained at
a slight negative pressure to the room.

Test Atmosphere Generation

      

	Figure I-1 presents a schematic of the test atmosphere generation and
exposure system.

Aliquots of the test substance for use in the daily conduct of the study
were received in gas cylinders (~20 L nominal volume) via a specially
constructed distribution manifold.  The manifold system maintained the
test substance under nitrogen pressure,  ensuring that the transferred
substance remained in liquid phase and retained the same composition as
the original container.  

The test substance was delivered via a diptube from the outlet valve of
the cylinder to a variable area rotameter which regulated the rate of
liquid flow into a heated glass round-bottom flask.  The test substance
volatilized within the flask and the resulting vapors mixed with the
supply air as they were drawn into the exposure chamber.  

Chamber Environmental Conditions

Chamber temperature and humidity were monitored by wet/dry bulb
hygrometers and recorded at approximately thirty minute intervals
throughout each exposure.

I-2

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

Analytical Procedures

Schematic of the analytical calibration system: Figure I-2.

Analytical calibration response curves: Figure I-3

Gas chromatograph operating conditions: Table I-2

Mean exposure data: Table I-1

Summary of exposure data: Table I-3

	Exposure concentrations were determined on both a nominal and
analytical basis.  Nominal concentrations for each exposure level were
calculated by weighing the tank containing the test substance before and
after exposure and dividing the net loss in weight by the total volume
of air passing through the chamber during the exposure.

	Analytical exposure concentrations were determined hourly during each
exposure by on-line gas chromatography (Hewlett Packard 6890).  Samples
of the chamber atmosphere were continuously delivered to the GC via
1/8” Teflon tubing connected to an automated 12-port multiposition gas
sampling valve.  The multiposition valve was programmed to sequentially
direct each stream to a sample loop which injected a fixed sample volume
(2 cc) directly onto the column for analysis.  A complete sampling cycle
was performed during each hour of exposure. 

	The analytical system was calibrated against a series of known
concentrations of the test substance in air.  The air concentrations
were determined by injecting a weighed amount of the test substance from
a gas-tight syringe into a closed loop system of a known air volume (see
schematic of drawing).  The closed loop system consisted of an infrared
vapor analyzer (MIRAN 1A-CVF, Foxboro Analytical)  connected to the gas
sampling valve of the GC.  A metal bellows pump was used to circulate
the injected test substance vapors through the sample cell of the
infrared monitor and the gas sampling valve of the GC.  The response of
the infrared analyzer was monitored until the air concentration appeared
equilibrated and stable,  then three replicate samples were taken using
the gas sample loop of the GC.  The entire closed loop system was
cleared with clean air between each calibration injection.  The average
response of the GC (total peak area) for the four main constituents of
the atmosphere, at each air concentration was used to construct a linear
calibration for the test substance.

	This method permitted the GC and the infrared analyzer (a backup
analytical method) to be calibrated simultaneously and  under conditions
similar to actual chamber sampling.  Once established, the calibration
was checked daily during the study by sampling a certified standard of
n-butane, the major component of the test substance mixture.

I-3

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

Chamber Homogeneity

	Table I-4 presents a summary of the chamber distribution data.

	During the method development trials for this study, samples were drawn
from twelve different points within the chamber at each target
concentration to demonstrate the homogeneity of test atmosphere
distribution.

Lighting, Noise and Oxygen Levels

	Table I-5 presents a summary of the lighting, noise, and oxygen level
data.

Light intensity was measured three times during the study (the first day
of exposures, during the second week of exposures, and the last day of
exposures) in both the animal room and the chamber room.  Light
intensity was measured in the animal room in a cage approximately three
feet above the floor level.  In the chamber room the light intensity was
measured three feet above floor level in the approximate center of each
generation room.

Additionally, the oxygen level and the noise level were measured in each
exposure chamber on the first day of exposures, during the second week
of exposures, and on the last day of exposures.

Particle Size Analysis

	Table I-6 presents a summary of the particle size data.

A particle size determination of the aerosol portion of the test
atmosphere was conducted during the chamber trials from the control and
20,000 mg/m3 concentration chambers.  The sample was taken using a
multistage cascade impactor.  Preweighed glass fiber filters were used
to collect aerosol on each stage, which are associated with specific
cutoff diameters for aerodynamic particle size in microns.  Since
minimal aerosol was present, no further calculations were performed for
the aerodynamic diameter, geometric standard deviation, or the estimated
percents of the aerosol less than or equal to 1, 10, and 15 microns in
size.

I-4

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

FIGURE I-1  -  SCHEMATIC OF GENERATION AND EXPOSURE SYSTEM

I-5

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

FIGURE I-2  -  SCHEMATIC OF THE ANALYTICAL CALIBRATION SYSTEM

I-6

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

TABLE I-1  - MEAN EXPOSURE DATA

GROUP:	1	2	3	4

Target Exposure Concentration

(mg/m3)	

0	

2000	

10000	

20000

Mean Analytical Exposure Concentration

(mg/m3)	

0	

2020	

10395	20772

Average Chamber Temperature

(OF)	72	72	75	72

Average Chamber Relative Humidity

(% RH)	62	62	57	62

I-7

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

TABLE I-2  -  GAS CHROMATOGRAPH OPERATING CONDITIONS

GAS CHROMATOGRAPH:	Hewlett Packard 6890GC

DETECTOR:	Flame Ionization

COLUMN:	Supelco Part # 13867, MTO-SS, 2M 1/8”,

	Carbopack C 80/100 0.19% Picric Acid 15g

GAS FLOWS (cc/min):	H2  -  45.0

	Air  -  450.0

	Makeup Gas (Helium)  -  30.0

INLET TEMPERATURE:	100oC

INLET FLOW (cc/min)	Helium - 19.8

OVEN TEMPERATURE:	110oC

DETECTOR TEMPERATURE:	250oC

SAMPLE LOOP SIZE:	2 cc

ATTENUATION:	0

RUN TIME:	8.5 Minutes

I-8

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

FIGURE  I-3 - ANALYTICAL CALIBRATION RESPONSE CURVES

I-9

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

TABLE I-3  -  SUMMARY OF EXPOSURE DATA

	Group 1	Group 2	Group 3	Group 4 

Date	Mean	Nominal	Chamber	Mean	Nominal	Chamber	Mean	Nominal	Chamber	Mean
Nominal	Chamber

	(mg/m3)	(mg/m3)	oF	% Rh	(mg/m3)	(mg/m3)	oF	% Rh	(mg/m3)	(mg/m3)	oF	% Rh
(mg/m3)	(mg/m3)	oF	% Rh

31-Aug-02	0	0	70	65	2033	1769	70	65	10406	9643	73	58	20818	18599	70	65

1-Sep-02	0	0	68	72	1717	1813	70	64	10337	10169	72	58	20672	19218	71	59

2-Sep-02	0	0	72	59	2099	1832	70	65	10120	9858	73	60	20835	19068	70	65

3-Sep-02	0	0	72	66	1968	1969	70	65	10244	10071	74	60	20232	19019	70	72

4-Sep-02	0	0	72	66	2053	1931	72	63	10181	9906	75	60	20693	18597	72	63

5-Sep-02	0	0	72	64	2122	1864	72	66	10440	10063	76	59	20775	18788	72	63

6-Sep-02	0	0	73	59	2144	1890	72	61	10127	9686	75	54	20609	18649	73	61

7-Sep-02	0	0	71	64	2045	1693	70	67	10381	9882	73	65	20982	19475	72	65

8-Sep-02	0	0	72	66	2053	1932	72	66	10004	8976	73	60	20113	17335	74	60

9-Sep-02	0	0	72	64	1950	1713	71	60	10498	9978	76	57	21048	18050	73	61

10-Sep-02	0	0	74	60	2075	1803	73	67	10410	9914	77	55	19881	17846	74	61

11-Sep-02	0	0	74	60	2040	1906	74	57	10465	9919	76	56	20627	18458	74	58

12-Sep-02	0	0	74	50	2077	1963	73	53	10373	9790	77	47	21534	18379	73	52

13-Sep-02	0	0	75	54	2054	2028	75	54	10088	9928	77	54	21140	18874	74	56

14-Sep-02	0	0	73	73	1995	1701	72	70	10622	10125	75	60	20629	18376	72	69

15-Sep-02	0	0	74	59	2092	1986	74	59	10882	10047	74	66	21371	18872	72	66

16-Sep-02	0	0	73	75	1911	1993	73	70	10117	9778	76	64	20451	18822	72	71

17-Sep-02	0	0	74	60	1738	2094	73	60	10676	9597	77	56	21153	18017	73	61

18-Sep-02	0	0	73	61	2065	1899	73	60	10578	9942	77	55	21214	18249	73	62

19-Sep-02	0	0	72	58	2065	1796	72	65	10687	9964	76	60	20885	18261	72	62

20-Sep-02	0	0	72	62	2119	1899	71	63	10676	9907	76	54	21065	18129	72	60

21-Sep-02	0	0	72	66	2069	2057	71	72	10359	10107	76	59	21177	19008	72	63

22-Sep-02	0	0	71	59	2137	2029	70	64	9985	9701	75	54	20245	18556	72	61

23-Sep-02	0	0	73	58	2054	1715	72	58	10539	10053	76	54	20858	18779	72	60

24-Sep-02	0	0	72	57	1893	1683	72	55	10530	9944	76	49	20905	18521	72	58

25-Sep-02	0	0	71	58	1991	1814	71	58	10402	9867	75	52	20321	18371	71	59

26-Sep-02	0	0	71	64	1973	1833	71	59	10542	10026	75	54	20606	18517	70	62

MEAN	0	0	72	62	2020	1874	72	62	10395	9883	75	57	20772	18549	72	62

s.d.	0	0	1.5	5.6	105.6	118.6	1.4	4.9	228.5	233.5	1.5	4.4	394.4	454.3	1.2
4.3

Minimum	0	0	68	50	1717	1683	70	53	9985	8976	72	47	19881	17335	70	52

Maximum	0	0	75	75	2144	2094	75	72	10882	10169	77	66	21534	19475	74	72

I-10

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

TABLE I-3 (CONT’D)  -  SUMMARY OF EXPOSURE DATA

GROUP 1  -  0 mg/m3

Nominal	Mean Analytical 	Mean	Mean

	Exposure	Concentration	Concentration	Temperature	Relative Humidity

Date	Number	(mg/m3)	(mg/m3)	(oF)	(%)

31-Aug-02	1	0	0	70	65

1-Sep-02	2	0	0	68	72

2-Sep-02	3	0	0	72	59

3-Sep-02	4	0	0	72	66

4-Sep-02	5	0	0	72	66

5-Sep-02	6	0	0	72	64

6-Sep-02	7	0	0	73	59

7-Sep-02	8	0	0	71	64

8-Sep-02	9	0	0	72	66

9-Sep-02	10	0	0	72	64

10-Sep-02	11	0	0	74	60

11-Sep-02	12	0	0	74	60

12-Sep-02	13	0	0	74	50

13-Sep-02	14	0	0	75	54

14-Sep-02	15	0	0	73	73

I-11

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

TABLE I-3 (CONT’D)  -  SUMMARY OF EXPOSURE DATA

GROUP 1  -  0 mg/m3

Nominal	Mean Analytical 	Mean	Mean

	Exposure	Concentration	Concentration	Temperature	Relative Humidity

Date	Number	(mg/m3)	(mg/m3)	(oF)	(%)

15-Sep-02	16	0	0	74	59

16-Sep-02	17	0	0	73	75

17-Sep-02	18	0	0	74	60

18-Sep-02	19	0	0	73	61

19-Sep-02	20	0	0	72	58

20-Sep-02	21	0	0	72	62

21-Sep-02	22	0	0	72	66

22-Sep-02	23	0	0	71	59

23-Sep-02	24	0	0	73	58

24-Sep-02	25	0	0	72	57

25-Sep-02	26	0	0	71	58

26-Sep-02	27	0	0	71	64

MEAN

0	0	72	62

Std. Dev.

0.0	0.0	1.5	5.6

I-12

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

TABLE I-3 (CONT’D)  -  SUMMARY OF EXPOSURE DATA

GROUP 2  -  2000 mg/m3 TARGET

Nominal

	Mean 	Mean	Mean

	Exposure	Conc.	Hourly Analytical Concentrations (mg/m3)	Concentration
Temperature	Relative

Date	Number	(mg/m3)	1	2	3	4	5	6	(mg/m3)	(oF)	Humidity (%)

31-Aug-02	1	1769	2184	2070	2003	1993	1947	2003	2033	70	65

1-Sep-02	2	1813	1848	2021	1978	1921	1844	688	1717	70	64

2-Sep-02	3	1832	2035	2382	1814	2048	2081	2231	2099	70	65

3-Sep-02	4	1969	1984	2086	2090	2170	1276	2200	1968	70	65

4-Sep-02	5	1931	1845	2167	2185	2119	1585	2414	2053	72	63

5-Sep-02	6	1864	1830	2279	1958	2108	1888	2670	2122	72	66

6-Sep-02	7	1890	2447	2169	1995	2111	2007	2135	2144	72	61

7-Sep-02	8	1693	1867	2014	1973	2199	2040	2178	2045	70	67

8-Sep-02	9	1932	2188	1893	2192	2030	2011	2004	2053	72	66

9-Sep-02	10	1713	2044	1928	2173	1882	2269	1405	1950	71	60

10-Sep-02	11	1803	1866	1980	2145	2094	2268	2098	2075	73	67

11-Sep-02	12	1906	1988	2075	2056	1998	1983	2138	2040	74	57

12-Sep-02	13	1963	1954	2074	2237	1617	2423	2160	2077	73	53

13-Sep-02	14	2028	1889	2374	2029	1639	2290	2106	2054	75	54

14-Sep-02	15	1701	2089	1942	1964	2070	2026	1880	1995	72	70

I-13

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

TABLE I-3 (CONT’D)  -  SUMMARY OF EXPOSURE DATA

GROUP 2  -  2000 mg/m3 TARGET 

Nominal

	Mean 	Mean	Mean

	Exposure	Conc.	Hourly Analytical Concentrations (mg/m3)	Concentration
Temperature	Relative

Date	Number	(mg/m3)	1	2	3	4	5	6	(mg/m3)	(oF)	Humidity (%)

15-Sep-02	16	1986	2313	2317	1645	2032	2206	2036	2092	74	59

16-Sep-02	17	1993	2034	2219	673*	2529	1948	2065	1911	73	70

17-Sep-02	18	2094	2074	2172	2159	1707	0*	2318	1738	73	60

18-Sep-02	19	1899	2069	2149	1304	2353	2126	2389	2065	73	60

19-Sep-02	20	1796	2080	2125	2189	1807	2231	1959	2065	72	65

20-Sep-02	21	1899	2067	2186	2066	2160	2110	2127	2119	71	63

21-Sep-02	22	2057	1992	2024	2231	2025	2335	1809	2069	71	72

22-Sep-02	23	2029	1096	3441	1862	2004	1957	2462	2137	70	64

23-Sep-02	24	1715	2176	2101	2012	2041	2052	1940	2054	72	58

24-Sep-02	25	1683	1964	2041	2154	1288	1692	2218	1893	72	55

25-Sep-02	26	1814	1767	2244	2045	1990	1788	2114	1991	71	58

26-Sep-02	27	1833	2316	1973	2320	1611	1722	1897	1973	71	59

MEAN

1874

	2020	72	62

Std. Dev.

188.6

	105.6	1.4	4.9

* Float in Rotameter stuck due to air bubble.

I-14

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

TABLE I-3 (CONT’D)  -  SUMMARY OF EXPOSURE DATA

GROUP 3 -  10000 mg/m3 TARGET

Nominal

	Mean	Mean	Mean

Exposure	Conc.	Hourly Analytical Concentration (mg/m3)	Concentration
Temperature	Relative

Date	Number	(mg/m3)	1	2	3	4	5	6	(mg/m3)	(oF)	Humidity (%)

31-Aug-02	1	9643	10496	10382	10653	10467	10257	10180	10406	73	58

1-Sep-02	2	10169	10447	10322	10134	10477	9761	10882	10337	72	58

2-Sep-02	3	9858	10100	10353	9360	9466	10171	11269	10120	73	60

3-Sep-02	4	10071	9729	10104	9675	10419	10548	10990	10244	74	60

4-Sep-02	5	9906	9075	10538	10500	10155	10211	10608	10181	75	60

5-Sep-02	6	10063	9755	10651	10704	10243	10362	10925	10440	76	59

6-Sep-02	7	9686	8985	8149	10852	10937	10904	10932	10127	75	54

7-Sep-02	8	9882	9915	9865	10758	10612	10145	10990	10381	73	65

8-Sep-02	9	8976	10209	9338	8600	10390	10801	10686	10004	73	60

9-Sep-02	10	9978	9297	10666	10519	10258	11491	10756	10498	76	57

10-Sep-02	11	9914	10134	10457	10229	10107	10952	10584	10410	77	55

11-Sep-02	12	9919	10182	10528	10494	10570	10575	10444	10465	76	56

12-Sep-02	13	9790	10412	10675	10462	10143	10329	10216	10373	77	47

13-Sep-02	14	9928	9654	9953	10367	10095	10253	10201	10088	77	54

14-Sep-02	15	10125	9951	10234	10302	11391	11150	10703	10622	75	60

I-15

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

TABLE I-3 (CONT’D)  -  SUMMARY OF EXPOSURE DATA

GROUP 3  -  10000 mg/m3 TARGET 

Nominal

	Mean 	Mean	Mean

	Exposure	Conc.	Hourly Analytical Concentration (mg/m3)	Concentration
Temperature	Relative

Date	Number	(mg/m3)	1	2	3	4	5	6	(mg/m3)	(oF)	Humidity (%)

15-Sep-02	16	10047	10563	11142	10419	11200	11054	10915	10882	74	66

16-Sep-02	17	9778	10200	10074	9607	10669	9865	10286	10117	76	64

17-Sep-02	18	9597	11123	10115	10442	10939	10630	10806	10676	77	56

18-Sep-02	19	9942	10321	10890	10481	10819	10538	10419	10578	77	55

19-Sep-02	20	9964	10379	10721	10964	10639	10653	10770	10687	76	60

20-Sep-02	21	9907	10413	10713	10610	10601	10630	11091	10676	76	54

21-Sep-02	22	10107	9898	10208	10398	10656	10326	10668	10359	76	59

22-Sep-02	23	9701	9839	10287	9563	10291	10090	9839	9985	75	54

23-Sep-02	24	10053	9640	10351	10530	10562	11216	10932	10539	76	54

24-Sep-02	25	9944	10258	10663	10677	10530	10243	10807	10530	76	49

25-Sep-02	26	9867	9838	10416	10646	10305	10570	10636	10402	75	52

26-Sep-02	27	10026	10804	10590	10600	10510	10449	10298	10542	75	54

MEAN

9883

	10395	75	57

Std. Dev.

233.5

	228.5	1.5	4.4

I-16

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

TABLE I-3 (CONT’D)  -  SUMMARY OF EXPOSURE DATA

GROUP 4 -  20000 mg/m3 TARGET 

Nominal

	Mean	Mean	Mean

Exposure	Conc.	Hourly Analytical Concentration (mg/m3)	Concentration
Temperature	Relative

Date	Number	(mg/m3)	1	2	3	4	5	6	(mg/m3)	(oF)	Humidity (%)

31-Aug-02	1	18599	21320	20363	20750	21099	20557	20820	20818	70	65

1-Sep-02	2	19218	20842	20220	20722	21788	20621	19840	20672	71	59

2-Sep-02	3	19068	20315	21067	20810	20192	21359	21270	20835	70	65

3-Sep-02	4	19019	19266	19397	19965	21027	20975	20762	20232	70	72

4-Sep-02	5	18597	19956	20784	20782	21122	21224	20290	20693	72	63

5-Sep-02	6	18788	19689	21885	21201	19713	20896	21270	20775	72	63

6-Sep-02	7	18649	21128	18951	21063	20881	21028	20604	20609	73	61

7-Sep-02	8	19475	19953	20539	20356	21399	21952	21692	20982	72	65

8-Sep-02	9	17335	12042	20955	22457	22071	21568	21586	20113	74	60

9-Sep-02	10	18050	20824	20103	21996	19951	22239	21176	21048	73	61

10-Sep-02	11	17846	20996	20877	17155	19774	20454	20033	19881	74	61

11-Sep-02	12	18458	20632	20219	20425	20809	20834	20841	20627	74	58

12-Sep-02	13	18379	20888	21603	21980	21764	21794	21177	21534	73	52

13-Sep-02	14	18874	21120	20823	21496	21155	20839	21409	21140	74	56

14-Sep-02	15	18376	20665	19309	20635	21251	20984	20933	20629	72	69

I-17

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

TABLE I-3 (CONT’D)  -  SUMMARY OF EXPOSURE DATA

GROUP 4  -  20000 mg/m3 TARGET 

Nominal

	Mean 	Mean	Mean

	Exposure	Conc.	Hourly Analytical Concentration (mg/m3)	Concentration
Temperature	Relative

Date	Number	(mg/m3)	1	2	3	4	5	6	(mg/m3)	(oF)	Humidity (%)

15-Sep-02	16	18872	21093	20876	20980	21661	21928	21688	21371	72	66

16-Sep-02	17	18822	19855	20041	20268	21158	20858	20527	20451	72	71

17-Sep-02	18	18017	21155	19119	21415	22411	22184	20634	21153	73	61

18-Sep-02	19	18249	20942	21483	21178	21971	20813	20895	21214	73	62

19-Sep-02	20	18261	20377	20401	20567	22117	21265	20583	20885	72	62

20-Sep-02	21	18129	21162	20801	20484	21046	20803	22092	21065	72	60

21-Sep-02	22	19008	20793	21628	20296	19370	22830	22146	21177	72	63

22-Sep-02	23	18556	20195	20268	19625	20361	20390	20633	20245	72	61

23-Sep-02	24	18779	19867	21049	20971	20752	20333	22173	20858	72	60

24-Sep-02	25	18521	20619	20596	20388	21168	20841	21818	20905	72	58

25-Sep-02	26	18371	19760	19887	21441	19970	20437	20432	20321	71	59

26-Sep-02	27	18517	20417	19685	21616	20845	20662	20408	20606	70	62

MEAN

18549

	20772	72	62

Std. Dev.

454.3

	394.4	1.2	4.3

I-18

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

TABLE  I-4 - SUMMARY OF DISTRIBUTION SAMPLES 

SAMPLE	TARGET EXPOSURE LEVELS

LOCATION	2000 MG/M3	10,000 MG/M3	20,000 MG/M3

Left Top Back	1918	10296	20555

Left Top Front	2038	10572	20473

Left Middle Back	2011	10121	20625

Left Middle Front	2017	10236	20415

Left Bottom Back	1910	9865	20691

Left Bottom Front	1939	9845	20905

Right Top Back	1941	10034	21990

Right Top Front	2027	10972	21142

Right Middle Back	1941	10606	20536

Right Middle Front	1972	10881	21053

Right Bottom Back	1912	10610	20903

Right Bottom Front	1996	10312	20642

MEAN	1968	10362	20828

SD	47.3	370.4	433.0

%CV	2.4	3.6	2.1

Minimum	1910	9845	20415

Maximum	2038	10972	21990

                                                     NOTE:  top, middle,
bottom sample locations represent horizontal planes within exposure
chamber.  Left, right, front, back represent 

                  	corners of each horizontal plane.  Samples taken in
series at approximately 8 minute intervals.  

I-19

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

TABLE I-5 LIGHTING, NOISE, AND OXYGEN LEVELS

Environmental Conditions

	August 31, 2002	September 18, 2002	September 26, 2002

Light Intensity: (fc)

	Room PE103  in a cage 3 feet above the floor.	11.1	11.8	7.31a

Center of room PE 102, 3 feet above the floor.	33.4	38.5	43.7

Room PE 110, 3 feet above the floor.	32.8	33.4	31.2

Noise level:  (db)

	1m - 1: Door open	78.7	76.3	79.5

1m - 1: Through port	80.1	82.2	82.9

1m - 2: Door open	78.5	75.8	75.3

1m - 2: Through port	80.4	77.8	81.4

1m - 3: Door open	78.5	77.1	73.9

1m - 3: Through port	80.0	79.1	79.9

1m - 4: Door open	79.2	73.8	70.8

1m - 4: Through port	81.2	76.5	76.8

O2 Level: (%)

	(Reading upon removal)	No Alarm	No Alarm	No Alarm

1m - 1	20.7	20.6	20.6

1m - 2	20.7	20.7	20.6

1m - 3	20.7	20.5	20.5

1m - 4	20.7	20.5	20.7

	a - Instrument only measures to 0.1 fc.  Correct measurement is
unknown.

1m-1, 1m-2, 1m-3, 1m-4 are exposure chamber designations.

fc = foot candles (measured with an Omega HHLM-2 Light Meter)

db = decibels (measured using an Omega HHSL-1 Sound Meter)

% = % oxygen (measured using a Biosystems Oxy Plus Single Sensor Gas
Detector with an alarm at 19.5% O2)

I-20

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

TABLE  I-6 - PARTICLE SIZE DATA 

0 MG/M3

 PRIVATE  IMPACTOR

STAGE	STAGE CONSTANT

(um)	FILTER WEIGHT

DIFFERENCE (UG)	PERCENT IN

SIZE RANGE

FILTER	0.30	0	0

8	0.54	0	0

7	0.84	0	0

6	1.50	0	0

5	2.60	0	0

4	4.10	0	0

3	6.80	10	100

2	17.0	0	0

1	28.0	0	0

TOTAL = 10

	PARTICLE CONCENTRATION = 0.5 MG/M3

	PARTICLE SIZE DETERMINED WITH A SIERRA SERIES 210 CASCADE IMPACTOR

	CONDITIONS:

		SAMPLE FLOWRATE (Liters/Minute):  4		SAMPLE DURATION (Minutes):  5

		CALCULATION OF PARTICLE CONCENTRATION:

		SAMPLE VOLUME = SAMPLE FLOW RATE*SAMPLE DURATION

		PARTICLE CONCENTRATION = 

		((TOTAL FILTER WEIGHT DIFFERENCE [ug]/1000 [ug/mg])/(SAMPLE VOLUME
[L]))*1000 [L/M3]

I-21

APPENDIX I  -  INHALATION EXPOSURE DATA (CONT'D)

TABLE  I-6 - PARTICLE SIZE DATA (CONT'D)

20,000 MG/M3 TARGET 

 PRIVATE  IMPACTOR

STAGE	STAGE CONSTANT

(um)	FILTER WEIGHT

DIFFERENCE (UG)	PERCENT IN

SIZE RANGE

FILTER	0.30	0	0

8	0.54	0	0

7	0.84	0	0

6	1.50	0	0

5	2.60	0	0

4	4.10	10	100

3	6.80	0	0

2	17.0	0	0

1	28.0	0	0

TOTAL = 10

	CONCENTRATION OF PARTICLES = 0.5 MG/M3

	PARTICLE SIZE DETERMINED WITH A SIERRA SERIES 210 CASCADE IMPACTOR

	CONDITIONS:

		SAMPLE FLOWRATE (Liters/Minute):  4		SAMPLE DURATION (Minutes):  5

		CALCULATION OF PARTICLE CONCENTRATION:

		SAMPLE VOLUME (Liters) = SAMPLE FLOW RATE*SAMPLE DURATION

		PARTICLE CONCENTRATION = 

		((TOTAL FILTER WEIGHT DIFFERENCE/1000 ug/mg)/(SAMPLE VOLUME))*1000
L/M3

I-22

TABLE  I-7 – CHAMBER TEMPERATURES AND HUMIDITIES

CHAMBER TEMPERATURES (ºF) - 0 mg/m3 Target Concentration

	Time from Start of Exposure (Hours)

	0	0.5	1	1.5	2	2.5	3	3.5	4	4.5	5	5.5	6

31-Aug-02	66	70	70	70	70	70	70	70	70	70	70	70	70

1-Sep-02	66	68	68	68	68	68	68	68	68	68	68	68	68

2-Sep-02	68	70	72	72	72	72	72	72	72	72	72	72	72

3-Sep-02	66	72	72	72	72	72	72	72	72	72	72	72	72

4-Sep-02	68	72	72	72	72	72	72	72	72	72	72	72	72

5-Sep-02	68	72	72	72	72	72	72	72	72	72	72	74	74

6-Sep-02	68	72	74	74	74	74	74	74	74	74	74	74	74

7-Sep-02	68	70	71	71	71	71	71	71	71	71	71	71	71

8-Sep-02	70	72	72	72	72	72	72	72	72	72	72	72	72

9-Sep-02	68	70	72	72	72	72	72	72	72	74	74	74	74

10-Sep-02	70	72	74	74	74	74	74	74	74	74	74	74	74

11-Sep-02	70	72	74	74	74	74	74	74	74	74	74	74	74

12-Sep-02	70	72	74	74	76	75	75	75	75	75	75	75	75

13-Sep-02	72	74	74	74	76	76	76	76	76	76	76	76	76

14-Sep-02	68	70	70	70	74	74	74	74	74	74	74	74	74

15-Sep-02	70	74	74	74	74	74	74	74	74	74	74	74	74

16-Sep-02	67	70	72	72	72	73	74	74	74	74	74	74	74

17-Sep-02	70	72	74	74	74	74	74	74	74	74	74	74	74

18-Sep-02	68	68	72	72	74	74	74	74	74	74	74	74	74

19-Sep-02	70	70	72	72	72	72	72	72	72	72	72	72	72

20-Sep-02	68	70	72	72	72	72	72	72	72	72	72	72	72

21-Sep-02	68	72	72	72	72	72	72	72	72	72	72	72	72

22-Sep-02	68	70	70	72	72	72	72	72	72	72	72	72	72

23-Sep-02	68	72	72	72	72	74	74	74	74	74	74	74	74

24-Sep-02	70	70	70	70	70	74	74	74	74	74	74	74	74

25-Sep-02	68	70	70	70	72	72	72	72	72	72	72	72	72

26-Sep-02	68	70	70	70	72	72	72	72	72	72	72	72	72

	

I-23

TABLE  I-7 – CHAMBER TEMPERATURES AND HUMIDITIES (CONT’D)

CHAMBER TEMPERATURES (ºF) - 2000 mg/m3 Target Concentration

	Time from Start of Exposure (Hours)

	0	0.5	1	1.5	2	2.5	3	3.5	4	4.5	5	5.5	6

31-Aug-02	66	68	70	70	70	70	70	70	70	70	70	70	70

1-Sep-02	66	70	70	70	70	70	70	70	70	70	70	70	70

2-Sep-02	68	70	70	70	70	70	70	70	70	70	70	70	70

3-Sep-02	66	70	70	70	70	70	70	70	70	70	70	70	70

4-Sep-02	68	72	72	72	72	72	72	72	74	74	74	74	74

5-Sep-02	68	70	72	72	72	72	72	72	72	72	74	74	74

6-Sep-02	70	72	72	72	72	72	72	72	72	72	72	72	72

7-Sep-02	70	70	70	70	70	70	70	70	70	70	70	70	70

8-Sep-02	70	72	72	72	72	72	72	72	72	72	72	72	72

9-Sep-02	68	70	70	70	70	70	70	70	70	74	74	74	74

10-Sep-02	70	70	73	74	74	74	74	74	74	74	74	74	74

11-Sep-02	70	72	74	74	74	74	74	76	76	76	76	76	76

12-Sep-02	70	70	74	74	74	74	74	74	74	74	74	74	74

13-Sep-02	70	74	74	74	76	76	76	76	76	76	76	76	76

14-Sep-02	68	70	70	72	72	73	73	73	73	73	73	73	73

15-Sep-02	70	74	74	74	74	74	74	74	74	74	74	74	74

16-Sep-02	68	72	72	72	72	70	74	74	74	74	74	74	74

17-Sep-02	70	70	74	74	74	74	74	74	74	74	74	74	74

18-Sep-02	70	72	72	72	74	74	74	74	74	74	74	74	74

19-Sep-02	70	72	72	72	72	72	72	72	72	72	72	72	72

20-Sep-02	68	70	70	70	72	72	72	72	72	72	72	72	72

21-Sep-02	66	70	70	70	70	70	70	72	72	72	72	72	72

22-Sep-02	68	70	70	70	70	70	70	70	70	70	70	70	70

23-Sep-02	68	70	72	72	72	72	72	72	72	72	72	72	72

24-Sep-02	70	70	72	72	72	72	72	72	72	72	72	72	72

25-Sep-02	68	70	70	70	70	70	70	70	72	72	72	72	72

26-Sep-02	68	70	70	72	72	72	72	72	72	72	72	72	72

I-24

TABLE  I-7 – CHAMBER TEMPERATURES AND HUMIDITIES (CONT’D)

CHAMBER TEMPERATURES (ºF) – 10,000 mg/m3 Target Concentration

	Time from Start of Exposure (Hours)

	0	0.5	1	1.5	2	2.5	3	3.5	4	4.5	5	5.5	6

31-Aug-02	68	72	74	74	74	74	74	74	74	74	74	74	74

1-Sep-02	66	72	72	72	72	72	72	72	72	72	72	72	72

2-Sep-02	66	72	74	74	74	74	74	74	74	74	74	74	74

3-Sep-02	66	74	74	74	74	74	74	74	74	74	74	74	74

4-Sep-02	68	74	74	76	76	76	76	76	76	76	76	76	76

5-Sep-02	68	74	76	76	76	76	76	76	76	76	76	78	78

6-Sep-02	70	74	74	74	76	76	76	76	76	76	76	76	76

7-Sep-02	70	73	73	73	73	73	73	73	73	73	73	73	73

8-Sep-02	70	72	72	74	74	74	74	74	74	74	74	74	74

9-Sep-02	68	72	74	76	76	76	76	76	76	78	78	78	78

10-Sep-02	70	74	76	78	78	78	78	78	78	78	78	78	78

11-Sep-02	68	74	76	76	76	78	78	78	78	78	78	78	78

12-Sep-02	70	74	76	78	78	78	78	78	78	78	78	78	78

13-Sep-02	70	74	76	78	78	78	78	78	78	78	78	78	78

14-Sep-02	68	73	76	76	76	76	76	76	76	76	76	76	76

15-Sep-02	70	72	74	74	74	74	74	74	74	74	74	74	74

16-Sep-02	66	72	74	76	76	76	78	78	78	78	78	78	78

17-Sep-02	70	73	76	76	78	78	78	78	78	78	78	78	78

18-Sep-02	70	74	76	76	78	78	78	78	78	78	78	78	78

19-Sep-02	70	72	74	74	76	76	78	78	78	78	78	78	78

20-Sep-02	70	74	76	76	76	76	76	78	78	78	78	78	78

21-Sep-02	68	72	74	74	76	76	76	78	78	78	78	78	78

22-Sep-02	68	72	74	76	76	76	76	76	76	76	76	76	76

23-Sep-02	66	74	76	76	76	78	78	78	78	78	78	78	78

24-Sep-02	70	74	76	76	76	76	76	76	78	78	78	78	78

25-Sep-02	70	74	74	74	76	76	76	76	76	76	76	76	76

26-Sep-02	70	74	74	76	76	76	76	76	76	76	76	76	76

I-25

TABLE  I-7 – CHAMBER TEMPERATURES AND HUMIDITIES (CONT’D)

CHAMBER TEMPERATURES (ºF) – 20,000 mg/m3 Target Concentration

	Time from Start of Exposure (Hours)

	0	0.5	1	1.5	2	2.5	3	3.5	4	4.5	5	5.5	6

31-Aug-02	66	68	70	70	70	70	70	70	70	70	70	70	70

1-Sep-02	66	68	72	72	72	72	72	72	72	72	72	72	72

2-Sep-02	66	70	70	70	70	70	70	70	70	70	70	70	70

3-Sep-02	66	70	70	70	70	70	70	70	70	70	70	70	70

4-Sep-02	68	70	72	72	72	72	72	74	74	74	74	74	74

5-Sep-02	68	70	72	72	72	72	72	74	74	74	74	74	74

6-Sep-02	68	72	72	74	74	74	74	74	74	74	74	74	74

7-Sep-02	68	70	72	72	72	72	72	72	72	72	72	72	72

8-Sep-02	70	70	74	74	74	74	74	74	74	74	74	74	74

9-Sep-02	68	70	72	74	74	74	74	74	74	74	74	74	74

10-Sep-02	68	70	72	74	74	74	74	74	76	76	76	76	76

11-Sep-02	68	70	72	74	74	74	74	76	76	76	76	76	76

12-Sep-02	68	71	72	74	74	74	74	74	74	74	74	74	74

13-Sep-02	70	72	74	74	74	74	74	74	74	74	76	76	76

14-Sep-02	68	70	72	72	72	72	72	72	72	72	72	72	72

15-Sep-02	70	72	72	72	72	72	72	72	72	72	72	72	72

16-Sep-02	66	68	70	70	72	72	74	74	74	74	74	74	74

17-Sep-02	68	70	72	74	74	74	74	74	74	74	74	74	74

18-Sep-02	68	70	72	72	72	72	74	74	74	74	74	74	74

19-Sep-02	68	70	70	72	72	72	72	74	74	74	74	74	74

20-Sep-02	66	70	72	72	72	72	72	74	74	74	74	74	74

21-Sep-02	66	70	72	72	72	72	72	74	74	74	74	74	74

22-Sep-02	68	70	72	72	72	72	72	72	72	72	72	72	72

23-Sep-02	66	70	70	70	72	72	72	74	74	74	74	74	74

24-Sep-02	68	70	72	72	72	72	72	72	72	72	72	72	72

25-Sep-02	68	70	70	70	72	72	72	72	72	72	72	72	72

26-Sep-02	68	70	70	70	70	70	70	70	70	72	72	72	72

I-26

TABLE  I-7 – CHAMBER TEMPERATURES AND HUMIDITIES (CONT’D)

CHAMBER HUMIDITIES (%RH) - 0 mg/m3 Target Concentration

	Time from Start of Exposure (Hours)

	0	0.5	1	1.5	2	2.5	3	3.5	4	4.5	5	5.5	6

31-Aug-02	71	64	64	64	64	64	64	64	64	64	64	64	64

1-Sep-02	71	72	72	72	72	72	72	72	72	72	72	72	72

2-Sep-02	72	64	57	57	57	57	57	57	57	57	57	57	57

3-Sep-02	80	65	65	65	65	65	65	65	65	65	65	65	65

4-Sep-02	72	65	65	65	65	65	65	65	65	65	65	65	65

5-Sep-02	72	65	65	65	65	65	65	65	65	65	65	58	58

6-Sep-02	72	57	58	58	58	58	58	58	58	58	58	58	58

7-Sep-02	67	64	64	64	64	64	64	64	64	64	64	64	64

8-Sep-02	72	65	65	65	65	65	65	65	65	65	65	65	65

9-Sep-02	72	68	65	65	65	65	65	65	65	58	58	58	58

10-Sep-02	72	69	58	58	58	58	58	58	58	58	58	58	58

11-Sep-02	72	65	58	58	58	58	58	58	58	58	58	58	58

12-Sep-02	64	57	51	51	45	48	48	48	48	48	48	48	48

13-Sep-02	57	58	58	58	52	52	52	52	52	52	52	52	52

14-Sep-02	81	72	72	72	72	72	72	72	72	72	72	72	72

15-Sep-02	72	58	58	58	58	58	58	58	58	58	58	58	58

16-Sep-02	95	90	82	82	82	78	66	66	66	66	66	66	66

17-Sep-02	72	65	58	58	58	58	58	58	58	58	58	58	58

18-Sep-02	72	72	65	65	58	58	58	58	58	58	58	58	58

19-Sep-02	64	64	57	57	57	57	57	57	57	57	57	57	57

20-Sep-02	72	64	57	57	57	57	57	65	65	65	65	65	65

21-Sep-02	72	65	65	65	65	65	65	65	65	65	65	65	65

22-Sep-02	72	64	64	57	57	57	57	57	57	57	57	57	57

23-Sep-02	64	57	57	57	57	58	58	58	58	58	58	58	58

24-Sep-02	57	57	57	57	57	57	57	57	57	57	57	57	57

25-Sep-02	64	57	57	57	57	57	57	57	57	57	57	57	57

26-Sep-02	64	64	64	64	64	64	64	64	64	64	64	64	64

I-27

TABLE  I-7 – CHAMBER TEMPERATURES AND HUMIDITIES (CONT’D)

CHAMBER HUMIDITIES (%RH) - 2000 mg/m3 Target Concentration

	Time from Start of Exposure (Hours)

	0	0.5	1	1.5	2	2.5	3	3.5	4	4.5	5	5.5	6

31-Aug-02	71	72	64	64	64	64	64	64	64	64	64	64	64

1-Sep-02	71	64	64	64	64	64	64	64	64	64	64	64	64

2-Sep-02	72	64	64	64	64	64	64	64	64	64	64	64	64

3-Sep-02	71	64	64	64	64	64	64	64	64	64	64	64	64

4-Sep-02	72	65	65	65	65	65	65	65	58	58	58	58	58

5-Sep-02	72	72	65	65	65	65	65	65	65	65	65	65	65

6-Sep-02	64	57	57	65	65	65	57	57	57	57	57	65	65

7-Sep-02	57	64	68	68	68	68	68	68	68	68	68	68	68

8-Sep-02	72	65	65	65	65	65	65	65	65	65	65	65	65

9-Sep-02	72	68	68	68	68	68	68	68	68	58	58	58	58

10-Sep-02	72	72	61	66	66	66	66	66	66	66	66	66	66

11-Sep-02	72	65	58	58	58	58	58	52	52	52	52	52	52

12-Sep-02	64	64	51	51	51	51	51	51	51	51	51	51	51

13-Sep-02	64	58	58	58	52	52	52	52	52	52	52	52	52

14-Sep-02	72	72	72	69	69	69	69	69	69	69	69	69	69

15-Sep-02	72	58	58	58	58	58	58	58	58	58	58	58	58

16-Sep-02	90	73	73	73	73	72	66	66	66	66	66	66	66

17-Sep-02	72	72	58	58	58	58	58	58	58	58	58	58	58

18-Sep-02	64	65	65	65	58	58	58	58	58	58	58	58	58

19-Sep-02	64	65	65	65	65	65	65	65	65	65	65	65	65

20-Sep-02	72	64	64	64	57	57	57	65	65	65	65	65	65

21-Sep-02	90	81	81	81	72	72	72	65	65	65	65	65	65

22-Sep-02	64	64	64	64	64	64	64	64	64	64	64	64	64

23-Sep-02	64	64	57	57	57	57	57	57	57	57	57	57	57

24-Sep-02	57	57	57	57	57	57	57	57	57	50	50	50	50

25-Sep-02	64	57	57	57	57	57	57	57	57	57	57	57	57

26-Sep-02	64	64	64	57	57	57	57	57	57	57	57	57	57

I-28

TABLE  I-7 – CHAMBER TEMPERATURES AND HUMIDITIES (CONT’D)

CHAMBER HUMIDITIES (%RH) – 10,000 mg/m3 Target Concentration

	Time from Start of Exposure (Hours)

	0	0.5	1	1.5	2	2.5	3	3.5	4	4.5	5	5.5	6

31-Aug-02	64	57	58	58	58	58	58	58	58	58	58	58	58

1-Sep-02	71	57	57	57	57	57	57	57	57	57	57	57	57

2-Sep-02	71	65	58	58	58	58	58	58	58	58	58	58	58

3-Sep-02	80	58	58	58	58	58	58	58	58	58	58	58	58

4-Sep-02	72	58	58	59	59	59	59	59	59	59	59	59	59

5-Sep-02	72	58	59	59	59	59	59	59	59	59	59	53	53

6-Sep-02	64	58	58	58	52	52	52	52	52	52	52	52	52

7-Sep-02	64	61	65	65	65	65	65	65	65	65	65	65	65

8-Sep-02	76	65	65	58	58	58	58	58	58	58	58	58	58

9-Sep-02	72	65	58	56	56	56	56	56	56	53	53	53	53

10-Sep-02	72	62	56	53	53	53	53	53	53	53	53	53	53

11-Sep-02	72	58	59	59	59	53	53	53	53	53	53	53	53

12-Sep-02	57	51	45	46	46	46	46	46	46	46	46	46	46

13-Sep-02	64	58	52	53	53	53	53	53	53	53	53	53	53

14-Sep-02	72	65	59	59	59	59	59	59	59	59	59	59	59

15-Sep-02	72	65	66	66	66	66	66	66	66	66	66	66	66

16-Sep-02	90	82	74	67	67	67	57	57	57	53	53	53	53

17-Sep-02	72	61	59	59	53	53	53	53	53	53	53	53	53

18-Sep-02	64	58	59	59	53	53	53	53	53	53	53	53	53

19-Sep-02	81	73	66	66	59	59	53	53	53	53	53	53	53

20-Sep-02	64	58	52	52	52	52	52	53	53	53	53	53	53

21-Sep-02	72	65	66	66	59	59	59	53	53	53	53	53	53

22-Sep-02	64	61	58	52	52	52	52	52	52	52	52	52	52

23-Sep-02	71	58	52	52	52	52	52	52	52	52	52	52	52

24-Sep-02	57	51	45	52	52	52	52	52	46	46	46	46	46

25-Sep-02	57	51	51	51	52	52	52	52	52	52	52	52	52

26-Sep-02	64	58	58	52	52	52	52	52	52	52	52	52	52

I-29

TABLE  I-7 – CHAMBER TEMPERATURES AND HUMIDITIES (CONT’D)

CHAMBER HUMIDITIES (%RH) – 20,000 mg/m3 Target Concentration

	Time from Start of Exposure (Hours)

	0	0.5	1	1.5	2	2.5	3	3.5	4	4.5	5	5.5	6

31-Aug-02	71	72	64	64	64	64	64	64	64	64	64	64	64

1-Sep-02	71	72	57	57	57	57	57	57	57	57	57	57	57

2-Sep-02	71	64	64	64	64	64	64	64	64	64	64	64	64

3-Sep-02	71	72	72	72	72	72	72	72	72	72	72	72	72

4-Sep-02	72	72	65	65	65	65	65	58	58	58	58	58	58

5-Sep-02	72	72	65	65	65	65	65	58	58	58	58	58	58

6-Sep-02	81	65	65	58	58	58	58	58	58	58	58	58	58

7-Sep-02	64	72	65	65	65	65	65	65	65	65	65	65	65

8-Sep-02	72	72	58	58	58	58	58	58	58	58	58	58	58

9-Sep-02	72	77	65	58	58	58	58	58	58	58	58	58	58

10-Sep-02	72	77	65	58	58	58	58	58	59	59	59	59	59

11-Sep-02	72	72	65	58	58	58	58	52	52	52	52	52	52

12-Sep-02	55	57	57	51	51	51	51	51	51	51	51	51	51

13-Sep-02	57	57	51	58	58	58	58	58	58	58	52	52	52

14-Sep-02	72	64	65	69	69	69	69	69	69	69	69	69	69

15-Sep-02	72	65	65	65	65	65	65	65	65	65	65	65	65

16-Sep-02	90	90	81	81	73	73	66	66	66	58	58	58	58

17-Sep-02	72	72	65	58	58	58	58	58	58	58	58	58	58

18-Sep-02	72	72	65	65	65	65	58	58	58	58	58	58	58

19-Sep-02	72	64	64	65	65	65	65	58	58	58	58	58	58

20-Sep-02	71	64	57	57	57	57	65	58	58	58	58	58	58

21-Sep-02	71	72	65	65	65	65	65	58	58	58	58	58	58

22-Sep-02	64	64	61	61	61	61	61	61	61	61	61	61	61

23-Sep-02	71	64	64	64	57	57	57	58	58	58	58	58	58

24-Sep-02	64	64	57	57	57	57	57	57	57	57	57	57	57

25-Sep-02	64	64	64	64	57	57	57	57	57	57	57	57	57

26-Sep-02	64	64	64	64	64	64	64	64	64	57	57	57	57

I-30

	APPENDIX J- ANALYTICAL CHEMISTRY REPORT

	

	SUMMARY

Charcoal tube sorbent tube samples were received by the Analytical
Chemistry Laboratory from  inhalation chamber exposures and were
characterized for hydrocarbon distribution using capillary gas
chromatography with flame ionization detection (GC/FID).  Sorbent tube
samples were stored in a freezer pending analysis.

	SAMPLE PREPARATION

The front and back sections of each charcoal sample tube were desorbed
and analyzed separately to 

assess potential sampling breakthrough.  The charcoal tube sections were
desorbed with 3.0 mL  5% 2-propanol / 95% carbon disulfide (5%
2-PrOH/95% CS2) for at least 30 minutes.  Aliquots were then analyzed by
GC-FID.

	STANDARDIZATION

A standard mixture was prepared in CS2 containing each of the 18 target
hydrocarbons plus TBA oxygenate.  Analysis of the standard mixture was
used to confirm the relative retention times of each target hydrocarbon
and was not used for quantitative purposes.  

CHARACTERIZATION

Characterization of the neat MRD-00-718 (gasoline vapor condensate with
TBA) was performed separately and will be reported as part of EMBSI
Study 167490. Neat test substance characterization included a similar
analysis of the relative distribution of target hydrocarbons and
oxygenate as was performed for the chamber sorbent tube samples. 

J-1

APPENDIX J- ANALYTICAL CHEMISTRY REPORT

INSTRUMENT CONDITIONS FOR MRD-00-718

ON CHARCOAL SORBENT TUBE 

The following GC conditions and equipment were used to determine the
hydrocarbon distribution of test substance on chamber characterization
sorbent tubes:

GC	Perkin Elmer XL Autosystem

FID Range	FID (2^5)

Detector Temperature; (gas flows)	225°C (H2 45 mL/min; Air  450 mL/min)

Injector Temperature (Split ratio)	200°C (split injection 20:1)

Injection Volume	0.2µL or 0.5µL*  

Analytical Column C-32	Supleco Petrocol DH 150 fused silica capillary
column (150 m x 250 µm; 1.0 µm film thickness)

Oven Temperature Program	35(C (hold 130 minutes); ramp @ 2(C/minute to
200(C  

Data Collection	Perkin Elmer Nelson Turbochrom (TC4) version 4.1.2 

Carrier Gas Program	65 psi (He)

*0.2µL injected of 10,000mg/m3 and 20,000mg/m3 samples, 0.5µL injected
of 2000mg/m3 samples.

RESULTS

Hydrocarbon characterization was performed on an area percent basis for
each of the 18 

target hydrocarbons and TBA oxygenate. Results are listed in Table J-1. 
 

The relative distribution of hydrocarbons and oxygenate measured on the
chamber characterization charcoal tubes was in good agreement with that
measured in the characterization of neat MRD-00-718 test substance. 

										

D. J. Letinski, Analytical Chemist			Date

J-2

APPENDIX J- ANALYTICAL CHEMISTRY REPORT

TABLE J - 1

MRD-00-718 CHAMBER CHARACTERIZATION - SORBENT TUBES HYDROCARBON
DISTRIBUTION

Sample Date

4-Sep-02	10-Sep-02	17-Sep-02

25-Sep-02

Inhalation ID

1	2	3	4	5	6	7	8	9

10	11	12

 target mg/m3	target  mg/m3	target  mg/m3

target  mg/m3

2000	10,000	20,000	2000	10,000	20,000	2000	10,000	20,000	2000	10,000
20,000

Compound

RESULTS   ARE   in   "AREA %"  of   TARGET   HYDROCARBONS

isobutane

2.1	2.0	2.0	2.2	2.2	0.3	2.2	2.0	2.0

2.2	2.0	2.1

n-butane

9.6	9.4	9.3	10.1	9.8	3.1	9.8	9.5	9.4

10.1	9.5	9.6

isopentane

25.9	26.1	26.5	26.3	26.2	21.4	25.9	26.1	26.2

26.6	25.7	25.9

n-pentane

12.0	12.1	12.3	12.1	12.1	11.8	12.0	12.1	12.2

12.3	12.0	12.0

trans-2-pentene

2.2	2.2	2.2	2.2	2.2	2.3	2.2	2.2	2.2

2.2	2.2	2.2

TBA

14.9	15.7	15.9	14.6	15.5	19.9	15.0	15.7	16.1

15.4	16.1	16.1

2-methyl-2-butene

3.3	3.3	3.4	3.3	3.3	3.6	3.3	3.3	3.4

3.3	3.3	3.3

2,3-dimethylbutane

1.9	1.9	1.9	1.9	1.9	2.3	1.9	1.9	1.9

1.9	1.9	1.9

2-methylpentane

6.4	6.4	6.4	6.3	6.3	7.8	6.3	6.4	6.3

6.3	6.3	6.3

3-methylpentane

4.0	4.0	3.9	3.9	3.9	5.0	3.9	4.0	3.9

3.9	4.0	3.9

n-hexane

3.5	3.5	3.4	3.5	3.4	4.5	3.4	3.5	3.4

3.4	3.5	3.5

methylcyclopentane

1.7	1.7	1.7	1.7	1.6	2.2	1.7	1.7	1.7

1.7	1.7	1.7

2,4-dimethylpentane

1.1	1.1	1.1	1.1	1.1	1.5	1.1	1.1	1.1

1.0	1.1	1.1

benzene

2.5	2.1	2.1	2.4	2.1	2.9	2.5	2.1	2.1

2.4	2.2	2.2

2-methylhexane

1.4	1.3	1.3	1.3	1.3	1.8	1.4	1.3	1.3

1.2	1.4	1.3

2,3-dimethylpentane

1.3	1.3	1.2	1.3	1.3	1.7	1.3	1.3	1.2

1.2	1.3	1.3

3-methylhexane

1.6	1.5	1.5	1.5	1.5	2.0	1.6	1.5	1.5

1.3	1.5	1.5

isooctane

1.6	1.6	1.5	1.5	1.6	2.1	1.6	1.6	1.5

1.3	1.6	1.5

toluene

3.0	2.9	2.6	2.8	2.9	4.0	3.0	2.9	2.6

2.4	2.9	2.8

Sum

100	100	100	100	100	100	100	100	100

100	100	100

	        No hydrocarbon target compounds were detected on the back
section of the sorbent tubes analyzed. 

	

J-3

APPENDIX K – STATISTICIAN’S REPORT

Analysis of Fetal Data from a Whole-Body Inhalation Developmental
Toxicity 

Study in Rats with Gasoline with TBA Vapor Condensate (MRD-00-718)

This report details the statistical analysis of fetal body weight and
anomaly data from ExxonMobil Study 171834.  The study was conducted to
evaluate the potential developmental toxicity of Gasoline with TBA Vapor
Condensate (GTVC).  GTVC was administered via whole-body inhalation
exposure to pregnant rats during the period of major organogenesis and
fetal growth.  GTVC was administered by whole-body inhalation exposure
to 25 confirmed-mated CD® (SD) IGS BR female rats at target exposures
of 0 (air control) 2000, 10,000, and 20,000 mg/m3 for six hours (plus
the theoretical equilibration time) daily from Gestation Day (GD) 5
through GD 20. 

The fetal body weight was analyzed by a mixed model analysis of variance
that provides an accurate statistical model of the biology.  The
analysis used the litter as the basis for analysis and effectively used
the litter size as a covariate.  Two alternative models were used: one
model considered exposure group, litter size, and fetal sex as
explanatory variables while the other model used these variables and
included the corpora lutea (CL) as an additional covariate.  When the
overall effect of exposure, or the interactions with exposure, were
statistically significant the exposure groups means were tested pairwise
vs. the control group using least squares means.  The least squares
means allows comparisons that account for differences in litter size and
sex.  The mathematical model is based on a paper by Chen, et al (1996). 
The analysis was run using SAS with code suggested in Little, et al
(1997).  

The number of implants per dam, the litter size per dam, and the dam
uterine weight were analyzed by a standard analysis of variance with CL
as a covariate.  When the overall effect of exposure, or the
interactions of exposure with CL, was statistically significant the
exposure groups’ means were tested pairwise vs. the control group
using least squares means (Snedecor and Cochran, 1989).  

K-1

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

The analysis of anomalies (malformations or variations) was based on a
Generalized Estimating Equation (GEE) application of the linearized
model, Ryan (1992).  The model used the litter as the basis for analysis
and considered correlation among littermates by incorporating an
estimated constant correlation and the litter size as a covariate.  When
the overall effect of exposure, or the exposure by sex effect, was
statistically significant the exposure groups were tested pairwise vs.
the control group using least squares means.  The least squares means
allows comparisons that account for differences in litter size.  There
were three categories of anomalies tested, and within each category
specific anomalies were also tested.  In addition to the category
specific anomalies a series of combined analyses were performed within
each category: 

Combined Malformations and Variations for All Fetuses

Combined Malformations and Variations for Alive Fetuses

Combined Malformations and Variations for Dead Fetuses 

Malformations for All Fetuses

Malformations for Alive Fetuses

Malformations for Dead Fetuses

Variations for All Fetuses

Variations for Alive Fetuses

Variations for Dead Fetuses

In some cases there were no dead fetuses in a category.

Table I lists the four categories and corresponding sub-categories. 
Within each category several subcategories were combined into a group of
similar anomalies.  For example in the Category Skeletal the separate
sub-categories of “Bifid vertebral centra” and “Dumbbell-shaped
vertebral centra” were combined into a sub-category “Hypoplastic
vertebral centra”.  In this combined category an animal is counted
once when he, or she, exhibits more than one characteristic.  The
sub-categories that were combined are listed in the Sub-categories
Combined column of Table 1 by the sub-category number.  The analyses
were run using SAS.  

K-2

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

Table I

Malformation Categories and Corresponding Sub-categories

Category	Sub-Category	Sub-categories combined

Head	1 - Retinal fold; Left

	External	1 - Adactyly forepaw; Bilateral

2 - Cleft palate

3 - Ectrodactyly hindpaw; Bilateral (2 digits on each paw)

4 - Hooked tail

5 - Malrotated hindpaw

6 – Microcephaly

7 - Protruding tongue

8 - Short tail

	Abdomen/Thorax	1 - Malpositioned kidney; Bilateral

2 - Umbilical artery arises from left side of urinary bladder

	Skeletal	1 - Multiple paw bones absent

2 Ribs - Fused; Right

3 Ribs - Multiple bones malformed

4 - Rudimentary supernumerary ribs

5 - Short last rib

6 Skull - Multiple bones malformed

7 Sternebrae – Bifid

8 Sternebrae – Fused

9 - Asymmetric sternebrae

10 - Hypoplastic sternebrae

11 - Unossified sternebrae

12 - Presacral vertebrae

13 - Bifid vertebral centra

14 - Dumbbell-shaped vertebral centra

15 - Dumbbell-shaped vertebral centra anlage

16 - Malformed vertebral arch

17 Vertebrae - Multiple bones malformed

18 - Delayed ossification of the sternebrae	10, 11

	19 - Hypoplastic vertebral centra	13, 14

K-3

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

RESULTS:

BODY WEIGHT ANALYSIS

Based on the bodyweight analysis that did not consider CL count, there
was no statistically significant difference in the mean fetal litter
weights among the exposure groups.  The exposure by sex interaction was
not statistically significant; therefore only the group means are
presented.  Table II shows the mean fetal weight and the least squares
mean fetal weight.  

Table II

Mean fetal weight, the least squares mean fetal weight not considering
CL count

Exposure Group

(mg/m3)	n litters 	n fetuses	observed fetus mean (gm)	Least squares
fetus mean (gm)

0	25	385	5.29	5.32

2,000	23	302	5.33	5.29

10,000	23	327	5.29	5.29

20,000	24	345	5.13	 5.16

The bodyweight analysis that included CL count and a CL by exposure
interaction indicated a statistically significant difference in the mean
fetal litter weights among the exposure groups and an exposure by CL
count interaction (p<0.0025 and p<0.0005 respectively); the 20,000 mg/m3
exposure group was different from the 0 exposure group (p<0.02).  When
the model as fit without the exposure by CL count interaction there was
not a significant difference in fetal weights among the exposure groups
(p<0.14).  Table III shows the mean fetal weight and the least squares
mean fetal weight based on the two models.  

Table III

Mean fetal weight, the least squares mean fetal weight considering CL
count

Exposure Group

(mg/m3)	n litters 	n fetuses	n CL	observed fetus mean (gm)	Least squares
fetus mean (gm)

with CL*exposure	Least squares fetus mean (gm)

without CL*exposure

0	25	385	16.3	5.29	5.31	5.31

2,000	23	302	14.0	5.33	5.36	5.30

10,000	23	327	14.9	5.29	5.26 	5.29

20,000	24	345	15.1	5.13	 5.15 *	5.16

               * statistically significantly different from control,
p<0.02

K-4

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

IMPLANTS, LITTER SIZE, AND UTERINE WEIGHT ANALYSES

The number of implants per dam, the litter size per dam, and the dam
uterine weight analyses that included a CL and an exposure by CL
interaction indicated statistically significant differences in the
exposure related means for all three measures. However, only the uterine
weight analyses indicated a statistically significant difference between
the control and an exposed group.  Table IV shows the means the least
squares means for these three measures.  When the analyses were repeated
with a model that did not include an exposure by CL interaction term
there were no statistically significant exposure related effects. 

Table IV

Mean number of implants, litter size, and uterine weight, and the

corresponding least squares means considering CL count and an exposure
by CL interaction

	Observed Means	Least Squares Means

Exposure Group

(mg/m3)	n litters

	n

CL	n implants	Litter Size	Uterine Weight	n implants	Litter Size	Uterine
Weight

0	25	16.3	15.68	15.40	114.3	14.73	14.58	109.2

2,000	23	14.0	13.30	13.13	100.6	14.35	14.17	107.7

10,000	23	14.9	14.61	14.22	105.5	14.82	14.44	106.6

20,000	24	15.1	14.71	14.38	104.1	14.71	14.38	103.7*

* statistically significantly different from control, p<0.02

MALFORMATION ANALYSES

Of the 31 anomaly analyses the count of skeletal rudimentary
supernumerary ribs, count of combined skeletal variations and
malformations and count of combined skeletal variations indicated a
statistically significant differences among the exposure groups
(p<0.05).  Individual comparisons indicated the high exposure group
(20,000 mg/m3) had a large incidence of rudimentary supernumerary ribs
than the control group.  None of the other measures indicated
statistically significant differences among the exposure groups.   See
Table V for the incidences of skeletal rudimentary supernumerary ribs.

Statistically significant differences in counts between control and
20,000 mg/m3 for count of combined skeletal variations and malformations
and count of combined skeletal variations can be explained by difference
in counts for skeletal rudimentary supernumerary ribs. Differences
between exposure groups become insignificant when the skeletal count of
rudimentary supernumerary ribs are removed from the definitions of count
of combined skeletal variations and malformations and count of combined
skeletal variations.  

Incidence tables for all measures are provided in the appendix.

K-5

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

Table V

Skeletal Count of Rudimentary Supernumerary Ribs

Numbers in parenthesis are percents

Exposure Group (mg/m3)	Dams

Examined	Fetuses Examined	Dams  Affected	Fetuses  Affected

0  	25	193	12 (48)	16 (8)

2000  	23	153	8 (35)	11 (7)

10000  	23	165	7 (30)	8 (5)

20000  	24	170	16 (67)	29*  (17)

		* statistically significantly different from control, p<0.05

DISCUSSION:

The analyses for fetal body weight, number of implants per dam, the
litter size per dam, and the dam uterine weight are complicated.  The
analyses that did not include CL count were not statistically
significant, those that included a term for CL and no exposure by CL
interaction terms were not statistically significant, but when there was
a CL term and an interaction term there were statistically significant
exposure effects (only the fetal weight and uterine weight endpoints
indicated a difference between an exposure group and the 0 exposure
group).  Supplementary diagnostics indicate that the changing pattern is
due to complex relationships among the endpoints, the exposure, and the
CL count.  The models for fetal weight indicate that at low CL counts
the bodyweight increases with increasing exposure, for moderate CL count
(in the 12 to 14 count range) there is no change in fetal weight as
exposure changes, and for high CL count (above 14 CL per dam) the fetal
weight decreases with increasing exposure (the rate of decrease in
weight becoming sharper as the CL count increases).  The specific least
squares analysis uses the overall mean CL count of 15.1, so the model
predicts a decrease in fetal weight with increasing exposure.  Because
of these complexities and the confounding of CL count and exposure it is
not clear that exposure is directly linked with adverse effects

CONCLUSION:

Based on these findings, administration of the test substance at the
exposures tested is associated with an increased incidence of skeletal
rudimentary supernumerary ribs in the 20,000 mg/m3 exposure group
relative to the control group.  Analyses of mean litter fetal body
weight and uterine weight are complex with equivocal results; observed
effects may be due to a confounding with CL count.  The confounding
effect may also apply to the number of implants per dam and the litter
size, but that has not been clearly shown with these data

K-6

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

										

Mark J. Nicolich, Ph.D.			Date

Statistician

ExxonMobil Biomedical Sciences, Inc

1545 Route 22 East

PO Box 971

Annandale, NJ 08801-0971

										

George Bukhbinder, Ph.D.			Date

Consultant

References:  

Chen, Gaylor, and Laborde, “Dose-response modeling of growth for
developmental toxicity”, Environmetrics, vol 7, pg 135-144, 1996. 

Little, Milliken, Stroup, and Wolfinger, “SAS System for Mixed
Models“, SAS Institute, Cary, NC, 1997, section 5.6.2, pg 203.

Ryan, L., “The use of generalized estimating equations for risk
assessment in developmental toxicity”, Risk Analysis, 12(3), pg
439-447, 1992.

  

SAS/STAT, V8.02, copyright © 1999-2001, SAS Institute, Inc., Cary, NC.

Snedecor, G.W. and Cochran, W.G., Statistical Methods, 8th Edition, Iowa
State University Press, Ames, Iowa, 1989. 

K-7

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

APPENDIX

Anomaly Counts

Study # 171834

                                       head - individual

                               VISCERAL/HEAD:  Retinal fold; Left

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          192          0          
0   

                   2000 MG/M3       22          149          0          
0   

                  10000 MG/M3       23          162          0          
0   

                  20000 MG/M3       24          175          1          
1   

 

 

 

 

                       External Variations and Malformations - combined 

                                          All Fetuses

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          385          1          
1   

                   2000 MG/M3       23          302          2          
3   

                  10000 MG/M3       23          327          1          
2   

                  20000 MG/M3       24          345          0          
0   

 

 

 

 

                       External Variations and Malformations - combined 

                                         Alive Fetuses

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          384          1          
1   

                   2000 MG/M3       23          302          2          
3   

                  10000 MG/M3       23          327          1          
2   

                  20000 MG/M3       24          345          0          
0   

 

 

 

K-8

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

                       External Variations and Malformations - combined 

                                          Dead Fetuses

                                 dams       fetuses      dams      
fetuses

                     DOSE      examined    examined    affected  
affected

                    0 MG/M3        1           1           0           0
  

 

 

 

 

                               External Malformations - combined 

                                          All Fetuses

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          385          1          
1   

                   2000 MG/M3       23          302          1          
2   

                  10000 MG/M3       23          327          1          
2   

                  20000 MG/M3       24          345          0          
0   

 

 

 

 

                               External Malformations - combined 

                                         Alive Fetuses

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          384          1          
1   

                   2000 MG/M3       23          302          1          
2   

                  10000 MG/M3       23          327          1          
2   

                  20000 MG/M3       24          345          0          
0   

 

 

 

 

                               External Malformations - combined 

                                          Dead Fetuses

                                 dams       fetuses      dams      
fetuses

                     DOSE      examined    examined    affected  
affected

                    0 MG/M3        1           1           0           0
  

 

 

 

K-9

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

                                     external - individual

                             EXTERNAL: Adactyly forepaw; Bilateral

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          385          0          
0   

                   2000 MG/M3       23          302          1          
1   

                  10000 MG/M3       23          327          0          
0   

                  20000 MG/M3       24          345          0          
0   

 

 

 

 

                                     external - individual

                                     EXTERNAL: Cleft palate

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          385          0          
0   

                   2000 MG/M3       23          302          1          
1   

                  10000 MG/M3       23          327          0          
0   

                  20000 MG/M3       24          345          0          
0   

 

 

 

 

                                     external - individual

		                EXTERNAL: Ectrodactyly hindpaw; Bilateral 

						(2 digits on each paw)

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          385          0          
0   

                   2000 MG/M3       23          302          1          
1   

                  10000 MG/M3       23          327          0          
0   

                  20000 MG/M3       24          345          0          
0   

 

 

 

 

                                     external - individual

                                     EXTERNAL: Hooked tail

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          385          0          
0   

                   2000 MG/M3       23          302          1          
1   

                  10000 MG/M3       23          327          0          
0   

                  20000 MG/M3       24          345          0          
0   

K-10

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

                                     external - individual

                                  EXTERNAL: Malrotated hindpaw

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          385          1          
1   

                   2000 MG/M3       23          302          1          
2   

                  10000 MG/M3       23          327          1          
2   

                  20000 MG/M3       24          345          0          
0   

 

 

 

 

                                     external - individual

                                     EXTERNAL: Microcephaly

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          385          0          
0   

                   2000 MG/M3       23          302          1          
1   

                  10000 MG/M3       23          327          0          
0   

                  20000 MG/M3       24          345          0          
0   

 

 

 

 

                                     external - individual

                                  EXTERNAL: Protruding tongue

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          385          0          
0   

                   2000 MG/M3       23          302          2          
2   

                  10000 MG/M3       23          327          0          
0   

                  20000 MG/M3       24          345          0          
0   

 

 

 

 

                                     external - individual

                                      EXTERNAL: Short tail

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          385          0          
0   

                   2000 MG/M3       23          302          1          
1   

                  10000 MG/M3       23          327          0          
0   

                  20000 MG/M3       24          345          0          
0   

 

K-11

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

                       Visceral Variations and Malformations - combined 

                                          All Fetuses

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          192          1          
1   

                   2000 MG/M3       23          151          1          
1   

                  10000 MG/M3       23          162          1          
1   

                  20000 MG/M3       24          175          0          
0   

 

 

 

 

                       Visceral Variations and Malformations - combined 

                                         Alive Fetuses

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          191          1          
1   

                   2000 MG/M3       23          151          1          
1   

                  10000 MG/M3       23          162          1          
1   

                  20000 MG/M3       24          175          0          
0   

 

 

 

 

                       Visceral Variations and Malformations - combined 

                                          Dead Fetuses

                                 dams       fetuses      dams      
fetuses

                     DOSE      examined    examined    affected  
affected

                    0 MG/M3        1           1           0           0
  

 

 

 

 

                                     visceral - individual

                        ABDOMEN/THORAX:  Malpositioned kidney; Bilateral

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          192          0          
0   

                   2000 MG/M3       23          151          1          
1   

                  10000 MG/M3       23          162          0          
0   

                  20000 MG/M3       24          175          0          
0   

 

 

 

K-12

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

                                     visceral - individual

			          ABDOMEN/THORAX:  Umbilical artery arises from 

					left side of urinary bladder

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          192          1          
1   

                   2000 MG/M3       23          151          0          
0   

                  10000 MG/M3       23          162          1          
1   

                  20000 MG/M3       24          175          0          
0   

 

 

 

 

                       Skeletal Variations and Malformations - combined 

                                          All Fetuses

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193         15         
24   

                   2000 MG/M3       23          153         13         
21   

                  10000 MG/M3       23          165         13         
15   

                  20000 MG/M3       24          170         20         
38   

 

  

 

                       Skeletal Variations and Malformations - combined 

                                         Alive Fetuses

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193         15         
24   

                   2000 MG/M3       23          153         13         
21   

                  10000 MG/M3       23          165         13         
15   

                  20000 MG/M3       24          170         20         
38   

 

 

				    Skeletal Variations and Malformations - 

				combined,without Rudimentary Supernumarary Ribs

                                          All Fetuses

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          7          
9   

                   2000 MG/M3       23          153          8         
10   

                  10000 MG/M3       23          165          8          
8   

                  20000 MG/M3       24          170          6         
10   

 

 

K-13

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

				    Skeletal Variations and Malformations - 

				combined,without Rudimentary Supernumarary Ribs

                                         Alive Fetuses

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          7          
9   

                   2000 MG/M3       23          153          8         
10   

                  10000 MG/M3       23          165          8          
8   

                  20000 MG/M3       24          170          6         
10   

 

 

 

 

                                Skeletal Variations - combined 

                                          All Fetuses

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193         15         
24   

                   2000 MG/M3       23          153         13         
21   

                  10000 MG/M3       23          165         13         
15   

                  20000 MG/M3       24          170         20         
38   

 

 

 

 

                                Skeletal Variations - combined 

                                         Alive Fetuses

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193         15         
24   

                   2000 MG/M3       23          153         13         
21   

                  10000 MG/M3       23          165         13         
15   

                  20000 MG/M3       24          170         20         
38   

 

 

 

 

			             Skeletal Variations - combined,without 

						Rudimentary Supernumarary Ribs

                                          All Fetuses

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          7          
9   

                   2000 MG/M3       23          153          8         
10   

                  10000 MG/M3       23          165          7          
7   

                  20000 MG/M3       24          170          6         
10   

K-14

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

			             Skeletal Variations - combined,without 

						Rudimentary Supernumarary Ribs

                                         Alive Fetuses

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          7          
9   

                   2000 MG/M3       23          153          8         
10   

                  10000 MG/M3       23          165          7          
7   

                  20000 MG/M3       24          170          6         
10   

 

 

 

 

                               Skeletal Malformations - combined 

                                          All Fetuses

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          2          
2   

                   2000 MG/M3       23          153          1          
1   

                  10000 MG/M3       23          165          1          
1   

                  20000 MG/M3       24          170          1          
1   

 

 

 

 

                               Skeletal Malformations - combined 

                                         Alive Fetuses

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          2          
2   

                   2000 MG/M3       23          153          1          
1   

                  10000 MG/M3       23          165          1          
1   

                  20000 MG/M3       24          170          1          
1   

 

 

 

                                     skeletal - individual

                            SKELETAL/PAW: Multiple paw bones absent

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          0          
0   

                   2000 MG/M3       23          153          1          
1   

                  10000 MG/M3       23          165          0          
0   

                  20000 MG/M3       24          170          0          
0   

 

K-15

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

                                     skeletal - individual

                           SKELETAL/RIBS (T1-2 anlage): Fused; Right

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          1          
1   

                   2000 MG/M3       23          153          0          
0   

                  10000 MG/M3       23          165          0          
0   

                  20000 MG/M3       24          170          0          
0   

 

 

 

 

                                     skeletal - individual

                            SKELETAL/RIBS: Multiple bones malformed

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          0          
0   

                   2000 MG/M3       23          153          1          
1   

                  10000 MG/M3       23          165          0          
0   

                  20000 MG/M3       24          170          0          
0   

 

 

 

 

                                     skeletal - individual

                         SKELETAL/RIBS: Rudimentary supernumerary ribs

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193         12         
16   

                   2000 MG/M3       23          153          8         
11   

                  10000 MG/M3       23          165          7          
8   

                  20000 MG/M3       24          170         16         
29   

 

 

 

 

                                     skeletal - individual

                                 SKELETAL/RIBS: Short last rib

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          3          
3   

                   2000 MG/M3       23          153          1          
1   

                  10000 MG/M3       23          165          1          
1   

                  20000 MG/M3       24          170          0          
0   

 

K-16

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

                                     skeletal - individual

                            SKELETAL/SKULL: Multiple bones malformed

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          0          
0   

                   2000 MG/M3       23          153          1          
1   

                  10000 MG/M3       23          165          0          
0   

                  20000 MG/M3       24          170          0          
0   

 

 

 

 

                                     skeletal - individual

                               SKELETAL/STERNEBRAE (I, II): Bifid

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          0          
0   

                   2000 MG/M3       23          153          1          
1   

                  10000 MG/M3       23          165          0          
0   

                  20000 MG/M3       24          170          0          
0   

 

 

 

 

                                     skeletal - individual

                               SKELETAL/STERNEBRAE (IV-VI): Fused

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          1          
1   

                   2000 MG/M3       23          153          0          
0   

                  10000 MG/M3       23          165          0          
0   

                  20000 MG/M3       24          170          0          
0   

 

 

 

 

                                     skeletal - individual

                          SKELETAL/STERNEBRAE:  Asymmetric sternebrae

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          0          
0   

                   2000 MG/M3       23          153          2          
2   

                  10000 MG/M3       23          165          1          
1   

                  20000 MG/M3       24          170          1          
1   

 

K-17

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

                                     skeletal - individual

                          SKELETAL/STERNEBRAE:  Hypoplastic sternebrae

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          1          
1   

                   2000 MG/M3       23          153          1          
1   

                  10000 MG/M3       23          165          0          
0   

                  20000 MG/M3       24          170          1          
2   

 

 

 

 

                                     skeletal - individual

                          SKELETAL/STERNEBRAE:  Unossified sternebrae

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          1          
1   

                   2000 MG/M3       23          153          4          
6   

                  10000 MG/M3       23          165          4          
4   

                  20000 MG/M3       24          170          1          
1   

 

 

 

 

                                     skeletal - individual

                          SKELETAL/VERTEBRAE (L): Presacral vertebrae

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          0          
0   

                   2000 MG/M3       23          153          0          
0   

                  10000 MG/M3       23          165          0          
0   

                  20000 MG/M3       24          170          1          
1   

 

 

 

 

                                     skeletal - individual

                          SKELETAL/VERTEBRAE:  Bifid vertebral centra

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          3          
4   

                   2000 MG/M3       23          153          0          
0   

                  10000 MG/M3       23          165          0          
0   

                  20000 MG/M3       24          170          3          
3   

K-18

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

                                     skeletal - individual

                     SKELETAL/VERTEBRAE:  Dumbbell-shaped vertebral
centra

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          1          
1   

                   2000 MG/M3       23          153          0          
0   

                  10000 MG/M3       23          165          0          
0   

                  20000 MG/M3       24          170          2          
2   

 

 

 

 

                                     skeletal - individual

               SKELETAL/VERTEBRAE:  Dumbbell-shaped vertebral centra
anlage

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          1          
2   

                   2000 MG/M3       23          153          1          
1   

                  10000 MG/M3       23          165          1          
1   

                  20000 MG/M3       24          170          3          
4   

 

 

 

 

                                     skeletal - individual

                         SKELETAL/VERTEBRAE:  Malformed vertebral arch

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          1          
1   

                   2000 MG/M3       23          153          0          
0   

                  10000 MG/M3       23          165          1          
1   

                  20000 MG/M3       24          170          1          
1   

 

 

 

 

                                     skeletal - individual

                          SKELETAL/VERTEBRAE: Multiple bones malformed

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          0          
0   

                   2000 MG/M3       23          153          1          
1   

                  10000 MG/M3       23          165          0          
0   

                  20000 MG/M3       24          170          0          
0   

 

K-19

APPENDIX K – STATISTICIAN’S REPORT (CONT/D)

                                      skeletal - combined

               SKELETAL/STERNEBRAE:  Delayed ossification of the
sternebrae

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          2          
2   

                   2000 MG/M3       23          153          5          
7   

                  10000 MG/M3       23          165          4          
4   

                  20000 MG/M3       24          170          2          
3   

 

 

 

 

                                      skeletal - combined

                       SKELETAL/VERTEBRAE:  Hypoplastic vertebral centra

                                   dams       fetuses      dams      
fetuses

                     DOSE        examined    examined    affected  
affected

                      0 MG/M3       25          193          3          
4   

                   2000 MG/M3       23          153          0          
0   

                  10000 MG/M3       23          165          0          
0   

                  20000 MG/M3       24          170          4          
5    

K-20

APPENDIX L - HISTORICAL CONTROL DATA FOR ANNANDALE, NJ FACILITY

TESTING FACILITY – ANNANDALE, NJ

SUPPLIER: Charles River Laboratories, Inc.

FEED: PMI Certified Rodent Chow (5002 Meal)

STUDY          NUMBER	STUDY DATES	SUPPLIER LOCATION/AREA	SPECIES/STRAIN
NUMBER OF LITTERS/FETUSES	% PREGNANT	DOSING ROUTE/CARRIER

9A	May 9, 2000 – 

June 2, 2000	Raleigh, NC/R04	Crl:CD®(SD)IGSBR VAF/Plus	25/398	100
Oral/Corn Oil

9B	May 9, 2000 – 

June 2, 2000	Raleigh, NC/R04	Crl:CD®(SD)IGSBR VAF/Plus	25/401	100
Oral/Corn Oil

10	May 19, 2001 – 

June 15, 2001	Raleigh, NC/R04	Crl:CD®(SD)IGSBR VAF/Plus	24/359	96
Inhalation/Air

11	August 19, 2001 – 

September 18, 2001	Raleigh, NC/R04	Crl:CD®(SD)IGSBR VAF/Plus	24/358	96
Inhalation/Air

12	November 18, 2001 -December 20, 2001	Raleigh, NC/R04
Crl:CD®(SD)IGSBR VAF/Plus	25/389	100	Inhalation/Air

13	February 3, 2002 – 

March 8, 2001	Raleigh, NC/R04	Crl:CD®(SD)IGSBR VAF/Plus	25/374	100
Inhalation/Air

14	April 22, 2002 – 

May 22, 2002	Raleigh, NC/R04	Crl:CD®(SD)IGSBR VAF/Plus	25/353	100
Inhalation/Air

15	June 17, 2002 – 

July 17, 2002	Raleigh, NC/R04	Crl:CD®(SD)IGSBR VAF/Plus	22/316	88
Inhalation/Air

L-1

APPENDIX L - HISTORICAL CONTROL DATA FOR ANNANDALE, NJ FACILITY
(CONT’D)

 (UTERINE IMPLANTATION DATA)

	NUMBER

OF

LITTERS	

LIVE	

MALE	

FEMALE	

RESORPTIONS	

IMPLANTS	

CORPORA LUTEA	

DEAD	

FETUS/ IMPLANTS	

RESORPTIONS/ IMPLANTS	

F/I TRANSFORMED

HIGH

16.04	7.92	8.36	0.72	16.48	17.16	0.04	0.98	0.05	80.376320

LOW

14.12	6.88	7.24	0.32	14.56	15.50	0	0.95	0.02	77.306160

STUDY #

	15	22	14.36	7.09	7.27	0.36	14.73	15.50	0	0.98	0.02	79.881591

STD

1.89	1.80	1.72	0.66	2.00	1.82	0	0.04	0.04	4.499537

(N)

22	22	22	22	22	22	22	22	22	22

14	25	14.12	6.88	7.24	0.40	14.56	15.88	0.04	0.95	0.04	78.128760

STD

3.11	2.44	2.15	0.58	3.00	1.54	0.2	0.10	0.10	8.029518

(N)

25	25	25	25	25	25	25	25	25	25

13	25	14.96	7.36	7.60	0.72	15.68	15.96	0	0.95	0.05	77.306160

STD

3.12	2.45	2.42	0.84	3.09	3.18	0	0.07	0.07	6.507916

(N)

25	25	25	25	25	25	25	25	25	25

12	25	15.56	7.92	7.64	0.32	15.88	16.40	0	0.98	0.02	80.376320

STD

2.92	2.64	2.38	0.56	2.88	2.99	0	0.04	0.03	3.947106

(N)

25	25	25	25	25	25	25	25	25	25

11	24	14.92	7.17	7.75	0.63	15.54	16.04	0	0.96	0.04	78.114083

STD

2.19	2.57	2.27	0.77	1.82	1.94	0	0.05	0.05	5.545914

(N)

24	24	24	24	24	24	24	24	24	24

10	24	14.96	7.54	7.42	0.58	15.50	16.42	0	0.97	0.04	78.883958

STD

3.07	2.90	2.55	0.83	3.18	3.41	0	0.05	0.05	5.408551

(N)

24	24	24	24	24	24	24	24	24	24

9(B)	25	16.04	7.84	8.20	0.44	16.48	17.16	0	0.97	0.03	79.840760

STD

2.24	1.57	1.91	0.77	2.02	1.93	0	0.05	0.05	5.232909

(N)

25	25	25	25	25	25	25	25	25	25

9(A)	25	15.92	7.56	8.36	0.52	16.44	16.88	0	0.97	0.03	79.294360

STD

1.53	1.69	1.60	0.71	1.42	1.48	0	0.04	0.04	4.836482

(N)

25	25	25	25	25	25	25	25	25	25

L-2

APPENDIX L - HISTORICAL CONTROL DATA FOR ANNANDALE, NJ FACILITY
(CONT’D)

 (UTERINE IMPLANTATION DATA)

	NUMBER

OF

LITTERS	

R/I TRANSFORMED	

D/I TRANSFORMED	

DEAD/ IMPLANTS	PRE IMPLANT LOSS	POST IMPLANT LOSS	

MALFORMATIONS	

VARIATIONS	

AFFECTED

HIGH

12.694280	8.238	0	7.9	5.1	0.28	1.70	1.00

LOW

9.624000	7.103	0	1.6	2.0	0.08	0.00	0.40

STUDY #

	15	22	10.118955	7.545	0	4.4	2.3	0.27	0.50	0.60

STD

4.499552	0.595	0	10.9	4.3	0.46	0.80	0.70

(N)

22	22	22	22	22	22	22	22

14	25	11.588840	8.238	0	7.9	4.6	0.28	1.70	0.70

STD

8.074369	2.934	0	17.7	10.2	0.46	1.20	0.70

(N)

25	25	25	25	25	25	25	25

13	25	12.694280	7.473	0	1.6	5.1	0.24	1.40	1.00

STD

6.507867	1.521	0	2.7	6.7	0.52	1.60	1.00

(N)

25	25	25	25	25	25	25	25

12	25	9.624000	7.326	0	3.0	2.0	0.10	1.40	0.40

STD

3.947128	0.905	0	3.9	3.4	0.30	1.20	0.60

(N)

25	25	25	25	25	25	25	25

11	24	11.886500	7.324	0	3.0	4.2	0.25	1.10	0.90

STD

5.545880	0.446	0	3.9	5.4	0.53	1.10	1.10

(N)

24	24	24	24	24	24	24	24

10	24	11.402500	7.455	0	5.1	3.3	0.17	0.70	0.80

STD

5.349722	1.087	0	12.6	5.4	0.38	0.80	0.80

(N)

24	24	24	24	24	24	24	24

9(B)	25	10.159600	7.117	0	3.9	2.8	0.08	0.00	0.50

STD

5.232766	0.478	0	7.0	5.0	0.40	0.00	0.80

(N)

25	25	25	25	25	25	25	25

9(A)	25	10.706120	7.103	0	2.5	3.1	0.12	0.10	0.60

STD

4.836645	0.318	0	4.3	4.3	0.33	0.40	0.70

(N)

25	25	25	25	25	25	25	25

L-3

APPENDIX L - HISTORICAL CONTROL DATA FOR ANNANDALE, NJ FACILITY
(CONT’D)

 (FETAL BODY WEIGHTS)

	NUMBER

OF

LITTERS	

MALE	

FEMALE

HIGH

5.75	5.50

LOW

5.41	5.16

STUDY #

	15	22	5.60	5.33

STD

0.41	0.38

(N)

156	160

14	25	5.46	5.18

STD

0.41	0.39

(N)

172	181

13	25	5.49	5.17

STD

0.33	0.37

(N)

184	190

12	25	5.59	5.36

STD

0.36	0.32

(N)

198	191

11	24	5.52	5.25

STD

0.38	0.45

(N)

172	186

10	24	5.75	5.50

STD

0.35	0.34

(N)

181	178

9(B)	25	5.41	5.16

STD

0.45	0.39

(N)

196	205

9(A)	25	5.61	5.31

STD

0.38	0.37

(N)

189	209

L-4

APPENDIX L - HISTORICAL CONTROL DATA FOR ANNANDALE, NJ FACILITY
(CONT’D)

 (EXTERNAL DATA)

STUDY #	15	14	13	12	11	10	9(B)	9(A)

NUMBER OF LITTER	22	25	25	25	24	24	25	25

NUMBER OF FETUSES	316	353	374	389	358	359	401	398

% STUNTED - F	0.63	0.85	0.27	0.26	0.84	0	1.25	0

% STUNTED - L	9.09	12.00	4.00	4.00	8.33	0	16.00	0

% EXT. VAR. - F	0	0	0	0	0	0	0	0

% EXT. VAR. - L	0	0	0	0	0	0	0	0

 

% EXT. MAL - F	0.94	0.85	0.53	0.26	0.56	0.28	0	0.50

% EXT. MAL. - L	13.64	12.00	8.00	4.00	8.33	4.17	0	8.00

Domed head - F

0.28

Domed head - L

4.00

Malrotated hindpaw - F	0.94	0.57	0.53	0.26	0.28	0.28

0.50

Malrotated hindpaw - L	13.64	8.00	8.00	4.00	4.17	4.17

8.00

Filamentous tail - F

	0.28

	Filamentous tail - L

	4.17

	NOTE:    F - Fetus

                L - Litter

	Blank entries for an observation indicate that the observation was not
present in that study

L-5

APPENDIX L - HISTORICAL CONTROL DATA FOR ANNANDALE, NJ FACILITY
(CONT’D)

 (INTERNAL DATA)

STUDY #	15	14	13	12	11	10	9(B)	9(A)

NUMBER OF LITTER	22	25	25	25	24	24	25	25

NUMBER OF FETUSES	158	177	182	195	181	178	197	201

% VIS. VAR. - F	1.27	2.26	0.55	0	0	0	0	1.00

% VIS. VAR. - L	9.09	12.00	4.00	0	0	0	0	4.00

% VIS. MAL. - F	1.9	2.26	2.19	0.51	2.21	1.69	1.02	0.50

% VIS. MAL. - L	9.09	16.00	12.00	4.0	16.67	12.50	4.00	4.00

Olfactory bulb: Misshapen  - F

0.51

Olfactory bulb: Misshapen - L

4.00

Microphthalmia - F

	0.51

	Microphthalmia - L

	4.00

	Retinal fold  - F

0.56	1.64

	1.12

Retinal fold - L

4.00	8.00

	8.33

Carotid artery: Malpositioned  - F

0.56

Carotid artery: Malpositioned - L

4.00

Innominate artery: Absent - F

0.56

Innominate artery: Absent - L

4.00

Subclavian artery: Malpositioned - F

0.56

Subclavian artery: Malpositioned - L

4.00

NOTE:    F - Fetus

               L - Litter

	Blank entries for an observation indicate that the observation was not
present in that study

L-6

APPENDIX L - HISTORICAL CONTROL DATA FOR ANNANDALE, NJ FACILITY
(CONT’D)

 (INTERNAL DATA)

STUDY #	15	14	13	12	11	10	9(B)	9(A)

NUMBER OF LITTER	22	25	25	25	24	24	25	25

NUMBER OF FETUSES	158	177	182	195	181	178	197	201

Spleen: Small - F	0.63

	Spleen: Small - L	4.55

	Kidney(s): Large - F	0.63

	Kidney(s): Large - L	4.55

	Hydronephrosis - F	1.26	1.13

	1.66

	Hydronephrosis - L	9.09	8.00

	12.50

	Ureter(s): Convoluted  - F

1.00

Ureter(s): Convoluted - L

4.00

Hydroureter - F	1.26	1.13

	0.55	0.56	0.51	0.50

Hydroureter - L	9.09	8.00

	4.17	4.17	4.00	4.00

Umbilical artery: Left of urinary bladder - F	1.26	2.26	0.55

	Umbilical artery: Left of urinary bladder - L	9.09	12	4.00

	Testis(es): Malpositioned  - L

	0.55

	Testis(es): Malpositioned - F

	4.00

	NOTE:    F - Fetus

               L - Litter

L-7

APPENDIX L - HISTORICAL CONTROL DATA FOR ANNANDALE, NJ FACILITY
(CONT’D)

 (SKELETAL DATA)

STUDY #	15	14	13	12	11	10	9(B)	9(A)

NUMBER OF LITTER	22	24	25	25	24	24	$	$

NUMBER OF FETUSES	157	176	192	194	177	181	$	$

% SKEL. VAR. - F	5.10	21.60	17.80	15.46	15.25	8.84	$	$

% SKEL. VAR. - L	27.27	70.83	76.00	60.00	54.17	50.00	$	$

% SKEL. MAL. - F	0	0.57	0	0	1.13	0	$	$

% SKEL. MAL. - L	0	4.17	0	0	8.33	0	$	$

Forepaw anlage: Misshapen - F

0.57

Forepaw anlage: Misshapen - L

4.17

Sternebrae: Advanced - F

2.84	1.05

	Sternebrae: Advanced - L

16.67	8.00

	Sternebrae: Bifid - F

	0.52

	Sternebrae: Bifid - L

	4.00

	Sternebrae: Hypoplastic - F

1.03

Sternebrae: Hypoplastic - L

4.00

Sternebrae: Unossified - F	0.64	1.70	1.05

1.7	1.10

Sternebrae: Unossified - L	4.55	12.5	8.00

8.33	8.33

Sternebral anlage: Hypoplastic - F

	2.82

	Sternebral anlage: Hypoplastic - L

	12.50

	Vertebrae: Absent multiple - F

	0.56

	Vertebrae: Absent multiple - L

	4.17

	Vertebral centra: Bifid- F	0.64	3.98	5.76	10.82	6.78	1.10

Vertebral centra: Bifid- L	4.55	25.00	36.00	48.00	29.17	8.33

L-8

APPENDIX L - HISTORICAL CONTROL DATA FOR ANNANDALE, NJ FACILITY
(CONT’D)

 (SKELETAL DATA)

STUDY #	15	14	13	12	11	10	9(B)	9(A)

NUMBER OF LITTER	22	24	25	25	24	24	$	$

NUMBER OF FETUSES	157	176	192	194	177	181	$	$

Vertebral centra: Dumbbell/8-shaped - F

1.14	0.52	0.52

1.10

Vertebral centra: Dumbbell/8-shaped - L

8.33	4.00	4.00

8.33

Vertebral centra: Misshapen - F

	0.56

	Vertebral centra: Misshapen- L

	4.17

	Vertebral centra: Unossified - F

	0.56

	Vertebral centra: Unossified - L

	4.17

	Vertebrae: Supernumerary presacral Lumbar - F

	0.52

0.56

	Vertebrae: Supernumerary presacral Lumbar - L

	4.00

4.17

	Vertebral centra anlage: Bifid - F

	0.52

	Vertebral centra anlage: Bifid - L

	4.00

	Vertebral centra anlage: Dumbbell/8 shaped - F

6.82	5.24	1.55

Vertebral centra anlage: Dumbbell/8 shaped - L

33.33	28.00	12.00

Vertebral centra anlage: Hypoplastic - F

	1.69

	Vertebral centra anlage: Hypoplastic - L

	12.50

	Vertebral centra anlage: Misshapen - F

	0.56

	Vertebral centra anlage: Misshapen - L

	4.17

	Rib(s): Cervical - F

0.57

Rib(s): Cervical  - L

4.17

Rib(s): Rudimentary lumbar - F	3.18	9.66	8.90	4.12	1.70	5.52

Rib(s): Rudimentary lumbar - L	22.73	37.50	40.00	24.00	12.50	25.00

Rib(s): Rudimentary thoracic - F

	0.52

	Rib(s): Rudimentary thoracic - L

	4.00

	Rib(s): Well formed lumbar - F

	0.52

	Rib(s): Well formed lumbar - L

	4.00

	Rib(s): Short last thoracic - F	0.64	1.14

Rib(s): Short last thoracic - L	4.55	8.33

Rib(s): Thick/wavy - F

Rib(s): Thick/wavy - L

L-9

APPENDIX L - HISTORICAL CONTROL DATA FOR ANNANDALE, NJ FACILITY
(CONT’D)

 (SKELETAL DATA)

STUDY #	15	14	13	12	11	10	9(B)	9(A)

NUMBER OF LITTER	22	24	25	25	24	24	$	$

NUMBER OF FETUSES	157	176	192	194	177	181	$	$

Rib(s): Cervical anlage - F

0.57

Rib(s): Cervical anlage - L

4.17

Rib(s) anlage: Fused - F

0.57

Rib(s) anlage: Fused - L

4.17

Rib(s) anlage: Hypoplastic - F

	2.82

	Rib(s) anlage: Hypoplastic - L

	12.50

	Rib(s) anlage: Site of ossification - F

	1.13

	Rib(s) anlage: Site of ossification - L

	4.17

	Calcaneus: Advanced - F

0.57

Calcaneus: Advanced - L

4.17

NOTE:    F - Fetus

               L - Litter

               $ - Not examined

L-10

APPENDIX M – FEED AND WATER ANALYSES

FEED ANALYSIS

M-1

APPENDIX M – FEED AND WATER ANALYSES (CONT’D)

FEED ANALYSIS

M-2

APPENDIX M – FEED AND WATER ANALYSES (CONT’D)

FEED ANALYSIS

M-3

APPENDIX M – FEED AND WATER ANALYSES (CONT’D)

FEED ANALYSIS

M-4

APPENDIX M – FEED AND WATER ANALYSES (CONT’D)

FEED ANALYSIS

M-5

APPENDIX M – FEED AND WATER ANALYSES (CONT’D)

FEED ANALYSIS

M-6

APPENDIX M – FEED AND WATER ANALYSES (CONT’D)

FEED ANALYSIS

M-7

APPENDIX M – FEED AND WATER ANALYSES (CONT’D)

FEED ANALYSIS

M-8

APPENDIX M – FEED AND WATER ANALYSES (CONT’D)

FEED ANALYSIS

M-9

APPENDIX M – FEED AND WATER ANALYSES (CONT’D)

FEED ANALYSIS

M-10

WHOLE-BODY INHALATION DEVELOPMENTAL TOXICITY STUDY IN RATS

WITH GASOLINE WITH TBA VAPOR CONDENSATE MRD-00-718: 171834

 PAGE   

Page   PAGE  268  of   NUMPAGES  268 

Page   PAGE  99  of   NUMPAGES  268 

WHOLE-BODY INHALATION DEVELOPMENTAL TOXICITY STUDY IN RATS

WITH GASOLINE WITH TBA VAPOR CONDENSATE MRD-00-718: 171834

WHOLE-BODY INHALATION DEVELOPMENTAL TOXICICTY STUDY IN RATS

WITH GASOLINE VAPOR CONDENSATE WITH TBA (MRD-00-718:  171834)

 PAGE   

 

 

 

 

Miran

Miran

Pump

Pump

 OUT

 

IN

IN

OUT

IN

OUT

GC

GC

Line inlet

Select Stream

Disconnect

Stream Vent

1.0 m3

CHAMBER

1.0 m3

CHAMBER

GENERATION

CHAMBER

MAGNAHELIC

CRITICAL

ORIFICE

TEST SUBSTANCE

TANKS

ROTAMETER

RO

T

AME

T

E

R

FLASK

FLASK